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Abstract  
ErbB receptors (ErbB1 - ErbB4) are a subfamily of tyrosine kinase receptors that regulate cell 
proliferation and differentiation. It has been proposed that the ErbB1 subtype is transactivated by 
Ang II to mediate cardiac hypertrophy. However, whether other ErbB receptors, in particular the 
abundant subtype ErbB4, are involved in this process is not known. ErbB4 has four isoforms due to 
alternative splicing, each of which might play a distinct role in regulating cell activity. However, the 
role of individual ErbB4 isoforms in hypertrophic signalling has not been investigated. In addition, 
ErbB4 activation is critical for cardiac development, cardiomyocyte survival in various rodent 
models of cardiovascular pathologies. However, the physiological role of ErbB4 in the adult heart 
remains poorly understood. The overall aim of my PhD project is to examine the role of the ErbB4 
receptor in mediating hypertrophic growth of cardiomyocytes in vitro, and maintenance of the adult 
heart in vivo. 
To investigate the role of ErbB1, ErbB2 and ErbB4 in mediating hypertrophy, I inhibited individual 
ErbB receptors in primary neonatal rat ventricular cardiomyocytes using RNA interference or a 
pharmacological inhibitor (AG1478). Hypertrophy induced with Ang II (100 nM) or NRG1 (10 
nM) was assessed by measuring the promoter activity of hypertrophic genes, ERK1/2 activation, 
and hypertrophic growth. The NRG1-induced hypertrophy was reduced by down-regulation of 
ErbB4 receptor but not other ErbB receptors. The down-regulation of individual ErbB receptor 
(ErbB1, ErbB2 and ErbB4) did not affect Ang II-induced hypertrophy. Similar results were 
observed with the receptor tyrosine kinase inhibitor, AG1478. This suggested that whilst ErbB4 is 
required for NRG1-induced hypertrophy, none of the individual ErbB receptor subtypes are 
required for Ang II-induced hypertrophy. 
Following the studies above, I investigated whether the different ErbB4 isoforms had any functional 
differences in the cardiomyocytes. Irrespective of any changes in total ErbB4 mRNA levels, 
expression of the non-cleavable JM-b isoform was always predominant in adult heart in both 
physiological and pathological conditions. Although the cleavable isoform JM-a was detectable, it 
is not cleaved in cardiomyocytes. I replaced the endogenous ErbB4 with exogenous individual 
isoform in cardiomyocytes and found that all four isoforms of ErbB4 could mediate the NRG1-
induced hypertrophic signalling. This suggests that the hypertrophy is triggered by a common 
feature of the four isoforms (ostensibly the kinase activity), and appears independent of isoform-
specific features, such as the cleavable domain.  
To investigate the physiological function of ErbB4 in adult heart, we adopted the tamoxifen-
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inducible αMHC-MerCreMer/loxP system to induce ErbB4 deletion from cardiomyocytes in the 
adult mouse. The expression of ErbB4 was reduced by ~ 90% at 10 days after tamoxifen treatment. 
Echocardiography revealed no differences in cardiac function (fractional shortening) between 
ErbB4-conditional knockout (ErbB4-cKO) and control groups at 3-4 months after deletion of 
ErbB4. However, the heart weight was increased in ErbB4-cKO animals. Interestingly, there is no 
change in cardiac structure (cardiomyocyte size and cardiac fibrosis) or the expression of genes 
associated with pathological hypertrophy. This suggests that the cardiac hypertrophy observed 
following ErbB4 deletion may be physiological, and raises the question as to how these animals 
developed cardiac hypertrophy without alteration in cardiomyocyte size or development of fibrosis. 
One possibility is more cardiac cells generated to cause the cardiac hypertrophy. Indeed, I found 
that the number of pH3 (phosphorylated histone 3, a marker of proliferation) positive cells was 
significantly increased in ErbB4-cKO animals. Consistent with this, the expression of NRG1, the 
ErbB4 selective agonist, was selectively up-regulated following ErbB4 receptor deletion. NRG1 has 
been suggested to induce cardiomyocyte proliferation and protect the heart under pathological 
conditions. Thus I proposed that this up-regulation in NRG1 may explain both the cardiac cell 
proliferation and the lack of cardiac dysfunction in the ErbB4-cKO animals, despite the loss of the 
ErbB4 receptor. Finally, we examined the long-term effects of cardiac ErbB4 deletion in mice at 7-
8 months after tamoxifen treatment. These ErbB4-cKO animals developed milder physiological 
cardiac hypertrophy than that seen in 3-4 months cohort. Surprisingly, the cardiac ErbB4 expression 
in the ErbB4-cKO mice was no longer different to the controls, whereas it was reduced by ~67% at 
3-4 months and ~90% at 10 days after tamoxifen treatment. The potential reasons for this reversal 
are not clear, but may explain the unexpected maintenance of cardiac physiology in this model. 
In conclusion, the data presented in this thesis demonstrates that activation of the ErbB4 receptor is 
required for NRG1-induced cardiomyocyte hypertrophy. All of the four isoforms of ErbB4 can 
mediate this hypertrophic response. Deletion of ErbB4 from cardiomyocytes in adult mice leads to 
physiological cardiac hypertrophy as well as an up-regulation of NRG1. We speculate that NRG1 
might protect the heart from the dysfunction caused by the loss of ErbB4, and promote cell 
proliferation to cause cardiac hypertrophy. 
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GENERAL INTRODUCTION 
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1. General introduction 
1.1 Cardiac hypertrophy  
1.1.1 Epidemiology and definition of cardiac hypertrophy 
Cardiovascular diseases (CVD) such as heart failure, stroke, heart attack, cardiomyopathy and 
peripheral arterial disease killed 17.3 million people in 2008, representing 30% of all global deaths. 
It is estimated that by 2030 CVD and its complications will still be the leading cause of death in the 
world, with 24 million people affected (WHO, 2010). Considerable numbers of CVD patients have 
cardiac hypertrophy, which is an increase in cardiac mass primarily occurring through the 
enlargement of individual cardiomyocytes. It is initially a compensatory growth response to 
increased demand for cardiac function caused by various physiological or pathological stimuli. At 
some point, this compensation fails to meet demand and the heart transitions to failure, 
accompanied by stiffening of the cardiac tissue (fibrosis). Heart failure is irreversible and continues 
despite best available therapies, and is a primary risk factor for early death.   
1.1.2 Cardiomyocyte hypertrophy 
The heart is mainly composed of cardiomyocytes and fibroblasts. Cardiomyocytes occupy 
approximately 75% of the normal myocardial tissue volume and comprise between 30-40% of the 
total cell numbers (Adler et al., 1981; Vliegen et al., 1991). During embryogenesis, cardiomyocytes 
can both proliferate and enlarge to cause cardiac growth. Shortly after birth in mammals, the 
cardiomyocytes exit the cell cycle and lose the ability to proliferate (Markwald et al., 2010). Thus, 
postnatal heart growth is mainly dependent on the enlargement (i.e., hypertrophy) of differentiated 
cardiomyocytes. Cardiomyocyte hypertrophy represents an increase in the mass of the cardiac 
muscle cells without proliferation (Dorn, 2007). It is a compensatory growth response to increased 
demand for cardiac function.  
1.1.3 Types of cardiac hypertrophy 
Cardiac hypertrophy can be categorised as physiological or pathological according to the nature 
of the stimuli and whether the hypertrophy is reversible or not (Frey et al., 2003; Heineke et al., 
2006; McMullen et al., 2007). Physiological cardiac hypertrophy is observed during pregnancy 
and as a consequence of exercise. Physiological cardiac hypertrophy is usually reversible - thus, 
the cardiac hypertrophy observed in athletes (Ellison et al., 2011) or pregnancy (Mone et al., 
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1996; Eghbali et al., 2005) (due a demand for increased cardiac output) often regresses after the 
cessation of training or delivery of the newborn. In contrast, pathological hypertrophy is usually 
caused by chronic hypertension, an overactive neurohormonal system (such as the renin-
angiotensin system or increased sympathetic drive), or other diseases associated with 
cardiovascular disease, such as diabetes. Pathological hypertrophy initially resembles 
physiological hypertrophy as an adaptive mechanism to preserve cardiac function in the short-
term (Iemitsu et al., 2001). However, in the longer term, the persistent cardiac hypertrophy will 
cause the death of cardiomyocytes, which are replaced by proliferating fibroblasts (Grossman, 
1980; Shiojima et al., 2005). The cardiac function declines due to the loss of cardiomyocytes and 
the ensuing fibrosis. This process is termed cardiac remodelling and eventually leads to heart 
failure. Pathological cardiac hypertrophy has been recognized as an important predictor for 
cardiovascular morbidity and mortality as well as an independent risk factor for heart failure, 
myocardial infarction, arrhythmias and sudden death (Wachtell et al., 2007; Artham et al., 2009; 
Bombelli et al., 2009; Søraas et al., 2010).  
Morphologically, cardiac hypertrophy can be categorised as concentric hypertrophy or eccentric 
hypertrophy (Grossman et al., 1975). Concentric hypertrophy is characterised by an increase in 
ventricular wall thickness, and at the cellular level the cardiomyocytes grow in a transverse 
direction without changes in cell length (Carabello, 2002). Eccentric hypertrophy is exemplified by 
ventricle cavity dilatation that can lead to dilated cardiomyopathy. At a cellular level, it is 
characterised by hypertrophic growth of cardiomyocyte hypertrophy in both the longitudinal and 
transverse directions (Grossman et al., 2013). The stimuli that cause pressure overload (e.g. 
hypertension) result in concentric hypertrophy, whilst stimuli that cause volume overload (e.g. 
aortic regurgitation) lead to eccentric hypertrophy (McMullen et al., 2007).  
At a molecular level, pathological cardiac hypertrophy is usually characterized by sarcomere 
reorganisation and induction of the fetal gene program in cardiomyocytes (Drazner, 2005). The 
sarcomere is the basic unit of muscle cells. Sarcomere reorganisation resulting in the remodelling of 
the cardiomyocytes, affecting the ability of the cardiomyocytes to contract (Telley et al., 2007). The 
activation of the “fetal gene program” involves the re-expression (in the adult) of genes normally 
only expressed during fetal development including of α-skeletal actin, β-myosin heavy chain (β-
MHC), atrial natriuretic peptide (ANP) and myosin light chain-2v (MLC-2V) (Parker et al., 1990; 
Taegtmeyer et al., 2010). Some of the induced fetal genes code for contractile proteins. The re-
induction of fetal gene expression is coupled with the down-regulation of genes which are normally 
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expressed at high levels in the adult ventricle, such as α-MHC and sarco/endoplasmic reticulum 
calcium ATPase (SERCA2) (Barry et al., 2008). The dysregulation of these contractile and Ca
2+
 
handling proteins potentially contributes to alterations in the contractile ability of cardiomyocytes 
(Razeghi et al., 2001; Taegtmeyer et al., 2010). 
1.1.4 Therapy for cardiac hypertrophy 
The presence of cardiac hypertrophy is usually an adverse characteristic of various cardiovascular 
disorders, and regression or prevention of cardiac hypertrophy has benefits in reducing the risk of 
CV events and sudden cardiac death in the hypertensive population (Wachtell et al., 2007; Artham 
et al., 2009; Bombelli et al., 2009; Søraas et al., 2010). As hypertension is commonly associated 
with the development of pathological left ventricle hypertrophy (LVH), most anti-hypertensive 
drugs can attenuate LVH, such as angiotensin converting enzyme (ACE) inhibitors and Ang II type 
1 receptor (AT1R) blockers (ARB) (Solomon et al., 2011; Müller et al., 2012), calcium channel 
blockers (Devereux et al., 2001), and β-blockers (Cabrera-Bueno et al., 2007). Each treatment may 
reduce the LVH to a different extent, which correlates with the degree of blood pressure reduced 
(Kjeldsen et al., 2002; Ruilope et al., 2008). However, meta-analysis of clinical trials has proposed 
that ACE inhibitors and ARBs have a better efficacy for LVH regression compared to other drugs 
(Devereux et al., 2001; Dahlöf et al., 2002; Klingbeil et al., 2003; Okin et al., 2003; Pitt et al., 
2003; Dahlöf et al., 2005), suggesting the importance of activation of RAS in cardiac hypertrophy.  
1.1.5 Factors and mechanisms that can induce cardiac hypertrophy 
Factors causing pathological cardiac hypertrophy can be categorized as mechanical or chemical. 
Pressure overload (due to increased systolic pressure) or volume overload (due to increased 
diastolic pressure) are forms of mechanical stress that can arise from hypertension (Roman et al., 
2010; Katholi et al., 2011), exercise, pregnancy, or cardiac dysfunction (Dorn, 2007). This causes 
an increase in cardiac wall tension and adaptive growth of the myocardium to normalize this 
tension, resulting in cardiac hypertrophy (Frey et al., 2003; Frey et al., 2004). The molecular 
mechanisms linking mechanical stress and cardiac hypertrophy have yet to be fully identified 
(Heineke et al., 2006). However, many hormonal factors such as endothelin-1 and Ang II are 
released in an autocrine or paracrine way during this process, which can contribute to the cardiac 
hypertrophy (Yamazaki et al., 1996). Cardiac homeostasis is maintained by a complex network of 
hormonal factors that regulate cardiac structure, growth, survival and function. Disorders in the 
production and regulation of these hormones can thus be a stimulus for pathological cardiac 
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hypertrophy. For instance, endothelin-1 has been found to be up-regulated in human and rat right 
ventricular hypertrophy (Nagendran et al., 2013), and cardiac specific deletion or inhibition of the 
endothelin-1 receptor attenuates aging-associated or pressure overload induced cardiac hypertrophy 
in rodents (Ceylan-Isik et al., 2013; Visnagri et al., 2013). The molecular mechanism by which 
hormonal stimuli such as endothelin-1 and Ang II cause cardiac hypertrophy is via binding and 
activating their receptors, which primarily are GPCRs (Sugden et al., 1998).  
G protein-coupled receptors (GPCRs) are seven-transmembrane spanning proteins that couple to 
GTP-binding proteins (heterotrimeric G proteins) and use the latter to transduce signals to activate 
effector enzymes and to open cell surface ion channels (Hanson et al., 2009). G proteins have three 
subunits: Gα, Gβ, and Gγ. Gα can be further divided into four classes according to the downstream 
effectors: Gαs, Gαi, Gαq and G12/13 (Wall et al., 1995). Gαs and Gαi have opposite effects in that 
Gαs activates adenylyl cyclase (AC), whereas Gαi inhibits AC. Gαq can activate the phospholipase 
C (PLC) pathway. The Gβ and Gγ subunits form a tight bond and in the inactive state they are 
associated with the Gα subunit. When GPCRs are activated, this catalyses the GTP-GDP exchange 
on the Gα subunit and causes the dissociation of Gα from the Gβ/γ subunits, which can then activate 
downstream effectors (Casey et al., 1988). The Gαq-coupled GPCRs are the predominant GPCRs 
that mediate cardiac hypertrophy (Esposito et al., 2002). Expression of a constitutively activate Gαq 
mutant in cardiomyocytes resulted in hypertrophic growth, which then rapidly progressed to 
apoptotic cardiomyocyte death (Adams et al., 1998). Consistent with this, genetic overexpression of 
Gq to autonomously activate Gq signalling in cardiomyocytes induced stable cardiac hypertrophy in 
heterozygous transgenic mice, whereas the persistent high level of the Gαq activation in double 
heterozygous transgenic mice resulted in heart failure (Adams et al., 1998). Amongst the agonists 
for Gαq-coupled GPCRs, Ang II is one of the prime agents that can induce cardiac hypertrophy 
both in vitro and in vivo. 
1.1.6 Ang II induces cardiomyocyte hypertrophy  
Ang II is a octapeptide produced by the renin-angiotensin system (Ferrario, 2011). Ang II is known 
to increase blood pressure by causing blood vessel constriction and increasing salt and water 
retention (Cassis et al., 2009), however Ang II can also induce cardiomyocyte growth directly. In 
isolated neonatal rat cardiomyocytes, stimulation with Ang II for 48 h induced a significant increase 
in cardiomyocyte protein synthesis without changing the DNA synthesis rate (Sadoshima et al., 
1993). The expression of “fetal gene program” genes (including myosin light chain 2v (MLC-2V), 
skeletal α actin, CyclinD, and atrial natriuretic factor (ANP)) was elevated at 6 hours of Ang II 
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stimulation (Sadoshima et al., 1993). In mice, chronic subpressor doses of Ang II significantly 
induced left ventricular hypertrophy and increased in cardiomyocyte cross section area without 
changes in blood pressure (Schultz et al., 2002). ACE inhibitor treatment to reduce the systemic 
production of Ang II in hypertensive rats (abdominal aorta banding model) inhibited cardiac 
hypertrophy, whereas normalisation of blood pressure with an arterial vasodilator or calcium 
antagonist did not (Linz et al., 1989), suggesting that Ang II is an independent factor for cardiac 
hypertrophy. However, whether Ang II can induce cardiac hypertrophy independently of its effects 
on blood pressure remains controversial. Coffman et al. showed that the increase in blood pressure, 
but not the direct effect of Ang II on cardiac cells, was responsible for cardiac hypertrophy in a 
model of Ang II-induced hypertension. The deletion of the major Ang II receptor subtype in the 
kidney inhibited Ang II-induced hypertension and cardiac hypertrophy, whereas extrarenal deletion 
of the receptor did not (Crowley et al., 2006). Although these experiments are well performed with 
proper controls, it is hard to refute the observations of other studies suggesting that Ang II directly 
targets cardiomyocytes to induce hypertrophic growth. 
Ang II induces cardiomyocyte hypertrophy by binding to and activating the AT1R receptor. The 
AT1R is the major receptor for Ang II in cardiomyocytes and is a member of the GPCR family with 
a molecular mass of approximately 41 kDa (Mukoyama et al., 1993; Yasuda et al., 2008). Upon 
binding Ang II, AT1R is activated and predominantly trigger Gq signalling pathways (Mehta et al., 
2007; Harris et al., 2009). The classical Gαq signalling pathway activated by AT1R is shown in 
Figure 1.1 (Dr. Hsiu-Wei Chan, PhD thesis): AT1R interacts with the Gq protein leading to the 
activation of protein kinase C (PKC) and mobilization of Ca
2+
 from intracellular stores. The 
activated PKC and mobilized Ca
2+
 trigger individual downstream signalling pathways (Ohtsu et al., 
2008). PKC is a critical kinase that regulates multiple cellular activities such as cell proliferation, 
survival and apoptosis. In cardiomyocytes, it is involved in the regulation of cardiomyocyte 
contraction and hypertrophic growth (Mackay et al., 2001; Braz et al., 2002). PKC has multiple 
subtypes, and by now at least 12 isoforms have been identified (Steinberg, 2012). In 
cardiomyocytes, the most abundant isoform is PKCα (Pucéat et al., 1994). The activation of PKCα 
promotes the hypertrophic growth of cardiomyocytes (Sabri et al., 2003) and PKC inhibition 
attenuates agonist-induced hypertrophy (Zou et al., 1996). Although some of these signalling 
pathways have been discovered, the detailed molecular mechanisms of how AT1R activation leads 
to hypertrophic growth have yet to be fully identified. There is evidence showing that activation of 
epidermal growth factor receptor (EGFR), a member of the ErbB family, is involved in, and critical 
for, the cardiomyocyte hypertrophy caused by Ang II.   
Chapter 1: General introduction 
 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Classic Gq signaling pathway mediated by AT1R with Ang II stimulation. In 
the inactive state, the GDP-bound α subunit is associated with the Gβγ subunits. Upon 
activation, GPCRs catalyse the GTP-GDP exchange on the Gα subunit and subsequently 
results in the dissociation of the Gα from the βγ subunits, each unit triggering different 
intracellular signalling cascades (Lee et al., 1992). The classical Gq signalling pathway 
activated by AT1R involves hydrolysis of phosphoinositides by active PLC, leading to the 
generation of diacylglycerol (DAG) and inositol trisphosphate (IP3) (Hepler et al., 1993; 
Smrcka et al., 1993). IP3 mobilises Ca
2+
 from its intracellular stores while DAG activates 
PKC. Figure from Dr. Hsiu-wen Chan (PhD thesis). 
 
Chapter 1: General introduction 
 
8 
 
1.2 The ErbB receptors 
1.2.1 Overview of ErbB receptors     
ErbB receptors are a subfamily of receptor tyrosine kinases that regulate cell proliferation, survival 
and differentiation (Burgess, 2008). There are currently four known ErbB receptor subtypes 
encoded by distinct genes - ErbB1, ErbB2, ErbB3 and ErbB4 (Scaltriti et al., 2006). The sequence 
identity of ErbB receptors ranges from 37% - 49% with a molecular mass of approximately 180 
kDa (Jorissen et al., 2003). The typical ErbB receptor comprises a large extracellular ligand-binding 
domain (ECD), a single transmembrane domain, an intracellular tyrosine kinase domain and a 
carboxyl-tail (Figure 1.2). Most ErbB receptors are in an inactive conformation in the absence of 
ligands. Ligand binding results in a conformational change in the ECD and tyrosine kinase domain, 
exposing previously embedded surfaces. The surface exposure in the ECD promotes dimer 
formation between ErbB receptors (Weiss et al., 1998) and the critical sites exposed in the tyrosine 
kinase domain results in the activation of the kinase (Zhang et al., 2006). The receptor dimerisation 
brings the intracellular kinase domains in each receptor into proximity to cross-phosphorylate the 
tyrosine residues in the cytoplasmic tail of its neighbour receptor in the dimeric complex (Hubbard 
et al., 1998) (Figure 1.2). The phosphotyrosine residues in the cytoplasmic tail provide binding sites 
for multiple factors containing Src-homology 2 (SH2) domain or phosphotyrosine binding (PTB) 
domains (Sweeney et al., 2000), which recruit downstream effectors to trigger signalling (Olayioye 
et al., 2000; Yarden et al., 2001; Mendelsohn et al., 2003). The recruitment specificity is 
determined by the amino acids surrounding the phosphotyrosine residues of the receptor. Thus, each 
ErbB receptor can trigger a unique complex of intracellular signalling pathways based on this 
specificity (Figure 1.3). ErbB receptors can form both homodimers and heterodimers (Figure 1.2). 
The diversity of the heterodimerisation formed by different ErbB receptors adds more variety to the 
ErbB signalling pathways (Burgess, 2008). ErbB2 differs from other subtypes as its extracellular 
region is unable to bind any identified ligand, and thus it mainly functions as the preferred ErbB 
dimerisation partner (Timolati et al., 2006). ErbB2 adopts an active conformation and can enhance 
the dimerisation and the downstream signalling. ErbB3 can bind ligands and provides multiple 
docking sites for downstream effectors in its cytoplasmic tail, however, due to an abrogated kinase 
activity, it has to trigger downstream signalling with the assistance of dimerising partners 
(Rohrbach et al., 2005). All ErbB receptors are detectable in the embryonic heart across different 
species. In postnatal cardiomyocytes, the expression level of ErbB receptors declines and the 
expressed subtypes include ErbB1, ErbB2 and ErbB4 (Zhao et al., 1998; Rohrbach et al., 1999), 
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with ErbB2 and ErbB4 being the most abundant subtypes. ErbB3 is not expressed at high levels in 
postnatal cardiomyocytes (Zhao et al., 1998; Rohrbach et al., 1999).  
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Figure 1.2 Structure of ErbB receptors in active and inactive conformation. The ectodomain of 
ErbB receptor is heavily N-glycosylated and characterised by two cysteine-rich regions which 
produce 25 disulfide bonds, forming a ligand binding site. The cytoplasmic region includes a tyrosine 
kinase domain and C-terminal domain containing binding sites for multiple factors. The majority of 
ErbB receptors stay in an inactive conformation without the ligand binding. The exception is ErbB2, 
which adopts the ligand binding conformation in the absence of ligand. Upon activation, the ErbB 
receptors can form homo- and hetero-dimers with each other. The typical dimers formed are shown in 
the bottom panel. 
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Figure 1.3 Downstream effectors potentially recruited to individual ErbB receptors. 
Each ErbB receptor can recruit multiple downstream effectors upon activation. The 
recruitment specificity is determined by the amino acids surrounding the phosphotyrosine 
residues in the carboxyl-tail of the receptor. The Shc and Grb2 proteins are commonly 
recruited by ErbB receptors and can lead to activation of MAPK signalling pathways. The 
numbers shown represents the amount of binding sites provided by each receptor for a 
particular protein. Together, each ErbB receptor induces a unique combination of 
downstream signalling patterns in addition to the fundamental Shc and Grb2 pathways. 
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1.2.2 The function of ErbB receptors in heart 
The importance of ErbB signalling in the heart is highlighted by observations from transgenic mice. 
Mutations in ErbB2 and ErbB4 lead to a lethal phenotype at embryonic day (E) 10.5 due to defects 
in ventricular trabeculae formation (Gassmann et al., 1995; Lee et al., 1995; Sibilia et al., 1995). 
ErbB3 null mice have normal heart trabeculation but have disrupted endocardial cushion formation 
and die at E13.5 (Erickson et al., 1997; Riethmacher et al., 1997). ErbB1 null mice have severe 
defects, and die before birth or within 2-3 weeks postnatally depending on the genetic background 
(Miettinen et al., 1995; Threadgill et al., 1995). Besides their essential function in heart 
development, ErbB receptors also play important roles in regulating cardiac growth, survival and 
function in the postnatal heart. Cardiomyocyte-specific expression of a dominant-negative ErbB1 in 
adult mice blocked both ErbB1 and ErbB2 phosphorylation, resulting in cardiac dilation and 
decreased cardiac contraction (fractional shortening) (Rajagopalan et al., 2008). The phenotype 
caused by cardiac specific deletion of ErbB2 in adult heart has not yet been reported. However, 
administration of an ErbB2 blocking antibody in humans increases the risk of heart failure 
(Seidman et al., 2002). Consistent with this, inhibition of ErbB2 activity causes myofibrillilary 
structural damage and associated inhibition of excitation-contraction coupling (Pentassuglia et al., 
2009b), suggesting that ErbB2 receptors are required for adult heart homeostasis. Currently, the 
phenotype of ErbB4 deletion in adult heart has not been reported, although accumulating evidence 
indicates that ErbB4 signalling may be important in regulating adult cardiomyocyte function (refer 
to section 1.6.7). 
In addition to its critical function in regulating cardiac homeostasis, activation of ErbB receptors 
mediates cardiac hypertrophy both in vivo and in vitro. Activation of ErbB1 has been reported to 
mediate cardiomyocyte hypertrophy to Ang II (Asakura et al., 2002). In cell culture, ErbB4 agonists 
induced potent cardiomyocyte hypertrophy (Zhao et al., 1998). More detail on the cardiomyocyte 
hypertrophy induced by direct administration of ErbB agonists is discussed in section 1.2.4. 
1.2.3 Signalling pathways of ErbB receptors 
As mentioned above, there are highly diversified pathways activated by ErbB receptors due to 
heterodimerisation of these receptors. Among them are two fundamental and critical pathways 
mediating cardiac hypertrophy, the MAPK and PI3K-Akt pathways. Upon activation, ErbB 
receptors activate Ras GTPases (Yarden et al., 2001). Ras GTPases are a family of mostly 
membrane resident proteins that shuttle between an inactive GDP-bound and active GTP bound 
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conformation (Scheffzek et al., 1997; Coleman et al., 2004). In its activation conformation, 
Ras·GTP binds to a number of effector molecules, including the serine/threonine kinase Raf and 
phosphoinositide 3-kinase and recruits them to the membrane compartment for activation and 
signalling (Kumar et al., 2005).  
The Ras-Raf-MEK-ERK (MAPK) pathway  
The MAPK pathway is a primary mechanism by which extracellular mediators, such as growth 
factors, can regulate cellular activities such as cell growth, survival, apoptosis and metabolism. 
After recruitment to the cell membrane by Ras·GTP, Raf activates upstream kinases to stimulate the 
extracellular signal-regulated kinases1/2 (ERK1/2). There are at least 5 members of the ERK family 
(ERK1 to 5), which are activated and regulated by different upstream kinases (Nishimoto et al., 
2006). ERK1/2 proteins are phosphorylated on threonine and adjacent tyrosine residues in the Thr-
Glu-Tyr motif. ERK1/2 are the most intensively studied and abundantly expressed ERK family 
members (Nishimoto et al., 2006). In cardiomyocytes, ERK1/2 activation plays an important role in 
mediating cardiomyocyte hypertrophy. Cardiac-specific activation of ERK1/2 by overexpression of 
activated MEK1 (the immediate upstream activator of ERK1/2) in 9 independent MEK1 transgenic 
mouse lines led to stable concentric hypertrophy in the majority of these mice lines. Most activated 
MEK1 transgenic lines demonstrated a 25-30% increase in heart to body weight ratio with increased 
cardiac function and no signs of cardiomyopathy until 12 months of age (Bueno et al., 2000). The 
mechanism by which ERK1/2 activation causes cardiomyocyte hypertrophy is complicated. It has 
been proposed that ERK1/2 regulates protein synthesis during cardiomyocyte hypertrophy via an 
association with p70 S6 kinase (Wang et al., 2001). ERK1/2 is also associated with phosphorylation 
of transcriptional factors such as GATA4 that regulate ribosomal RNA transcription in 
cardiomyocytes (Morimoto et al., 2000; Liang et al., 2001). GATA4 is a cardiac-enriched 
transcriptional factor critical in the regulation of most cardiac-expressed structural genes such as α-
myosin heavy chain, myosin light chain 1/3, and cardiac troponin C and I (Molkentin, 2000);(Liang 
et al., 2002; Akazawa et al., 2003), as well as hypertrophy responsive genes such as BNP 
(Hasegawa et al., 1997).  
PI3K-Akt pathway 
Another important downstream pathway activated by ErbBs in cardiac hypertrophy is the 
phosphoinositide 3-kinase (PI3K) pathway. PI3Ks belong to a family of lipid kinases which convert 
phosphatidylinositol (4, 5)-bisphosphate (PIP2) into phosphatidylinositol (3, 4, 5)-trisphosphate 
(PIP3). PIP3, in turn, causes the phosphorylation of the kinase Akt. Akt can activate multiple 
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transcriptional factors such as GATA4, β-catenin, c-Myc and NFAT to promote cardiac 
hypertrophy (Heineke et al., 2006). Akt also promotes cardiac hypertrophy by enhancing protein 
synthesis via activation of mTOR pathways (Proud, 2004). PI3K consists of two subunits. One is 
the regulatory subunit that contains p85, p55α, p50α, p85β and p55γ, and is responsible for 
anchorage to the docking site of other proteins, such as ErbB receptors. The other is the p110 
subunit, containing p110α, p110β and p110δ, which are associated with recruitment of Akt to the 
cellular membrane and activation of downstream signalling (Vanhaesebroeck et al., 2010). The p85 
and p110α subunits are the most studied. Expression of the constitutively active p110α in the heart 
leads to physiological cardiac hypertrophy with preserved cardiac function (Shioi et al., 2000). 
Myocardial expression of a dominant negative form of p110α inhibits the physiological hypertrophy 
during postnatal cardiac developmental growth or in response to exercise (McMullen et al., 2003). 
Similarly, genetic mutations in the p85 subunit decrease heart size at baseline as well as 
physiological hypertrophy after exercise training (Luo et al., 2005). These studies suggested an 
important role of PI3K in mediating physiological cardiac hypertrophy.  
1.2.4 EGF-like factors 
EGF-like factors are the agonists for ErbB receptors (Harris et al., 2009). All EGF-like ligands are 
made as type I transmembrane proteins that are inserted into the plasma membrane and are cleaved 
by cell surface proteases to release mature growth factors (Schneider et al., 2009). The selectivity of 
EGF-like factors in binding the ErbB receptors is shown in Table 1.1 (Linggi et al., 2006; Edwards 
et al., 2008). 
Matrix metalloproteases (MMPs) and a disintegrin and metalloproteases (ADAMs) are part of the 
metalloprotease family (Page-McCaw et al., 2007; Reiss et al., 2009). They are anchored in the 
membrane and are responsible for the ectodomain shedding of EGF-like ligand precursors to 
produce the mature soluble EGF-like ligands (Nagase et al., 2006; Klein et al., 2011). Among 38 
identified subtypes, ADAM 17 and ADAM 10 seem to be the principal sheddases for EGF-like 
ligands, and the current understanding of ADAM-mediated shedding is largely based on studies of 
ADAM17 and ADAM10 (Mochizuki et al., 2007). Among the many EGF-like ligands, only HB-
EGF is known to be a substrate for MMPs (Yu et al., 2002; Hao et al., 2004).  
The EGF-like factors that have been identified in the cardiovascular system include EGF, TGF-α, 
HB-EGF, amphiregulin (AREG), betacellulin (BTC), epigen, epiregulin (EREG), and neuregulin 
(NRG)-1. Accumulated evidence from transgenic mice suggests a requirement of these factors in 
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regulating cardiac development and homeostasis, consistent with the observations for the ErbB 
receptors. In addition, administration of growth factor peptides or over-expression of growth factors 
induces cardiomyocyte hypertrophy both in vitro and in vivo (Zhao et al., 1998; Schneider et al., 
2005; Yoshioka et al., 2005). In our laboratory (Dr Hsiu-wen Chan, PhD thesis), the ability of 
various EGF ligands to mediate hypertrophic growth (measured as protein:DNA ratio) in primary 
isolated cardiomyocytes was compared. These EGF-like factors were categorized into three classes 
according to their ability to promote cardiomyocyte hypertrophy. The most potent hypertrophic 
agonists include BTC, NRG1β1 and NRG2β, which are primarily agonists for ErbB4. These 
agonists increased the mass of cardiomyocytes (total protein content) by 33%-49% in absence of 
changes in DNA content. Amphiregulin, TGFα, epiregulin and NRG2α caused a 16%-24% increase 
in cell mass, and these ligands (except NRG2α) selectively activate ErbB1. EGF, HB-EGF, epigen 
and NRG1α weakly induced hypertrophic growth (~10% increase), and are a mixture of ErbB1 
agonists and ErbB4 agonists. Together, these studies suggested that the ErbB4 might have a 
stronger ability to mediate cardiomyocyte hypertrophy than ErbB1. 
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Table 1.1 The specificity of ligand binding to ErbB receptor subtypes and activation by 
specific ADAMs. 
Ligand 
Receptor 
ADAM 
ErbB1 ErbB2 ErbB3 ErbB4 
EGF + - - - ADAM-8, -10, -12, -17 
TGF- α + - - - ADAM-17 
HB-EGF + - - + ADAM-8, -9, -12, -17, -19 
Amphiregulin + - - - ADAM-17, -19 
Betacellulin + - - + ADAM-8, -10, -17 
Epigen + - - - ADAM-17 
Epiregulin + - - + ADAM-17 
Neuregulin-1 - - + + ADAM-17, -19 
Neuregulin-2 - - + + Unknown 
Neuregulin-3 - - - + Unknown 
Neuregulin-4 - - - + Unknown 
 
This table was modified from table 1 in Edward et.al. (Linggi et al., 2006; Edwards et al., 2008) 
and the table 2 in Linggi et.al. (Linggi et al., 2006; Edwards et al., 2008). 
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1.3 Transactivation of ErbB receptors 
1.3.1 Transactivation of ErbB by GPCRs 
As discussed above, growth factors can cause cell growth via activating their receptors to trigger 
downstream growth signalling pathways, such as the MAPK pathway. The growth induced by 
activation of various GPCRs can also be mediated by activation of the MAPK pathway. However, 
the mechanisms by which GPCRs activate growth signalling pathway is less clear compared to the 
growth factor receptors. In 1996, for the first time, Daub et al. found that GPCRs could 
transactivate the EGFR to trigger downstream growth signalling. They demonstrated that 
endothelin-1, lysophosphatic acid (LPA) and thrombin treatment rapidly phosphorylated the EGFR 
followed by activation of MAPK pathway in Rat-1 fibroblasts (an immortalized cell line). All of 
these agonists activated GPCR receptors: endothelin-1 activated the endothelin receptor isoform 
ETA, lysophosphatic acid activated the LPA receptor and thrombin activated proteinase-activated 
receptors. Inhibition of EGFR (ErbB1) with tyrophostin AG1478 or a dominant-negative EGFR 
inhibited the GPCR-activated MAPK signalling, confirming that the GPCR mitogenic signalling is 
mediated by the transactivation of EGFRs (Daub et al., 1996).  
The transactivation of ErbB1 by Ang II was first reported by Eguchi et al. in primary vascular 
smooth muscle cells (Eguchi et al., 1998). Since then, increasing evidence demonstrates that the 
transactivation of EGFR by Ang II occurs in various cells, including renal epithelial cells, hepatic 
C9, cos-7, MCF-7 and importantly, cardiomyocytes (Asakura et al., 2002; Thomas et al., 2002; 
Muscella et al., 2003; Shah et al., 2004; Chen et al., 2006). Infusion of antisense 
oligodeoxynucleotides to ErbB1 in adult rats significantly attenuated the cardiac hypertrophy 
induced by Ang II (Kagiyama et al., 2002). Transgenic mice expressing dominant negative ErbB1 
are resistant to the Ang II induced cardiac hypertrophy (Zhai et al., 2006). Taken together, these 
studies indicate that ErbB1 is required for Ang II induced cardiac hypertrophy in vivo. 
1.3.2 Potential mechanisms for ErbB1 transactivation by Ang II: the TMPS 
pathway 
How does Ang II transactivate ErbB1? One proposed mechanism is the triple membrane-passing 
signalling (TMPS) pathway. In this process, activation of the AT1R by Ang II leads to the activation 
of metalloproteases that release ErbB1 ligands from the membrane. These ligands subsequently 
bind to ErbB1 and trigger downstream signalling (Figure 1.4). The TMPS mechanism describes the 
inside-outside-inside route of transactivation in three steps. 
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In the first step of this process, Ang II binding to the AT1R triggers Gq signalling (Ohtsu et al., 
2008), which in turn activates PKC and Ca
2+
 signalling. Both PKC and Ca
2+
 can potentially 
contribute to triggering the next step in the TMPS pathway. In hepatic or breast cancer cell lines, 
PKC mediates the release of EGF-like factors, contributing to transactivation (Shah et al., 2002; 
Muscella et al., 2003). In cardiomyocytes and vascular smooth muscle cells, it has been shown that 
Ca
2+
 but not PKC is essential for ErbB1 transactivation (Eguchi et al., 1998; Thomas et al., 2002; 
Smith et al., 2011).  
The second step involves cleavage of EGF-like factors. There is evidence to indicate that EGF-like 
factor shedding (particularly of HB-EGF) might be required for the transactivation of ErbB1 by 
Ang II. Inhibition of HB-EGF with a small molecule inhibitor or a blocking antibody reduces the 
transactivation of EGFR by Ang II in various cell types, including Cos-7 cells, cardiomyocytes, 
renal epithelial cells and hepatocytes (Asakura et al., 2002; Saito et al., 2002; Mifune et al., 2005; 
Ohtsu et al., 2006b). HB-EGF shedding can be mediated by ADAM12, ADAM17 or MMP2/9 
(Saito et al., 2002; Shah et al., 2004; Asakura et al., 2002). Dominant negative expression or 
pharmacological inhibition of ADAM12, ADAM17 or MMP2/9 blocked HB-EGF shedding and 
subsequent transactivation of EGFR by Ang II (Asakura et al., 2002; Saito et al., 2002; Ohtsu et al., 
2006b). Thus, ADAM 12, ADAM17 and MMP2/9 and HB-EGF are essential for the transactivation 
of ErbB1, and ADAM/MMP activity may mediate transactivation by shedding HB-EGF.  
The transactivation of ErbB1 by Ang II leads to dimerisation of ErbB receptors and the 
phosphorylation of intracellular tyrosine residues (Scaltriti et al., 2006). The phosphorylated ErbB1 
eventually recruits proteins and leads to phosphorylation of ERK1/2 (Shah et al., 2002). 
Phosphorylated ERK1/2 proteins are imported into the nucleus where they phosphorylate specific 
transcription factors involved in cell growth (Hill et al., 1995; Gaestel, 2006). To date,  ErbB1 is the 
only member of the ErbB family identified to be transactivated by Ang II to induce hypertrophy 
(Asakura et al., 2002; Thomas et al., 2002; Muscella et al., 2003; Shah et al., 2004; Chen et al., 
2006).  
The TMPS paradigm provides a potential scheme for transactivation mechanisms, however the 
details of transactivation signalling pathways are more complicated and involve more kinases than 
just those mentioned above. There is evidence showing that Src kinase links the activation of EGFR 
and GPCRs (Dikic et al., 1996; Fischer et al., 2003). Pharmacological inhibition or RNAi-silencing 
of Src abrogated the Ang II induced phosphorylation of EGFR (Bokemeyer et al., 2000; Yano et al., 
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2007). The non-receptor tyrosine kinase Pyk2 has also been proposed to mediate the transactivation 
of EGFR by GPCRs (Soltoff, 1998; Keely et al., 2000). In vascular smooth muscle cells, Pyk2 
binds Src and this was associated with activation of EGFR by Ang II (Eguchi et al., 1999). 
However, the roles of these factors are controversial. For instance, some studies have proposed 
pathways for GPCR-mediated EGFR transactivation that are independent of Src activation: 
expression of a kinase-mutant Pyk2 did not affect the EGFR activation induced by bradykinin 
(which activates the bradykinin 2 GPCR) in PC-12 cells (Zwick et al., 1999). In addition, inhibition 
of Pyk2 in cardiomyocytes did not affect the endothelin-1 induced activation of EGFR, suggesting 
that there is no requirement for Pyk2 in the transactivation of EGFR by endothelin-1 (Kodama et 
al., 2002). Despite this controversy, these studies suggested that it is highly possible that there are 
more factors involved in transactivation that are yet to be discovered. Recently, a siRNA screen 
identified multiple new candidates such as TRIO, BMX and CHKA that may mediate the 
transactivation of EGFR by Ang II in a human mammary epithelial cell line (George et al., 2013). 
Individual down regulation of TRIO, BMX or CHKA attenuated the activation of EGFR by Ang II, 
but not by the EGFR agonist EGF, suggesting that these factors are located upstream of EGFR and 
required for EGFR transactivation (George et al., 2013). These studies suggested that the pathway 
for GPCR to transactivate EGFR is much more complicated than that previously proposed. 
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Figure 1.4 Triple membrane-passing signaling (TMPS) pathway. Activation of the AT1R 
by Ang II leads to the activation of metalloproteases that release ErbB1 ligands from the 
membrane. These ligands subsequently bind to ErbB1 and trigger downstream signaling. 
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1.4 Characteristics of the ErbB4 isoforms 
1.4.1 Introduction to the ErbB4 isoforms 
Among the ErbB family, ErbB4 is unique in having distinct isoforms as a result of alternative 
splicing. The four isoforms of ErbB4 structurally differ in two domains: the extracellular 
juxtamembrane (JM) domain (JM-a and JM-b) and intracellular CYT domain (CYT-1 and CYT-2) 
(Figure 1.5). The four combinations of the JM and CYT domains form the four primary isoforms of 
ErbB4. The JM-a isoform contains 23 amino acids in the JM domain that allow for ectodomain 
shedding by ADAMs (Junttila et al., 2000). JM-b contains an alternative 13 amino acids that makes 
it resistant to shedding (Junttila et al., 2000). Cleavage of the JM-a isoform occurs in 2 steps, and 
produces an 80-kDa soluble fragment. First, the JM-a isoform can be subjected to ectodomain 
cleavage by the metalloprotease ADAM17 to produce a 120-kDa ectodomain fragment and an 80-
kDa fragment (Vecchi et al., 1997; Rio et al., 2000; Zhou et al., 2000). The 120-kDa ectodomain 
fragment is released into the extracellular medium and the 80-kDa fragment remains in the 
membrane, containing the cytoplasmic and transmembrane domains and several ectodomain 
residues. The 80-kDa fragment can be subsequently cleaved by γ-secretase within the lipid bilayer 
to release the intracellular domain (Chang-Yuan et al., 2001). 
The CYT-1 isoform has 16 amino acids inserted in the cytoplasmic tail when compared to the CYT-
2 isoform. It has been identified that the 16 amino acids of CYT-1 provide a docking site for PI3K, 
WWOX containing proteins and other proteins, allowing the activation of specific signalling 
pathways (Veikkolainen et al., 2011). The structural differences of the four ErbB4 isoforms could 
lead to the functional differences between these isoforms. 
The expression of each isoform is tissue specific. In human and mouse adult heart, the most 
abundant isoform is the JM-b CYT-1, in kidney it is JM-a CYT-2, and in cerebellum it is JM-a 
CYT-2 and JM-b CYT-2 (Elenius et al., 1997; Elenius et al., 1999). The tissue-specific expression 
proposes a potentially distinct biological function of each isoform. In some tissues (e.g. mammary 
cells, neurons) differences in biological function between isoforms has been shown (Naresh et al., 
2006; Feng et al., 2007; Law et al., 2007; Muraoka-Cook et al., 2009). For instance, during the 
brain development only the cleavable JM-a isoform can regulate the time of astrogenesis in the 
mouse (Sardi et al., 2006). However, whether there are functional differences between isoforms in 
cardiomyocytes is unknown.   
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Figure 1.5 Structural differences of ErbB4 isoforms. The four isoforms of ErbB4 
structurally differ in two domains: the extracellular juxtamembrane (Jm) domain (JM-
a and JM-b) and intracellular CYT domain (CYT-1 and CYT-2). The four 
combinations of the Jm and CYT domains form the four isoforms of EbB4. The JM-a 
isoform contains 23 amino acids in the Jm domain that allow for ectodomain 
shedding. JM-b contains an alternative 13 amino acids that resistant to shedding. The 
whole receptor containing 1292 -1318  amino acids depends on which isoform it is. 
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1.4.2 Cleavage in the JM-a domain 
As mentioned above, the defining feature of JM-a-containing ErbB4 isoforms is the potential to be 
cleaved. ADAM 17 is involved in the cleavage of ErbB4 (Rio et al., 2000). Thus, stimuli that 
activate ADAM 17 such as PKC activators (e.g. the phorbol ester PMA), ErbB4 agonists (e.g. 
NRG) and ligands that activate certain GPCRs (e.g. gonadotropin-releasing hormone) potentially 
possess the ability to trigger the cleavage process. PMA was the first agonist found to trigger the 
cleavage of the ErbB4, and can release the ICD of ErbB4 from the membrane in a wide range of 
cell types, including breast cancer cells, ovarian cancer cells, lung cancer cells, and a glioma cell 
line (Vecchi et al., 1996; Zhou et al., 2000; Määttä et al., 2006; Zeng et al., 2009). Cleavage of the 
ErbB4 induced by NRG is also observed in multiple cell types such as T47D (breast cancer cell 
line), OVCAR3, and OVCA432 (ovarian cell lines) (Vecchi et al., 1996; Zhou et al., 2000). It has 
been shown recently that gonadotropin-releasing hormone (a GPCR agonist) caused ADAM 17-
dependent cleavage of the ErbB4 and production of 80 kDa fragment in immortalized neurons that 
endogenously express the JM-a isoform (Higa‐Nakamine et al., 2012). 
After being released from the membrane, the 80 kDa ICD can enter the nucleus. The residues 676-
684 of the ICD domain are essential for nuclear accumulation of the ICD. Mutation of these 
residues destroyed the ICD localization to the nucleus without affecting production of the ICD 
(Williams, Allison et al. 2004). Furthermore, it has been shown that the tyrosine kinase activity of 
ErbB4 is essential for the nuclear localiztion of the ICD (Sundvall et al., 2007). The regulatory 
mechanism for ICD nuclear localization is not clear. However, the CYT-2 ICD has been shown to 
accumulate in the nucleus more than CYT-1 ICD due to enhanced tyrosine kinase activity in the 
intracellular domain of the CYT-2 ICD (Sundvall et al., 2007). Both CYT-2 ICD and CYT-1 ICD 
possess phosphorylation sites in the intracellular domain, but none of these are specifically located 
in the extra 16 amino acid sequence possessed by CYT-1. The reason why CYT-2 ICD possesses 
stronger tyrosine kinase activity than CYT-1 is still unknown.  
1.4.3 Biological function of the ICD 
By homing to the nucleus and interacting with transcriptional regulatory proteins, the 80 kDa ICD 
may regulate cell proliferation, apoptosis, differentiation, and DNA damage responses. The 
transcriptional regulatory proteins identified as interacting with the ErbB4 ICD include AP-2, Yes-
associated protein (YAP), signal transducer and activator of transcription 5A (STAT5A), estrogen 
receptor α (ER α) and Krab-associated protein 1 (Kap1) (Omerovic et al., 2004; Williams et al., 
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2004; Zhu et al., 2006a; Gilmore-Hebert et al., 2010; Gough, 2010). In a mouse fibroblast cell line, 
AP-2 was found to interact with the ICD of JM-a CYT-2 to positively regulate the platelet-derived 
growth factor receptor-alpha (PDGFA) promoter leading to cell proliferation under normal 
conditions and survival during serum starvation (Gough, 2010). The interaction between YAP and 
ICD interferes with p73-stimulated proapoptotic signalling (Komuro, Nagai et al. 2003; Omerovic, 
Puggioni et al. 2004), whereas interaction of STAT5A with the ICD leads to nuclear localization of 
STAT5A and activation of the milk genes, such as β-casein and whey acidic protein, thus 
contributing to the differentiation of the mammary cells (Long et al., 2003; Williams et al., 2004). 
In addition, interaction of ICD with ERα promotes cell proliferation in the T47D breast cancer cell 
line (Zhu et al., 2006b); and the ErbB4 ICD interaction with Kap1 mediates the response to DNA 
damage (Gilmore-Hebert et al., 2010). Clearly, the release and trafficking of the ICD into the 
nucleus provide a new paradigm for ErbB4 signalling.  
In the above section, I described how the ICD interacts with regulatory proteins to regulate cell 
activity. However, it should be noted that there are two types of ICD. The CYT-1 ICD is different 
from the CYT-2 ICD in possessing 16 extra amino acids. Compared to the CYT-2 ICD, the 16 
amino acid insertion in CYT-1 ICD contains a unique PI3K binding site (“YTPM”) and extra PPXY 
domain that binds WW-containing proteins, such as WWOX and YAP (Junttila et al., 2000; 
Aqeilan et al., 2005). It has been proposed that this difference in structure may lead to differences in 
regulatory ability.  
Both in vitro and in vivo experiments have shown that CYT-1 ICD and CYT-2 ICD may have 
different functions in promoting the growth, death and differentiation of cells. Mammary cell lines 
expressing exogenous CYT-2 ICD grow more rapidly than the same cell line expressing the CYT-1 
ICD (Muraoka-Cook et al., 2009). The CYT-1 ICD probably decreases mammary epithelial cell 
proliferation by reducing of the rate of cell cycle progression, whereas CYT-2 ICD promotes cell 
proliferation by increasing cyclinD via the wnt-β-catenin signalling pathway (Sartor et al., 2001; 
Muraoka-Cook et al., 2006b; Strunk et al., 2007). CYT-1 ICD expression promotes cell apoptosis 
during serum starvation, whereas the CYT-2 ICD prevented this effect (Naresh et al., 2006; Feng et 
al., 2007; Muraoka-Cook et al., 2009). A mammary cell line exogenously expressing CYT1-ICD 
formed more acinar structures in 3D culture when compared with the cells expressing CYT2-ICD 
(Muraoka-Cook et al., 2006a), indicating that CY1-ICD promotes differentiation of these cells. In 
vivo, transgenic mice expressing CYT-1 ICD have distended mammary ducts filled with secretory 
material and ductal epithelium that consists of multiple cell layers. Furthermore, fewer terminal end 
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buds were observed in the mammary glands of mice expressing CYT-1 ICD compared to those of 
mice expressing CYT-2 ICD (Muraoka-Cook, Sandahl et al. 2009). These studies suggest that 
CYT-1 ICD and CYT-2 ICD have different roles in the regulation of mammary development. 
Taken together, this work shows that the CYT-1 ICD and CYT-2 ICD can exert divergent functions 
in cells. 
In addition to studies where the CYT-1 ICD and/or CYT-2 ICD are expressed in cells, others have 
noted profound differences in the function of full length ErbB4 receptors in vivo. One seminal study 
directly compared the functions of the intact JM isoforms by overexpressing full-length JM-a and 
JM-b in mouse embryonic astrocytes in an ErbB4-null background. The findings demonstrated that 
only the cleavable JM-a isoform is capable of suppressing astrocyte differentiation (Sardi et al., 
2006). This supports the idea that the intact isoforms of ErbB4 may also have distinct functions in 
vivo. In the heart, there have been no studies examining the distinct function of each ErbB4 isoform.   
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1.5 Cardiomyocyte proliferation 
Amphibia and fish can repair their injured hearts by cardiac regeneration. Initially, this regeneration 
was attributed to stem cells inherent in the heart (Lepilina et al., 2006), but the contemporary view 
challenges this idea. Recently, with the assistance of genetic fate mapping technology, researchers 
have been able to follow the fate of newly generated cells and this has been applied to trace the 
source of newly generated cardiomyocytes (Jopling et al., 2010; Kikuchi et al., 2010). In a genetic 
fate mapping model, zebrafish with the cardiac-specific cmlc2a (cardiac myosin light chain 2a) 
promoter driving the expression of tamoxifen-inducible Cre recombinase were crossed with animals 
possessing a GFP gene with its stop codon flanked by loxP sites. In the offspring, the pre-existing 
cardiomyocytes can be induced to express GFP by tamoxifen treatment. If the newly generated 
cardiomyocytes also expressed GFP, this suggests that the new cells are generated from pre-existing 
cardiomyocytes; if not, it is potentially from other source, such as stem cells. With this method, two 
groups independently demonstrated that heart regeneration in zebrafish occurs principally from the 
proliferation of pre-existing cardiomyocytes (Jopling et al., 2010; Kikuchi et al., 2010).  
In mammals, it is believed that cardiomyocyte proliferation only occurs during the embryonic stage, 
and that shortly after birth the majority of cardiomyocytes exit the cell cycle and lose the ability to 
proliferate. A study showed that in neonatal mice retain the capacity to regenerate the intact heart 
after the left ventricle apex is resected (Porrello et al., 2011). However, this regenerative capacity is 
only observed in the mice up to seven days. Older mice completely lose the ability for cardiac 
regeneration, suggesting the proliferative potential in neonatal cardiomyocytes is reduced 1-2 weeks 
after birth (Porrello et al., 2011). Genetic fate mapping in this study indicated that the majority of 
new cardiomyocytes originated from preexisting cardiomyocytes (Porrello et al., 2011). This 
suggested that the capacity to regenerate the heart is similar between fish and mammals at or around 
birth. It is generally believed that the adult mammalian heart is not capable of fully regenerating the 
heart following damage (e.g. a myocardial infarction), however the degree to which adult 
mammalian cardiomyocytes can proliferate remains highly controversial.   
Cardiomyocyte proliferation can be measured by immunofluorescence staining for Ki67 or 
phosphorylated histone H3 (pH3), or BrdU incorporation. Ki67 and pH3 are proliferation markers 
that label the cardiomyocytes in the transient mitosis stage. Due to the transient nature of the 
mitosis stage and low proliferation levels of adult cardiomyocytes, pH3 and Ki67 will usually stain 
only the small number of cells that are currently in mitosis. BrdU is a synthetic analog of thymidine. 
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It can be incorporated in the genomic DNA when cells undergo DNA synthesis, and is subsequently 
detected via immunofluorescence. Thus, BrdU incorporation can reflect the total number of 
proliferating cardiomyocytes over a longer time period. However, this method can induce a false 
positive stain in the presence of DNA repair and thus potentially exaggerate the results. Despite the 
limitations of these methods, there is an accumulation of evidence to propose that cardiomyocytes 
can proliferate in postnatal mice in response to injury or various stimuli. Beltrami et al. showed that 
in the infarcted heart, the fraction of myocytes undergoing mitosis (labeled by Ki67) is 4 percent in 
the region adjacent to the infarct and 1 percent in those in regions distant from the infarct (Beltrami 
et al., 2001). Treatment with periostin to induce the reentry of differentiated cardiomyocytes into 
the cell cycle contributed to a reduction in infarct size and improvement of cardiac function in a 
rodent infarction model (Kühn et al., 2007). Similarly, infusion of the ErbB4 ligand (NRG1) in 
adult mice significantly increased the proliferation of mononucleated cardiomyocytes (measured by 
BrdU incorporation) (Bersell et al., 2009). Interestingly, both the NRG1 and periostin-induced 
cardiomyocyte proliferation is PI3K-dependent. Inhibition of ERK1/2 with compound PD985059 
(1µM) did not inhibit the periostin-induced cell-cycle reentry, whereas inhibition of the PI3K 
pathway by LY294002 (10 µM) or its downstream signalling Akt pathway by SH-6 (10 µM) fully 
inhibited periostin-induced cardiomyocyte cell-cycle reentry (Kühn et al., 2007). Using functional 
inhibition with PTEN (a PI3K inhibitor), Bersell et al. demonstrate that the NRG1-induced 
proliferation of adult cardiomyocytes also required the PI3K pathway (Bersell et al., 2009).  
Although these observations strongly suggest that cardiomyocytes in the adult mouse can proliferate 
in response to various stimuli, there is a study that argues against this. With genetic fate mapping in 
mice, Hsieh et al. showed that the percentage of GFP positive cardiomyocytes was significantly 
reduced after infarction, indicating dilution of the pre-existing cardiomyocytes by the proliferation 
of stem or progenitor cells and their subsequent differentiation into new cardiomyocytes. This 
suggested that in the adult mouse heart, injury-induced cardiac repair depends more on the 
proliferation of cardiomyocyte progenitor cells or stem cells rather than fully differentiated 
cardiomyocytes (Hsieh et al., 2007). Irrespective of the source of the regenerated cardiomyocytes, 
these studies describe above demonstrated that adult mammalian cardiomyocytes can be 
regenerated to at least some degree.  
The proliferation of cardiac cells discussed above has all been investigated in animal models. 
Measuring the degree of cardiomyocyte regeneration in humans is more challenging. Two recent 
studies have directly measured cardiomyocyte proliferation rates in the human heart. Bergmann et 
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al. established the age of cardiomyocytes in human heart by taking advantage of the integration into 
DNA of carbon-14 generated by nuclear bomb testing during the cold war (Bergmann et al., 2009). 
With mathematical modelling, they revealed that the cardiomyocyte turnover rate gradually 
decreased from 1% per year at the age of 25 to 0.45% at the age of 75. In contrast, the non-
cardiomyocyte turnover rate is up to 18% per year depending on the cell type. All together, less 
than half the cardiomyocytes are refreshed during a normal life span, and 55% of cardiomyocytes 
persist from birth. In another study, cardiomyocyte proliferation in human heart was examined by 
analysing the incorporation of iododeoxyuridine (Idu, a thymidine analog) in postmortem samples 
obtained from cancer patients who were treated with this drug (Kajstura et al., 2010). The portion of 
cardiomyocytes labeled with Idu was 2.5-46%. The large variation in the Idu incorporation rate is 
attributed to the great differences in frequency, period and interval of Idu treatment given to 
patients. Mathematical modelling of this data suggested that the rate of cardiomyocyte renewal is 
around 22%. There is a large variation in the cardiomyocyte renewal rate reported in these two 
studies, from 1% to nearly 22% per year in humans. It is hard to determine which is more accurate 
by direct comparison of the studies given the totally different methods employed. Compared with 
other observations, the annual 22% turnover rate of adult cardiomyocytes seems to be the highest 
report, and thus needs to be carefully considered. Although these studies confirm that there is the 
potential for cardiomyocytes to renew during human lifespan, the functional regeneration of a 
damaged heart appears not to occur. While the innate rate of cardiomyocyte replacement seems 
insufficient to permit complete repair of a damaged heart, the mere existence of a demonstrable 
regenerative response (and its potential to be augmented by various stimuli) is encouraging in 
moving towards directed therapies aimed at improving cardiac repair and function.  
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1.6 Importance of the NRG1-ErbB4 signalling axis 
1.6.1 An introduction to NRG1 
NRG1 (Neuregulin1) is encoded by a large gene (around 1400kb), less than 0.3% of which encodes 
protein (Stefansson et al., 2002). Due to splicing, at least 15 different NRG1 isoforms are generated 
(Buonanno et al., 2001; Falls, 2003). The motif common to all NRG isoforms is an epidermal 
growth factor-like (EGF) domain that is responsible for binding and activation of receptors. NRG1 
can be synthesized as either a secreted protein or membrane precursor. Based on differences in the 
N-terminal sequence, the membrane-inserted NRG1 can be further divided into 3 types, I - III. Both 
type I and type II isoforms are single-transmembrane spanning proteins. Cleavage of these isoforms 
by ADAMs releases bioactive fragments into the circulation, where they then participate in 
paracrine regulation. Type III isoforms are two-transmembrane spanning and will generate a 
membrane anchor fragment containing the EGF-like receptor binding domain after cleavage by 
ADAMs, and thus participate in juxtacrine regulation (Buonanno et al., 2001). Alternative splicing 
at the C-terminus of the EGF-like domain leads to the generation of NRG1α and NRG1β variants. 
NRG1α and NRG1β isoforms have different affinities for the ErbB receptors. The NRG1β isoform 
possess 10-100 times greater bioactivity and a higher affinity for ErbB3 and ErbB4, whereas the 
predominant isoform expressed in cardiovascular system is NRG1α (Cote et al., 2005). Thus, 
although NRG1α is the predominant isoform in heart, the NRG1β isoforms may be equally 
important. Combined with the structural differences in other domains, at least 3 different NRG1α 
isoforms and 8 NRG1β isoforms are expressed in the adult heart (Pentassuglia et al., 2009a). 
NRG1 is mainly distributed in the endocardial endothelium and the cardiac microvascular 
endothelium (Kuramochi et al., 2004; Lemmens et al., 2006), which share a common embryonic 
lineage (Misfeldt, 2008). Whether it is expressed in larger veins is controversial - some studies have 
reported NRG1 expression in human coronary artery endothelial cells (Hedhli et al., 2011), whereas 
others have failed to detect it in coronary arteries or aortic endothelium (Lemmens et al., 2006). The 
released NRG1 can target cardiomyocytes and regulate their growth (Zhao et al., 1998; Giraud et al., 
2005), survival (Liu et al., 2006), contraction (Brero et al., 2010) and proliferation (Bersell et al., 
2009).  
1.6.2 NRG1 signalling and cardiomyocyte hypertrophy  
NRG1 potently induces cardiomyocyte hypertrophy in vitro. Treatment of neonatal cardiomyocytes 
with 20-30 ng/ml NRG1 increased L-leucine uptake (a marker of protein synthesis), expression of 
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the hypertrophic genes ANP and α-skeletal actin, and promoted sarcomeric reorganization (Zhao et 
al., 1998; Giraud et al., 2005). Similar results were observed in primary isolated adult 
cardiomyocytes (Zhao et al., 1998; Giraud et al., 2005). NRG1-induced cardiomyocyte hypertrophy 
is thought to be mediated by ErbB2/ErbB4-ERK1/2 signalling. Treatment with 20 ng/ml NRG1for 
5 min induced phosphorylation of ErbB4 and its preferential dimerisation partner ErbB2 in both 
neonatal and adult cardiomyocytes (Zhao et al., 1998). Intravenous administration of 10μg/kg 
recombinant human NRG1 (rhNRG1) in mice for 10 min induced phosphorylation of ERK in the 
heart, which reached a 7-fold increase after 90 min treatment (Liu et al., 2006). The rhNRG1-
enhanced sarcomeric organization was blocked by the ERK pathway inhibitor PD98059, but not the 
PI3K kinase inhibitor Wortmannin, suggesting that the rhNRG1-enhanced sarcomere organization 
is via ERK, but not PI3K, signalling pathways (Liu et al., 2006). Activation of ERK1/2 promotes 
protein synthesis and sarcomere reorganization during NRG1 induced cardiomyocyte hypertrophy. 
Activation of ErbB2 by treating cardiomyocytes with an ErbB2 activating antibody induced 
phosphorylation of ERK1/2, demonstrating that ErbB2 phosphorylation is sufficient for activation 
of ERK1/2. In contrast, ErbB2 inhibition reduces basal phosphorylation of ERK1/2 (Fukazawa et 
al., 2003).  
1.6.3 NRG1 signalling in cardiac protection 
NRG1 can be released from cardiac microvascular endothelial cells (CMEC) under conditions of 
oxidative stress. H2O2 increased the NRG1 level in culture medium of CMECs (Kuramochi et al., 
2004) in vitro, whilst in vivo ischaemia-reperfusion injury increased the NRG1 level in the perfused 
coronary effluent (Kuramochi et al., 2004). The released NRG1 appears to have a cardioprotective 
effect. Liu et al. showed that NRG1 improved both cardiac performance and survival in various 
models of LV failure, including the LAD ligation infarct model, doxorubicin-induced 
cardiomyopathy model, Coxsackie virus B3-induced myocarditis model, and a chronic rapid pacing 
model (Liu et al., 2006). The cardioprotective effect of NRG1 is attributed, at least in part, to its 
ability to promote cardiomyocyte survival and enhance myofibril organization.  
Primary neonatal cardiomyocytes deprived of serum in culture exhibit a gradual loss in cell viability 
(Zhao et al., 1998). Addition of NRG1 into the culture medium increases cell viability by 30% 
compared to the control (as measured by the activity of NAD(P)H-dependent cellular 
oxidoreductase enzymes using the colorimetric assay MTT) (Zhao et al., 1998). In addition, NRG1 
treatment also significantly decreases apoptosis (measured by TUNEL) of primary cardiomyocytes 
in serum-free medium (Zhao et al., 1998). A microarray study showed that NRG1 increased the 
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expression of oxidative stress defense related factors (e.g. thioredoxin) and reduced expression of 
the apoptosis factors, harakiri (HRK) and programmed cell death 2 (PDCD2) in cardiomyocytes, 
which may also contribute to cardiomyocyte survival (Giraud et al., 2005). 
During cardiomyocyte damage, myofibrillar disarray and myofibril loss are often observed. NRG1 
treatment significantly attenuates the myofibrillar disarray and myofibril loss induced by 
doxorubicin. This attenuation contributes to the preservation of cardiac function in these animals 
(Bian et al., 2009). Troponin is a complex of three regulatory proteins (troponin C, troponin I, and 
troponin T) that is integral to cardiac muscle contraction. The degradation of myofibrils releases the 
troponin subunits into the blood, where they are important markers for detection of myocardial 
injury (Katus et al., 1991; Adams et al., 1993). Doxorubicin treatment significantly decreases levels 
of cardiac troponin in mice, an effect that is attenuated by administration of NRG1 (Bian et al., 
2009). In agreement with this, another study showed that NRG1 reduces both troponin I release into 
serum (which occurs during cardiomyocyte damage) and histological alterations associated with 
myocarditis (Muraoka-Cook et al., 2006a).   
The ErbB-PI3K-Akt pathway was proposed to be the central downstream signalling pathway that 
mediates the ability of NRG to modulate the survival and function of cardiomyocytes (Brero et al., 
2010; Fang et al., 2010; Jie et al., 2012; An et al., 2013). For instance, treatment of cardiomyocytes 
with the PI3-kinase inhibitor wortmannin or overexpression of a dominant-negative Akt abolished 
the protective effect of NRG1 on daunorubicin-induced caspase-3 activation and apoptosis 
(Fukazawa et al., 2003). Pretreating cardiomyocytes with anti-ErbB2 antibodies abolished the 
protective actions of cardiac microvascular endothelium (a source for NRG1) against 
cardiomyocyte apoptosis (Lemmens et al., 2006). AG879 (an ErbB2 inhibitor) treatment abolished 
the ability of NRG1 to attenuate the doxorubicin- induced decrease in cardiac troponin I and 
troponin T (Bian et al., 2009), suggesting that the NRG1 induced cardioprotective effect is ErbB2-
dependent.   
1.6.4 NRG1 signalling in cardiomyocyte contraction/relaxation 
Calcium is a critical factor for regulating cardiomyocyte contraction and relaxation. Disorders of 
Ca
2+
 homeostasis contribute to the development of heart failure. Myocyte contraction is regulated 
by Ca
2+
 release from the sarcoplasmic reticulum (SR) into the cytoplasm, and relaxation by uptake 
of Ca
2+
 into the SR. This Ca
2+
 uptake is mediated by SR Ca
2+
 ATPase (SERCA2a). NRG1 can 
enhance cardiomyocyte relaxation by regulating the Ca
2+
 uptake. NRG1 induced activation of 
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PI3K/Akt promotes the activation of PKG (Mery et al., 1991; Brero et al., 2010), which enhances 
the relaxation of cardiomyocytes by regulating major components of excitation-contraction 
coupling, such as L-type Ca
2+
 channel (LTCC) , phospholamban (PLB) and troponin I (Blumenthal 
et al., 1978). PLB activation promoted the SERCA2a activation (Macdougall et al., 1991; 
Verboomen et al., 1992) and caused Ca
2+
 uptake into the SR (Brero et al., 2010) to enhance 
cardiomyocyte relaxation.  
1.6.5 NRG1 signalling in cardiomyocyte proliferation  
In addition to the functions mentioned above, a role for NRG1 in promoting cardiomyocyte 
proliferation has also been proposed. Zhao et al. demonstrated that treatment with NRG1 for 30h 
caused an approximately 2 fold increase in DNA synthesis in embryonic cardiomyocytes as 
measured by [
3
H]-thymidine uptake. NRG1 also significantly increased the [
3
H]-thymidine uptake 
in neonatal cardiomyocytes cultured in serum-free medium (Zhao et al., 1998). In addition to 
promoting DNA synthesis, NRG1can also stimulate cell division, including both karyokinesis and 
cytokinesis. Bersell et al. detected cytokinesis in cardiomyocytes by using immunofluorescence to 
stain the marker protein aurora B kinase, which is required for contractile ring formation in 
cytokinesis. They found the number of positively stained cells was significantly increased by NRG1 
treatment. A similar result was observed for karyokinesis measured with video microscopy (Bersell 
et al., 2009). Interestingly, the effect of NRG1 on cardiomyocyte proliferation may be dictated by 
the degree of stimulation. Zhou et al. showed that the maximum proliferative effect of NRG1 
occurs at 0.1 nM (Zhou et al., patent application published as WO00/37095). Similar to this, Bersell 
et al. also showed an increased DNA synthesis in response to NRG1, which was maximal between 
0.1-1nM (Bersell et al., 2009). At higher concentrations, NRG1 may inhibit DNA synthesis due to 
the persistent activation of the MAPK signalling pathway, which inhibits CyclinD to arrest the cell 
at G1 phase (Zhou et al., patent application published as WO00/37095). Direct evidence that NRG-
induced cardiomyocyte proliferation is mediated by ErbB4 is also provided by Bersell et.al. (2009). 
Administration of NRG1 induced 14.3% of mononucleated cardiomyocytes to proliferate (as 
indicated by BrdU incorporation) in the adult mice heart, and this proliferation was attenuated in 
transgenic mice with cardiac-specific deletion of ErbB4. In cultured adult cardiomyocytes, blocking 
ErbB4’s preferential dimerisation partner ErbB2 with an inhibitory antibody also decreased DNA 
synthesis (Bersell et al., 2009), suggesting an critical role of the ErbB2/ErbB4 dimer in mediating 
NRG1-induced proliferation. 
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1.6.6 Interactions between NRG1 signalling and the endocrine system 
As a critical paracrine factor that is potentially beneficial to the heart, it is important that the 
synthesis and release of NRG1 is adaptive to cardiac activity. Indeed, the expression and release of 
NRG1 is controlled, at least partially, by endocrine factors or stimuli such as pressure overload. As 
mentioned earlier, NRG1 (detected in perfused coronary effluent) can be released from the 
microvascular endothelium in response to ischaemia-reperfusion (Kuramochi et al., 2004). In 
addition to that, stretch induces the expression of NRG1 in cardiac microvascular endothelium. 
Correspondingly, transverse aortic constriction (TAC) induces the up-regulation of NRG1 in the 
heart (Lemmens et al., 2006). A study showed that NRG1, in primary isolated microvascular 
endothelial cells, is increased by endothelin-1 treatment (Zhao et al., 1998). In contrast, Ang II and 
phenylephrine decreased the expression of NRG1 in cardiac microvascular endothelium (Lemmens 
et al., 2006). Due to the beneficial effects of NRG1 on cardiac tissues (as discussed above), the up-
regulated NRG1 might serve as a mechanism to counterbalance the effect of pathological stimuli 
and thus protect the cardiomyocytes to some degree in these pathological conditions. In contrast, in 
other conditions, such as activation of RAS system, the NRG1 down-regulation might facilitate the 
progression of the cardiac disease. NRG1 also provides a negative feedback on these stimuli. 
Treatment with NRG1 in LAD ligation mice significantly reduced the increased concentrations of 
renin, AngI, Ang II and aldosterone in the circulation, suggesting that the rhNRG1 attenuated 
activation of the renin-angiotensin-aldosterone axis (Muraoka-Cook et al., 2006a). Besides, NRG1 
can interact with adrenergic signalling to regulate cardiomyocyte contractility, where it has been 
demonstrated that NRG1 reduces the contractile response of cardiomyocytes to α-adrenergic 
stimulation (Lemmens et al., 2004). Cardiomyocytes lacking effective neuregulin signalling (NRG-
gene mutant animals) are unable to counterbalance the adrenergic effect (Okoshi et al., 2004). 
1.6.7 Function of ErbB2 and ErbB4 in the heart  
The importance of NRG1 signalling highlights the potential role of its receptor, ErbB4 and its 
preferred dimerisation partner (ErbB2) in adult heart function. ErbB3 can also bind with NRG1, 
however, ErbB3 expression is not detectable in the adult heart (Campreciós et al., 2011). ErbB2 is 
overexpressed in breast cancer (Houston et al., 1999; Sørlie et al., 2001), and monoclonal 
antibodies targeting ErbB2 have been used in treatment of this disease. The monoclonal antibody 
for ErbB2, trastuzumab, has been trialled for breast cancer therapy, but its administration increases 
the risk for cardiac dysfunction: the incident rate was 27% in patients receiving trastuzumab and 
anthracycline-containing chemotherapy, compared with 8% incidence among patients who received 
chemotherapy alone (Seidman et al., 2002). Despite the fact that anthracycline is also cardiac toxic 
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and trastuzumab-induced cardiac dysfunction is reversible (79% patients improved after receiving 
standard treatment for congestive heart failure), this clinical observation led to the idea that ErbB2 
signalling is critical in the adaptive response of adult heart to stress (Seidman et al., 2002). A 
further study using ErbB2 conditional knockout animal models confirmed the importance of ErbB2 
in cardiac function and structural maintenance (Özcelik et al., 2002). In this study, the MLC-2V 
promoter was used to drive expression of Cre recombinase to specifically induce deletion of ErbB2 
from 50-60% cardiomyocytes in heterozygous ErbB2
flox/+
 animals. There were no functional or 
morphological differences between the wild type and mutant animals at birth, but the mice with 
ErbB2 deletion developed severe cardiomyopathy in adulthood. This cardiomyopathy was 
characterised by cardiac dysfunction (i.e., a decreased fractional shortening measured by 
echocardiography), dilatation of both ventricles (i.e., increased chamber size with thinned walls) 
and cardiac hypertrophy (Özcelik et al., 2002). In support of this, cultured adult myocytes treated 
with a non-activating ErbB2 specific antibody display myofilament disarray (Pentassuglia et al., 
2009b), which was significantly increased following co-treatment with chemotherapeutic agents 
like doxorubicin.   
Given ErbB2 does not bind EGF ligands and is instead activated by forming dimers with other 
ligand-stimulated ErbB receptors (particularly ErbB4 in heart), the above observations lead to the 
hypothesis that the NRG1-ErbB4 interaction likely plays an important role in adult heart. 
Accordingly, global deletion of ErbB4 leads to death during mid-embryogenesis due to the 
defective development of myocardial trabeculae in the ventricles (Gassmann et al., 1995). The heart 
defects in ErbB4 mutant mice could be rescued by cardiac-specific expression of ErbB4 (driven by 
a myosin promoter). These rescued mice reached adulthood and were fertile, suggesting that ErbB4 
is critical for heart development (Tidcombe et al., 2003). In contrast to global deletion, cardiac-
specific deletion of ErB4 using Cre (under the MLC-2V promoter) did not cause embryonic 
lethality, nor did it alter cardiac morphology or function in neonatal mice. It is important to note 
that the MLC-2v promoter becomes active during the differentiation of ventricular cardiomyocytes, 
which might be later than the initiation of the heart generation (Klug et al., 1996; Franco et al., 
1999). However, when mice with cardiomyocyte-specific deletion of ErbB4 reached adulthood, 
they developed dilated cardiomyopathy that was characterised by thinning of the ventricular walls, 
eccentric hypertrophy, reduced contractility and conduction delays (Garcia-Rivello et al., 2005). 
Interestingly, conditional knockout of ErbB4 also caused alterations in the morphology of 
intercalated disks and an abnormal distribution of ErbB2 on the plasma membrane, indicating that 
Chapter 1: General introduction 
 
35 
 
ErbB4 may play an important role in maintaining cell-cell contact and ErbB2 localisation (Garcia-
Rivello et al., 2005).   
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1.7 The rationale and aims for this project 
In the past 10 years, the transactivation of ErbB1 by Ang II has been shown in various cell types, 
including cardiomyocytes, renal epithelial cells, and cell lines such as hepatic C9, cos-7 and MCF-7 
cells (Eguchi et al., 1998; Thomas et al., 2002; Muscella et al., 2003; Shah et al., 2004; Chen et al., 
2006). However, previous experiments in our laboratory (Hsiu-wen Chan, PhD thesis) showed that 
ErbB4 agonists selectively induce cardiomyocyte hypertrophy (as measured by the increase in 
protein/DNA ratio and reorganisation of the actin cytoskeleton), whereas the ErbB1 selective 
agonist, EGF, did not. Thus, it seems that in cardiomyocytes, ErbB4 receptor activation might be a 
stronger stimulus for hypertrophy than ErbB1 activation, and opens up the untested possibility that 
Ang II/AT1R may transactivate ErbB4 in this setting. As a consequence, based on the studies 
above, the first aim of my PhD project is to investigate the role of ErbB4 receptors in Ang II-
mediated cardiomyocyte hypertrophy. 
As discussed above, ErbB4 is spliced into four isoforms (JM-a CYT-1, JM-a CYT-2, JM-b CYT-1 
and JM-b CYT-2) that have unique characteristics. Whilst preliminary observations indicate that 
these four ErbB4 isoforms are present in rat cardiomyocytes (Hsiu-wen Chan, PhD thesis), this 
finding needs to be confirmed and quantified. There is also no information as to whether the 
processing of the ErbB4 receptor (to cleave and release the extracellular and intracellular domains) 
occurs in cardiomyocytes and if this can be stimulated by GPCRs like the AT1R. Furthermore, 
whether ErbB4 isoforms and/or their processing contribute equally to cardiomyocyte hypertrophy 
has not been examined. Thus, the second major aim of my study will be to investigate the role 
of ErbB4 isoforms in mediating cardiomyocyte hypertrophy.   
Finally, NRG1-ErbB4 signalling is critical for heart development, anti-apoptosis and hypertrophy 
(refer to section 1.6). Despite the power of the elegant transgenic approaches (detailed above) to 
reveal potential functions for ErbB4 in heart, it is critical to appreciate that these models all 
modulate deletion of ErbB2 or ErbB4 in the embryo. Thus, the likelihood that the phenotypes 
observed in adulthood are caused by defects in cardiac development cannot be completely excluded. 
In order to unambiguously link the ErbB4 receptor to cardiac function in the adult, my final aim is 
to develop a cardiomyocyte-specific conditional deletion of ErbB4 in mice and investigate the 
cardiac phenotype of these mice. 
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2. General Methods 
2.1 Animal Ethics statement  
1-2 day old neonatal rats (Sprague Dawley) were used for cardiomyocyte isolation and handled in 
accordance with the Australian code of practice for care and use of animals for scientific purposes 
under ethics approval number SBMS/237/09/NHMRC/NHF “Regulation of cardiac hypertrophy” 
from the University of Queensland Ethics Committee. 
All experiments in Chapter 5 were done under the ethics approval number SNMS/253/12/NHMRC 
“Growth factor receptors in cardiac hypertrophy”. The animals were bred under the ethics approval 
numbers SBMS/295/11/NHMRC/BREED “Cardiac-specific gene deletion-floxed ErbB4 mice” and 
SBMS/294/11/NHMRC/BREED “Cardiac-specific gene deletion-creER mice”. 
2.2 Chemicals and reagents 
All chemicals and reagents were analytical or cell culture grade and purchased from Sigma-Aldrich 
(New South Wales, Australia), Invitrogen (Victoria, Australia), Applied Biosystem (Victoria, 
Australia), Thermo Fisher Scientific (Victoria, Australia), Qiagen (Victoria, Australia), Gibco 
(Victoria, Australia) and New England Biolabs (Massachusetts, USA). Plasticware such as Falcon 
tube, Eppendorf tube, pipette tips, cell culture flasks/plates were purchased from Corning Life 
Science (New South Wales, Australia), Biopointe Scientific (California, USA) and Eppendorf South 
Pacific (New South Wales, Australia). Suppliers for each chemical or reagent will be listed in each 
research chapter where they were used.  
2.3 Vector constructs 
 The ErbB1 shRNA and ErbB2 shRNA expressing vectors (shErbB1 and shErbB2) were 
constructed by James Goonan and the ErbB4 shRNA expressing vector (shErbB4) by Dr Hsiu-wen 
Chan. The shRNA knockdown-resistant isoform of ErbB4 (kdr-JM-a CYT1; kdr-JM-a CYT2; kdr-
JM-b CYT1; kdr-JM-b CYT2) were constructed and tested by Dr Hsiu-wen Chan. The luciferase 
reporter plasmids driven by hypertrophic gene promoters (MLC-2V, ANP-328, and CyclinD) were 
gifts from Dr Mona Nemer (Canada). The GFP tagged isoforms of ErbB4 (pEGFP-N1-JM-a CYT-
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1, pEGFP-N1-JM-a CYT-2, pEGFP-N1-JM-b CYT-1 or pEGFP-N1-JM-b CYT-2) were 
constructed by myself as described in Chapter 4 method 4.2.5. 
2.4 Cell culture 
2.4.1 Cardiomyocyte culture 
Neonatal ventricular cardiomyocytes preparations were performed by myself, Dr. Brooke Purdue, 
Dr. Simon Foster, Dr. Tamara Paravicini and Mr. Gregory Quaife-Ryan. 1-2 day old Sprague 
Dawley rat pups were sacrificed by decapitation. Hearts were harvested and atria were carefully 
removed. The ventricles were cut into multiple pieces and subject to 7 enzyme digestions (0.03% 
collagenase and 0.08% pancreatin). Each digestion was processed at 37°C for 20 min using a water 
jacketed spinner flask. The first collection rich in blood cells was discarded. The other collections 
were kept on ice and combined with newborn calf serum to neutralize the enzymes. The cells were 
centrifuged at 1000×g for 6 min at 4°C and then resuspended with ADS buffer (refer to the 
Appendix A). The cardiomyocytes were isolated from non-myocardial cells using discontinuous 
percoll gradient centrifugation. The percoll gradient was prepared by adding 4 ml 40% percoll 
(diluted in ADS) on top of 3 ml 59 % percoll in 15 ml sterile falcon tube. Around 2 ml of cell 
suspension was overlaid on top of the percoll gradient before centrifugation (3000 rpm for 30 min). 
After centrifugation, there were two cell layers: the upper layer is rich in fibroblasts, whilst the 
lower layer is rich is cardiomyocytes. The purified cardiomyocytes were collected and washed in 
ADS buffer twice before being seeded in 0.1% gelatin-coated cell culture plates with MEM culture 
medium (supplemented with 10% newborn calf serum, 5- bromo-2’-deoxyuridine (BrdU) and 
antibiotics). The next day, cardiomyocytes were washed twice with PBS and maintained in DMEM 
CCT SS2 (refer to Appendix A). DMEM CCT SS2 is the serum free media (using vitamins, amino 
acids, insulin etc. to replace FBS) used for ongoing cardiomyocyte culture, with BrdU to prevent 
fibroblast proliferation and 50 mM KCl to stop spontaneous contraction. 
2.4.2 Maintenance of CHO and HEK293-T cell lines 
 HEK293-T cell and CHO cells were maintained in DMEM supplemented with 10% FBS and 
antibiotics. All cells were incubated at 37°C in a humidified 5% CO2 incubator. When confluent, 
cells were passaged by washing once with PBS and then incubating with 0.25% Trypsin-EDTA 
(Invitrogen Australia) at 37°C for 1-3 min. Culture media was added to stop the digestion followed 
by centrifugation (3000 rpm for 3min). The supernatant was removed and the cells were 
resuspended in culture medium before plating. 
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2.4.3 Drug treatment 
Cells were incubated in serum free media for a day prior to drug treatment. Cells were treated with 
various agonists (Ang II and NRG1β1) and inhibitors (AG1478) at certain concentrations for the 
indicated time at 37°C. Treatment was terminated by washing cells with ice-cold PBS and 
incubating cells on ice. 
2.5 DNA/siRNA Transfection 
2.5.1 DNA Transfection 
DNA were transfected into cells using lipofectamine 2000
TM
 (Invitrogen) according to the 
manufacturer’s instruction. The protocols used for transfection of cardiomyocytes and cell lines are 
slightly different and will be briefly described here.  
For luciferase assay, cardiomyocytes in 12 well plates were transfected in 360μl Opti-MEM 
(Invitrogen) containing 0.8 μl lipofectamine 2000TM and total of 500ng DNA for luciferase assays. 
The lipofectamine 2000
TM
 and DNA were individually diluted in 45µl Opti-MEM and incubated 
separately for 5 min at room temperature before mixed together for another 30 min incubation. 
Then the DNA and lipofectamine 2000
TM 
mixture was added to individual cell culture wells 
containing 270 μl Opti-MEM. After 6 hours or overnight, the transfection medium was changed 
into the normal culture medium for cardiomyocytes (DMEM CCT SS2). 
HEK293-T cells or CHO cells were seeded onto 6 well plates and transfected in 2ml Opti-MEM 
containing 500-600 ng DNA and three times the amount lipofectamine 2000
TM
 relative to the DNA 
amount (1.5-1.8 µl). The lipofectamine 2000
TM
 and DNA were individually diluted in 100 µl Opti-
MEM and incubated separately for 5 min at room temperature before mixed together for another 30 
min incubation. The DNA and lipofectamine 2000
TM 
mixture was then added to individual cell 
culture wells containing 1.8 ml Opti-MEM. The cells were incubated with the transfection reagents 
for 6 hour before the Opti-MEM was replaced with normal culture media (DMEM supplemented 
with 10% FBS). At 24-48 hours after transfection, cells were harvested and subjected to Western 
blot analysis. 
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2.5.2 siRNA transfection 
The cardiomyocytes can be transfected with siRNA via forward or reverse methods. Both methods 
can induce efficient knockdown and were developed separately by myself (reverse method) and Ms. 
Choon Boon Sim (forward). For forward transfection, 5 µl Lipofectamine® RNAiMAX  
(Invitrogen) and 2 µl siRNA (20 µM) was individually suspended in 250 µl DMEM CCTSS2 
(antibiotic free) and incubated at room temperature for 5-10 min. siRNA and lipid were mixed 
together and subject to 30 min incubation before being applied to one well of a 6 well-plate, which 
already contained 1.5 ml DMEM CCTSS2. For reverse transfection, the same amount of 
Lipofectamine® RNAiMAX and siRNA was suspended in 250 µl DMEM (antibiotic and serum 
free). After incubation, the DNA and lipid mixture was mixed with 1.5 ml cell suspension (1.8×10
6
 
cells in antibiotic free DMEM supplied with 13% serum) and then added to one well of a 6 well-
plate. For both reverse and forward methods, the transfection medium was changed into normal 
cardiomyocyte culture medium (DMEM CCTSS2) 24 h later. For detection of phosphorylated 
ERK1/2 in cardiomyocytes (Figure 3.6), the reverse transfection method was used. For the 
hypertrophy assay, the forward transfection (Figure 3.7) was used. The forward transfection 
efficiency is shown in Figure 3.5, and the reverse transfection had a similar efficiency with the same 
siRNA (data not shown). The reason I switched from reverse transfection to forward transfection is 
because the latter is easier to handle. The forward transfection method was developed by Ms. 
Choon Boon Sim in our lab after I finished the experiments shown in Figure 3.6. 
2.6 Luciferase assays 
To detect the activation of the hypertrophic genes (ANP, CyclinD and MLC-2V), hypertrophic gene 
promoter driven luciferase reporters were constructed by fusing the core sequence of each promoter 
to the firefly luciferase reporter. The reporter constructs for ANP, CyclinD and MLC-2V have been 
described previously (Henderson et al., 1989; Knowlton et al., 1991; Suzuki-Yagawa et al., 1997). 
Cardiomyocytes seeded in 12 well plates were transfected with 300 ng of luciferase reporters along 
with other DNA constructs (100 ng AT1R and 100 ng shRNA). 24-48 h after transfection, 
cardiomyocytes were stimulated with agonists for 48 h. Then cells were washed with ice-cold PBS 
twice and lysed with 150 μl of Luciferase Cell Culture Lysis Reagent (Promega). To ensure 
sufficient lysis, cells were subjected to a cycle of freezing and thawing at -80°C and room 
temperature and scraped off from the plates. Cell lysates were collected into 1.5 ml Eppendorf tube 
before centrifuged at 12,000 x g for 2 min at 4°C. 20 μl aliquots of supernatant were transferred to a 
96-well white flat-bottomed assay plates. Luminometry was performed with an Optima microplate 
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Reader (BMG LABTECH Company) and 100 μl Luciferase Assay Mix (Promega) was injected into 
each well containing cell lysate. 
2.7 Protein extraction and Western analysis 
2.7.1 Protein extraction and BCA assay 
To detect ErbB receptors, total and phosphorylated ERK1/2 proteins were extracted from 
cardiomyocytes or cell lines (HEK-293 or CHO). Cells were washed with PBS and harvested with 
RIPA lysis buffer (a strong denaturing buffer). For cell lines cultured on 6 well plates, 200 µl RIPA 
lysis buffer was applied per well. For cardiomyocytes, 70-80 µl RIPA lysis buffer was applied to 
each well. Cells were scraped off on ice and the lysate collected into 1.5 ml Eppendorf tube and 
vortexed before centrifugation at 12000 x g for 15 min at 4°C. The supernatant was transferred into 
new Eppendorf tubes (pre-chilled). The concentration of total protein was estimated with the BCA 
assay according to the manufacturing instruction (Thermo Scientific Pierce BCA Assay Kit). 
Briefly, 25 μl cell lysates were added into 96 well plates (in triplicate) and mixed with 200 μl BCA 
working reagent (Thermo Scientific Pierce BCA Assay Kit). Standard samples were prepared using 
Bovine Serum Albumin (Sigma) dissolved in the same lysis buffer. After 30 min of incubation at 
37°C (with plates covered by membrane), samples were analysed for absorbance at 560nm with an 
Optima microplate reader (BMG Labtech). 
2.7.2 SDS-PAGE and Western blot analysis 
To separate proteins according to their size, total proteins were resolved by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using the Mini-PROTEAN gel system 
(Bio-Rad) (for samples ≤ 50 µl) or SE600 gel system (Hoefer) (for samples ≥ 50 µl). Protein 
samples were mixed with SDS loading buffer and boiled for 5 minutes at 95°C. Protein samples and 
a molecular weight standard (Precision Plus Protein™ Dual Color standards, BIO-RAD) were 
electrophoresed at 100V for approximately 2 h (Mini-PROTEAN gel) or at 25 mA for 5 h (SE600 
gel) using PowerPac
TM
 Basic Power Supply (Bio-Rad). Then proteins were transferred onto 
polyvinylidene fluoride (PVDF) membrane using Mini Trans-Blot Cell system (for small gels) at 60 
volts for 1.5 h (for small size proteins such as ERK1/2) or Trans-Blot Cell system (for large gels) 
(Bio-Rad) at 400 mA for 5-6 h (for larger proteins such as ErbB receptors). The membrane was 
incubated with blocking buffer (Odyssey) at RT for 1h and then with primary antibody (1:1000 
dilution in blocking buffer) at 4°C overnight. The membrane was washed with washing buffer (PBS 
with 0.1% Tween20) for 4 times for 5 min each and incubated with the secondary antibody for 1 h 
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at RT (1:10000 dilution in blocking buffer). After further washing, membranes were scanned using 
an Odyssey Licor Scanner (LI-COR Biosciences). 
2.8 RT-qPCR 
2.8.1 RNA extraction 
To analyse mRNA for gene expression, RNA was extracted from animal tissues or cultured cells 
using TRIzol reagent (Invitrogen) according to the company’s instruction. Briefly, for cells cultured 
in 6 well plates, media was removed and cells washed with PBS before adding 1 mL of TRIzol per 
well. For animal tissues (heart and skeletal muscle), ~20 mg of tissue was homogenised in a 2 ml 
Eppendorf tube containing 500 µl TRIzol reagent using a Polytron tissue homogeniser 
(Kinematica). To remove the fat and extracellular connective tissues, tissue samples were 
centrifuged at 12000×g for 10 min at 4°C following homogenization, The supernatant containing 
RNA was collected into a new tube and the pellet containing fat and extracellular connective tissues 
were discarded. Then chloroform (1/5 volume relative to the amount of TRIzol) was added to the 
cell lysate or homogenised tissue sample. After vigorously mixing by hand, the samples were 
incubated at room temperature for 2-3 min and then centrifuged at 12000×g for 15 min at 4°C. 
Three separate layers were observed after centrifugation. The top aqueous phase was carefully 
transferred into a new tube without drawing any of the interphase or organic layer in the bottom. 
Then ½ volume isopropanol (relative to the TRIzol reagent amount) was added to the aqueous 
phase followed by 10 min incubation at RT. Samples were centrifuged at 12000×g for 10 min at 
4°C and the supernatant removed. The pellet was washed with 1 volume of 75% ethanol (relative to 
the TRIzol reagent amount). The wash was discarded after centrifuge at 7500 g for 5 min at 4°C. 
The pellet was air dried for 5-10 min and resuspended in nuclease-free water at 55°C for 10 min. 
2.8.2 DNase treatment 
DNase I is a nuclease which causes the degradation of almost all forms of DNA (single-strand or 
double strand DNA, DNA-RNA hybrids and chromatin). DNase I treatment is a routine method to 
remove the potentially contaminating genomic DNA from RNA preparation. For this, the isolated 
RNA was treated with using TURBO DNA free kit (Applied Biosystem) according to company’s 
instructions. Briefly, the RNA was treated with DNase I in a 25 µl reaction volume (containing 2 µg 
RNA, 1 µl TURBO DNase, and 1×TURBO DNase buffer) at 37°C for 30 min. The reaction was 
stopped by adding 5 µl DNase inactivation reagent (supplied in TURBO DNA free kit). After 5 min 
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incubation at room temperature, the mixture was centrifuged at 10000 g for 90s. The supernatant 
was carefully collected using a 20 µl pipette without touching the bottom pellet.  
2.8.3 cDNA synthesis 
The mRNA was reverse transcribed into cDNA using the SuperScript
TM 
III Reverse Transcriptase 
Kit (Invitrogen). Briefly, 250 ng of random primers, 500 ng RNA and 10 nM dNTPs were mixed 
and topped up to 13 µl reaction volume with nuclease-free water. After incubation at 65°C for 5 
min, the samples were left on ice for 1 min and supplemented with 200 units SuperScript™ III RT, 
40 units RNaseOUT
TM
 Recombinant RNase Inhibitor, 100 nM DTT, and 1× First-Strand Buffer 
(final concentration). The mixture was collected to the bottom of the PCR tube by brief 
centrifugation and then mixed thoroughly by pipetting. The reverse transcription was performed 
using a PCR machine with the following conditions: 25°C for 5 min (incubation), 50°C for 60 min 
(reverse transcription) and then 70°C for 15 min (inactivation). 
2.8.4 Real-time PCR 
Real-time PCR is a technology that detects the amount of PCR product formed following each cycle 
of the reaction. It uses fluorescent chemicals to detect the generated DNA and combines the 
amplification and detection into one step. Currently, two common types of fluorescent systems are 
used: the SYBR Green reagent and TaqMan probe. SYBR Green dye binds with double-stranded 
DNA formed during PCR and emits much stronger fluorescence signal when bound than when free 
in solution. Thus, the fluorescence signal is in proportion to the amount of total DNA product 
formed. Because the SYBR Green dye binds to all double-stranded DNA, the strength of the 
fluorescence signal does not always reflect the amount of PCR product from the target gene, 
especially if there is non-specific amplification. It is important that the primers are designed to 
specifically amplify the targeted sequence. For some genes, this is very hard due to the shortness 
and/or homology of gene sequences. Thus, a more specific method is often used, such as TaqMan. 
The TaqMan method employs a TaqMan probe and a pair of normal PCR primers. A TaqMan probe 
consists of 18-30 oligonucleotide annealed to the target gene. The primer pair is designed to amplify 
the region the probe anneals to. TaqMan probe is labelled with a reporter dye on the 5’ end and a 
quencher dye on the 3’ end. The quencher reduces the reporter fluorescence by FRET when the 
probe is intact. During the extension step of the PCR, the probe annealed to the DNA template will 
be degraded by the 5’ exonuclease activity of Taq polymerase. The reporter dye then emits the 
fluorescence signal. As the fluorescence signal is only generated if the probe is annealed to 
complementary template, the TaqMan method has higher specificity than SYBR green PCR. The 
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primers or probes and detection method for the targeted genes are listed in Appendix B. The SYBR 
Green PCR assay contained 3 µM of primers, 1× Advanced FAST SYBR Green PCR reagent 
(Applied Biosystems) and 5-10 ng cDNA or DNA template in a 10 µl reaction volume. Thermal 
cycling was performed with StepOnePlus Real-Time PCR system (Applied Biosystem) as: 95°C for 
20 s, followed by 40 cycles of 3s at 95°C and 30s at 60°C. The TaqMan PCR was performed in a 10 
µl reaction volume containing 300 nM of primers (Sigma), 200 nM of probe, 1×Taqman advanced 
fast master mix (Applied Biosystems) and 5-10 ng cDNA templates. Cycling was initiated 20s at 
95°C, followed by 40 cycles of 1s at 95°C and 20s at 60°C.  
2.8.5 Relative quantification of the real-time PCR  
Data from real-time PCR can be analysed using absolute quantification or relative quantification. 
Absolute quantification requires a standard curve, which is used to determine the initial copy 
number of the transcript interest (refer to section 4.2.3). Relative quantification describes the 
expression of target gene in treated group(s) relative to a control. To perform relative quantification, 
the expression of the gene of interest needs to be normalized to an internal control. The internal 
control is usually a house-keeping gene and expressed abundant in majority cell types. In my 
studies, 18S was consistently used as an internal control. Except for the ErbB4 isoforms in Chapter 
4 (described in section 4.2.3), the gene expression data presented in this thesis were all analysed by 
relative quantification using 2
(-ΔΔCT) 
method as described (Livak et al., 2001). 
2.9 Data presentation and statistical analysis 
Results are presented as mean ± standard error of the mean (SEM) throughout. Statistical analysis 
was performed using Graphpad Prism 6 for Windows. For comparison between two groups, 
Student’s t-tests were utilised for data analysis. For multiple comparisons, One-way or Two-way 
ANOVA with Bonferroni or Dunnett’s post-hoc comparisons were used. The adopted statistical 
analysis method is indicated in the figures or the method section in each chapter 
. 
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3. The role of ErbB receptors in Ang II-induced 
cardiomyocyte hypertrophy  
3.1 Background 
Cardiac hypertrophy is characterised by cardiomyocyte growth and extracellular matrix 
accumulation. It is an independent risk factor for heart failure, myocardial infarction, arrhythmias 
and other cardiac morbidity and mortality (Frey et al., 2003; Adabag et al., 2010). Cardiac 
hypertrophy can be induced by physiological stimuli (e.g. pregnancy or exercise training) or 
pathological stimuli (e.g. the pressure/volume overload associated with hypertension, or increased 
production of circulating or paracrine pro-hypertrophic factors) (Solomon et al., 2009; Iwata et al., 
2011). Angiotensin II (Ang II) is a key component of the renin-angiotensin system that is a major 
regulator of blood pressure and cellular growth. Whilst Ang II can cause cardiac hypertrophy 
subsequent to hypertension, it can also directly induce cardiomyocyte hypertrophy (Paradis et al., 
2000; Schultz et al., 2002). We have previously shown that Ang II can directly promote 
cardiomyocyte hypertrophy via activation of the AT1AR and Gq protein coupling (Thomas et al., 
2002; Smith et al., 2011). At the molecular level, Ang II-induced cardiomyocyte hypertrophy is 
characterized by the re-induction of the ‘fetal gene program’ (increased expression of ANP, 
CyclinD and MLC-2V), along with reorganization of the cardiomyocyte sarcomere (Sadoshima et 
al., 1993; Aoki et al., 1998). However, the exact molecular mechanisms responsible for the 
hypertrophic growth of cardiomyocytes are yet to be fully elucidated. 
One paradigm for Ang II-induced cardiomyocyte hypertrophy is the transactivation of receptor 
tyrosine kinases, such as the epidermal growth factor receptors (ErbBs) (Asakura et al., 2002; 
Thomas et al., 2002). ErbB receptors are a subfamily of receptor tyrosine kinases that regulate cell 
proliferation, survival and differentiation (Burgess, 2008). There are four known ErbB receptor 
subtypes (ErbB1-4), three of which (ErbB1, ErbB2 and ErbB4) (Scaltriti et al., 2006) are expressed 
in postnatal rat cardiomyocytes (Zhao et al., 1998). The ErbB receptors can be selectively activated 
by EGF family ligands, such as EGF (an agonist for ErbB1) and NRG1β1 (the agonist for ErbB4). 
ErbB2 is not directly activated by ligand binding, but is the preferred dimerisation partner for the 
other isoforms. Upon activation by agonists, the receptors form hetero- or homodimers (Burgess et 
al., 2003), phosphorylate intracellular tyrosine residues and thus activate downstream signalling 
pathways (Olayioye et al., 2000; Yarden et al., 2001; Mendelsohn et al., 2003). There is evidence 
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for a role of ErbB1, 2 and 4 in cardiac development and function (Gassmann et al., 1995; Wadugu 
et al., 2012). Mutations in any of ErbB1, ErbB2 and ErbB4 lead to embryonic death or postnatal 
death due to defects in cardiac development (Gassmann et al., 1995; Lee et al., 1995; Miettinen et 
al., 1995; Sibilia et al., 1995; Threadgill et al., 1995). Cardiomyocyte-specific expression of the 
dominant-negative ErbB1 in adult mice results in dilated cardiomyopathy (Rajagopalan et al., 
2008), and administration of an ErbB2 blocking antibody in humans increased the risk of heart 
failure (Seidman et al., 2002).  
We and others have shown that one mechanism for Ang II-induced hypertrophy is via the 
‘hijacking’ or transactivation of EGFR (ErbB1) (Thomas et al., 2002; Ohtsu et al., 2006b; Smith et 
al., 2011). Given previous studies showing important roles for ErbB2 and ErbB4 in cardiac 
physiology (Zhao et al., 1998; Özcelik et al., 2002) we speculated that these receptors may also be 
involved in AT1R-ErbB transactivation and cardiomyocyte hypertrophy. Thus, in this study we have 
compared and contrasted the contribution of different ErbB receptor isoforms in AT1R 
transactivation using both pharmacological and RNAi-based approaches.  
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3.2 Methods 
3.2.1 Animal ethics 
All experiments were conducted in accordance with the Australian Code of Practice for Care and 
Use of Animals for Scientific Purposes and approved by the institutional ethics committees of The 
University of Queensland. 
3.2.2 Vector constructs 
The ErbB1 shRNA and ErbB2 shRNA expressing vectors were constructed by James Goonan and 
the ErbB4 shRNA expressing vector by Dr Hsiu-wen Chan. The shRNA knockdown-resistant 
ErbB4 constructs were constructed and tested by Dr Hsiu-wen Chan. The luciferase reporter 
plasmids driven by hypertrophic gene promoter (MLC-2V, ANP-328, and CyclinD) were gifts from 
Dr Mona Nemer (Canada). 
3.2.3 Cardiomyocyte culture 
Cardiomyocytes were isolated from ventricles of 1-2 day old Sprague Dawley rats and purified via 
gradient centrifugation as previously described (Thomas et al., 2002). To mimic the up regulation 
of AT1R during hypertrophy, a modest level of AT1R was delivered into cardiomyocytes using 
DNA transfection or adenoviral vectors as required and indicated in the figures (Thomas et al., 
2002).  
3.2.4 Drug treatment  
Cardiomyocytes were stimulated with the following hypertrophic agents: Ang II (100 nM), 
NRG1β1 (10 nM), EGF (10 nM). Drugs to inhibit ErbB receptors (AG1478, 500 nM or 5 μM) or 
Gq (YM254890, 100nM) were added to cells 30 min before stimulation. AG1478 was purchased 
from Sigma-Aldrich Corporation (New South Wales, Australia). Human recombinant EGF and 
NRG1β1 were purchased from R&D Systems (Minnesota, USA). Human Angiotensin II was 
sourced from Auspep Pty Ltd (Victoria, Australia). YM254890 was a gift from Astellas 
Incorporation, Japan. 
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3.2.5  DNA transfection and luciferase reporter assay 
Reporter assays were used to measure the re-activation of the prototypic ‘hypertrophic genes’ ANP, 
cyclin D and MLC2v. Cardiomyocytes were transiently transfected with equal amounts (total 500 
ng) of DNA constructs (promoter driven luciferase reporters, AT1R and shRNAs targeting specific 
ErbBs) using Lipofectamine
TM
 2000 (Life Technologies). Twenty four hours after transfection, 
hypertrophic signalling was induced by treatment with Ang II, NRG1β1 or EGF, and another forty-
eight hours later, the cells were harvested and assayed with a luciferase assay kit (Promega).  
3.2.6 siRNA transfection 
The siRNAs specific for ErbB1, ErbB2 and ErbB4 (ON-TARGETplus, Dharmacon) were 
transfected (Lipofectamine
®
 RNAiMAX, Life Technologies) into cells 24 hours after isolation. 
Non-targeting siRNA was used as a control.  
3.2.7  Real-time PCR 
RNA was isolated from cardiomyocytes using TRIzol
®
 reagent (Life Technologies) and DNase-
treated before reverse transcription. The cDNA was amplified with Taq polymerase (FAST SYBR 
Green PCR Master Mix, Life Technologies). The primer sequence used were: for ErbB1 forward 
5’-TCCCTTTGGAGAACCTGCAG-3’ Reverse 5’-TCGCACAGCACCGATCAGAA-
3’(Mizobuchi et al., 2013); for 18S forward 5’-TCGAGGCCCTGTAATTGGAA-3’ Reverse 5’-
CCCTCCAATGGATCCTCGTT-3’ (Advani et al., 2009).   
3.2.8 Western blot 
Western Blotting was performed as described in detail previously (Carabatsos et al., 2000). Western 
blots of cellular protein lysates were probed with primary antibodies to ErbB4 (sc-283, Santa Cruz), 
ErbB2 (Ab-3, Calbiochem), ErbB1 (1005, Santa Cruz), p-Erk1/2 (#9106, Cell Signalling), Erk1/2 
(#4695, Cell Signalling) and β-actin (AC-15, Sigma). IRDye-conjugated secondary antibodies and 
the LI-COR odyssey infrared imaging system (Millennium Science) were used to quantify protein 
expression. 
3.2.9 Hypertrophy assay 
Cells were lysed in TE buffer containing 0.06% SDS for 4 hours at room temperature. Lysates were 
then assayed for both protein (BCA assay, Thermo Scientific) and DNA content (Picogreen dsDNA 
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assay kit, Life Technologies). Before the DNA assay, cell lysates were treated with 0.2g/L 
proteinase K (Life Technologies) overnight. Hypertrophy was defined by the increase in the total 
protein in the absence of change of DNA levels. 
3.2.10 Phalloidin stain  
Cardiomyocytes were fixed with 4% PFA followed by staining with Alexa594-labelled phalloidin 
as per the manufacturer’s protocol (Invitrogen). The cardiomyocytes were then subjected to 
confocal microscopy to examine the F-actin reorganization into the sarcomere. For each treatment, 
images of cardiomyocytes were taken randomly under 400 × magnification. 
3.2.11 Statistical analysis 
Data are shown as mean ± SEM. Data were analysed by Student’s t-test, or One-way or Two-way 
ANOVA with Bonferroni post-hoc comparisons, as indicated in the figures. P＜ 0.05 was 
considered statistically significant.  
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3.3 Results 
3.3.1 Different ErbB ligands produce different effects on hypertrophy and 
remodelling 
Ang II produces cardiomyocyte hypertrophy (Thomas et al., 2002) and cytoskeletal remodelling 
(Figure 3.1) as has been previously described. EGF (an ErbB1 selective agonist) does not increase 
protein:DNA ratio or induce sacromeric reorganization in cardiomyocytes across a range of 
concentrations, suggesting that ErbB1 receptor activation is not tightly coupled to the hypertrophic 
response (Figure 3.1). In contrast, NRG1β1 (an ErbB4 selective agonist) produces robust 
cardiomyocyte hypertrophy, increasing protein:DNA ratio by up to 35% with a corresponding 
alteration in cell morphology and F-actin reorganization (Figure 3.1). 
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Figure 3.1 Different ErbB ligands produce different effects on hypertrophy and 
remodeling A. CM were subjected to hypertrophic assay following treatment with increasing 
concentrations of NRG1β1 or EGF for 60-72h. B.CM were fixed and stained with phalloidin 
after treated with 100 nM Ang, 10 nM NRG1β1 or 10nM EGF for 72h. The white bar in the first 
panel is a 100 μm indicator. These images are representative images of three independent 
experiments. Data shown as mean ± SEM (n=3).  
 
Chapter 3: The role of ErbB receptors in Ang II-induced cardiomyocyte hypertrophy 
 
55 
 
3.3.2 Ang II-induced activation of hypertrophic gene promoter activity does not 
require ErbB receptors  
We designed shRNA plasmid constructs specifically targeting ErbB1, ErbB2 and ErbB4 receptors, 
and confirmed that these constructs could down-regulate receptor expression (Figure 3.2). These 
shRNA constructs were then used to selectively silence individual ErbB receptors in 
cardiomyocytes, and subsequently examine the role of these receptors in hypertrophic signalling 
responses to Ang II and NRG1β1. Ang II and NRG1β1 both increased promoter activity for MLC-
2v (Figure 3.3 A), ANP (Figure 3.3 B) and cyclin D (Figure 3.3 C), indicating re-activation of the 
hypertrophic gene program. Knockdown of ErbB4, but not ErbB1 or ErbB2, significantly reduced 
NRG1β1-induced activation of MLC-2v promoter activity by 62 % (Figure 3.3 A). NRG1β1-
induced activation of ANP and cyclin D were also inhibited by ErbB4 shRNA (Figure 3.3 B and C). 
In contrast, knockdown of ErbB1, 2 or 4 did not reduce Ang II-induced activation of MLC-2v 
(Figure 3.3 A), nor did knockdown of ErbB4 affect Ang II-induced activation of ANP or cyclin D  
(Figure 3.3 B and C). 
To complement our observation that ErbB receptors are not essential for Ang II-induced activation 
of the hypertrophic gene program, we also used AG1478 to pharmacologically inhibit ErbB 
activity, and used phosphorylation of ERK1/2 as a measure of ErbB1 or ErbB4 activation in 
cardiomyocytes (Figure 3.4 A and B). At higher concentrations of AG1478 (5 μM), the ERK1/2 
phosphorylation induced by both EGF (an ErbB1 agonist) and NRG1β1 (an ErbB4 agonist) was 
blocked. However, at lower concentrations of AG1478 (0.5 μM) only the EGF-induced ERK1/2 
phosphorylation was abolished (Figure 3.4 A). This suggests that at 0.5 μM AG1478 selectively 
inhibits ErbB1 receptors, whereas at 5 μM AG1478 inhibits both ErbB1 and ErbB4 receptors. 
Similarly, NRG1β1-induced ANP promoter activity was inhibited by 5 μM of AG1478 but not by 
0.5 μM AG1478 (Figure 3.4 C), confirming that at higher concentrations, AG1478 has inhibitory 
effects on hypertrophic signalling via ErbB4 receptors. In contrast, neither concentration of 
AG1478 inhibited Ang II-stimulated ANP promoter activity (Figure 3.4 C), suggesting that neither 
ErbB4 nor ErbB1 is involved in Ang II-induced activation of hypertrophic signalling. These results 
are consistent with those obtained from the shRNA experiments described above. The Gq inhibitor 
YM254890 (0.1 μM) significantly inhibited Ang II-stimulated activation of ANP, confirming that 
the Gq signalling pathway is essential for this process. NRG1β1-induced activation of ANP 
promoter activity was unaffected by YM254890 (Figure 3.4 C). Taken together, these data suggest 
that in isolated cardiomyocytes the activation of hypertrophic signalling pathways by Ang II is 
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independent of ErbB receptor activation, whereas ErbB4 receptors are important for NRG1β1-
induced hypertrophic signalling.  
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Figure 3.2 ErbB silencing by shRNA in a cell line. CHO cells were transfected with 500 ng of 
plasmids expressing either ErbB1, ErbB2 or ErbB4, and with 500 ng of shControl (shCont) or 
shErbB1, shErbB2 or shErbB4 (shB1, shB2 and shB4). Controls were left untransfected. 
Expression of ErbB receptors was measured by Western blot with β-actin as control.  
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Figure 3.3 A role for ErbB receptors in hypertrophic gene promoter activity. CMs were 
transfected with 100 ng AT1R, 100 ng ErbB shRNA or non-silencing shRNA (shControl), and 
300 ng of either MLC-2V (A), ANP (B) or CyclinD (C) promoter-driven luciferase reporter 
constructs. 24 h after transfection cells were stimulated with NRG1β1 (10 nM) or Ang II (100 
nM) for 48 h. Data are presented as mean ± SEM (A, n=5; B, n=4; C, n=3) of relative light units 
(RLU) expressed as a percentage of the shControl. Data were analysed by Two-way ANOVA 
with Bonferroni post-test (**P<0.01 vs shControl with NRG1β1 stimulated; ####P<0.0001, 
###P<0.001, ##P<0.01, #P<0.05 vs unstimulated in each shRNA treated group).  
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Figure 3.4 Divergent effects of the ErbB inhibitor AG1478 and Gq inhibitor YM254890 on 
ERK1/2 phosphorylation and ANP promoter activity in response to NRG1β1 and Ang II 
stimulation. CMs were infected with AT1R adenovirus for 48h. Cells were then treated with 
AG1478 (0.5 or 5 μM) or YM254890 (0.1 μM) for 30 min before stimulating with (A) EGF (10 
nM) or (B) NRG1β1 (10 nM) for 5 min. Levels of total and phosphorylated ERK1/2 were 
measured by Western blot; images are representative of two independent experiments. In (C) 
CMs were transfected with 100 ng AT1R, 100 ng shControl and 300 ng ANP promoter-driven 
luciferase reporter constructs. 24 h after transfection cells were treated with either AG1478 or 
YM254890 and stimulated with NRG1β1 or Ang II, as described above. Data are presented as 
mean ± SEM (n=3) of RLU expressed as a percentage of the unstimulated control and were 
analysed by Two-way ANOVA with Bonferroni post-test (***P<0.001 vs control treated with 
Ang II, **P<0.01 vs control treated with NRG1β1; ; ####P<0.0001, ###P<0.001, ##P<0.01 vs 
unstimulated in each shRNA treated group).  
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3.3.3 Ang II-induced MAPK signalling does not require ErbB receptors 
Given the potential controversy of the above findings, we were concerned that the reporter 
constructs used above are limited by only being transfected into a very small proportion (1-2%) of 
cardiomyocytes. Thus, we wanted to expand our studies to measure indices of hypertrophic 
signalling in the wider, more representative population of cardiomyocytes. To do so, we used 
siRNA oligonucleotides that can be transfected into cells at much higher efficiencies than plasmid 
constructs to silence individual ErbB receptors. Western blots confirmed successful siRNA-
mediated knockdown of ErbB1, ErbB2 and ErbB4 for up to 96 hours after transfection (Figure 3.5 
A-C). This knockdown was selective for the targeted isoform, as knockdown of one ErbB subtype 
did not affect expression of other ErbB receptors (Figure 3.5). 
Both NRG1β1 and Ang II increase ERK1/2 phosphorylation (Figure 3.6 A). Stimulation with 
NRG1β1 increased the activation of ERK1/2 by 21-fold relative to the unstimulated group. siRNA-
mediated knockdown of ErbB4 reduced this activation by approximately 40% relative to the 
siControl (Figure 3.6 B), confirming that ErbB4 is required for the NRG1β1-induced ERK1/2 
signalling. However, similar to the results for hypertrophic gene promoter activity, Ang II-
stimulated ERK1/2 activation was unaffected by knockdown of ErbB receptors (Figure 3.6 C). 
Together, these data further indicate that whilst ErbB4 is required for NRG1β1-induced activation 
of hypertrophic signalling pathways, ErbB receptors are not involved in Ang II-induced 
hypertrophic signalling in cardiomyocytes.  
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Figure 3.5 Selective knockdown of ErbB receptor expression with siRNA. CMs were 
transfected with 20 nM siRNA targeting individual ErbB receptors. Expression of ErbB receptors 
was determined via Western blotting or qPCR 48 - 96 h after transfection. A. Left panel shows a 
representative image of two independent Western blot experiments probing ErbB1. The right is 
quantification of the ErbB2 and ErbB4 expression by qPCR 48 h later after transfection (using 
18S as internal control and expressed as a percentage of the siControl). Data shown as mean ± 
SEM (n=3) and analysed by Student’s t-test. B and C. The left images are representative images 
of three independent Western blots probing for ErbB2 or ErbB4. The right shows quantification 
of ErbB2 and ErbB4 expression using Image Studio Lite software (version 3.1). Data shown as 
mean ± SEM (n=3-4) and analysed by two way ANOVA (***P <0.001 vs. siControl).  
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Figure 3.6 Selective knockdown of ErbB receptors differentially affects activation of 
ERK1/2 by NRG1β1 and Ang II. CMs were transfected with 20 nM of siErbB1, siErbB2, 
siErbB4 or siControl 24h prior to infection with AT1R adenovirus. 48 h later, the cells were 
stimulated with either NRG1β1 (10 nM) or Ang II (100 nM) for 5 min. Activation of ERK1/2 
was determined by Western blotting (A). The data were quantified and presented as mean ± SEM 
(n=4) for NRG1β1 (B) and Ang II (C). Data were analysed by Two-way ANOVA with 
Bonferroni post-test, ***P <0.001 vs siControl; ####P<0.0001, ###P<0.001, ##P<0.01 vs 
unstimulated in each siRNA treated group).  
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3.3.4 NRG1β1-induced hypertrophic growth requires ErbB4 
Finally, we sought to confirm that NRG1β1 acts via the ErB4 receptor to cause hypertrophic growth 
as well as activation of hypertrophic signalling pathways. Stimulation with NRG1β1 increased the 
protein:DNA ratio by 18% in cardiomyocytes compared to unstimulated controls (Figure 3.7 A). 
This NRG1β1-induced hypertrophic growth was significantly reduced (~ 40 % reduction compared 
to siControl) by down-regulation of ErbB4. Knockdown of ErbB1 and ErbB2 caused a small 
reduction in NRG1β1-induced hypertrophy (16% and 14% increases in protein:DNA ratios 
respectively compared to unstimulated controls) however this was not statistically significant 
(Figure 3.7 A). Consistent with this, NRG1β1 induced sarcomere reorganization was affected by 
knockdown of ErbB4, but not ErbB1. The down regulation of ErbB2 seems to attenuate the 
NRG1β1-induced sarcomere reorganization but this effect is less pronounced compared to the 
siErbB4 treated cells (Figure 3.7 B). 
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Figure 3.7 Effect of ErbB receptor knockdown on NRG1β1-induced hypertrophy. CMs 
were transfected with 20 nM of siErbB1, siErbB2, siErbB4 or siControl for 48 h prior to 
stimulation with NRG1β1 (10 nM) for an additional 48 h. A. Protein:DNA ratio was determined 
and data normalized to the unstimulated control. Data are presented as mean ± SEM (n=4) and 
analysed by two-way ANOVA with Bonferroni post-test, **P<0.01 vs siControl; ####P<0.0001, 
###P<0.001, ##P<0.01 vs unstimulated in each siRNA treated group. B. Representative images 
of sarcomere reorganization measured by Phalloidin staining.  
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3.4 Discussion 
The mechanism of AT1R-EGFR transactivation has generated substantial interest due to the role of 
this pathway in cardiac hypertrophy (Kagiyama et al., 2002; Thomas et al., 2002), renal growth and 
dysfunction (Lautrette et al., 2005) and vascular remodelling (Ohtsu et al., 2006b). The central 
paradigm for transactivation has involved the AT1R-mediated activation of metalloproteases that 
cleave cell surface EGF ligand precursors that then activate EGFR (ErbB1). The number and 
diversity of both metalloproteases (MMPs and ADAMs) (Edwards et al., 2008; Hadler-Olsen et al., 
2011), EGF ligands and ErbB receptors means that it has been difficult to identify the specific 
players involved in any individual transactivation process. Based on the prevailing literature, we 
were surprised to discover in this study that ErbB1 appears to play little or no role in cardiomyocyte 
hypertrophy. In contrast, we have confirmed a significant role for ErbB4 in this process. Based on 
this, we then hypothesized that the pro-hypertrophic effects of Ang II may in fact be mediated by 
ErbB4; however, this was not the case. Using a variety of approaches (RNA interference, 
pharmacological blockade) we were unable to demonstrate any link between AT1R activation and 
ErbB4. In total, our data raise questions concerning the role of individual ErbB receptors in Ang II-
mediated cardiomyocyte hypertrophy.  
However, a lack of involvement of ErbB receptors in Ang II-mediated cardiomyocyte growth does 
not discount these receptors from playing a major role in the heart. Indeed, a major finding of our 
study is that the ErbB4 receptor is critical for NRG1β1-induced cardiomyocyte hypertrophy. This 
supports previous studies which found that NRG1β1 induced hypertrophy in both neonatal and 
adult ventricular myocytes accompanied by up-regulation of hypertrophic genes (Zhao et al., 1998). 
Indeed, NRG1β1-ErbB4 signalling is important in cardiac development: deletion of either gene 
causes embryonic lethality due to heart malformations (Gassmann et al., 1995; Meyer et al., 1995). 
NRG1β1-ErbB4 signalling also induces cardiomyocyte proliferation both in vitro and in vivo 
(Bersell et al., 2009). We now show that ErbB4 activation by NRG1β1 can also stimulate ERK1/2 
activity and hypertrophy in cardiomyocytes, further illustrating the important role of this 
mechanism in cardiac physiology. 
We were surprised to observe that ErbB1 activation does not cause cardiomyocyte hypertrophy. In a 
variety of cells, we and others have previously demonstrated that AT1R activation leads to 
phosphorylation of the ErbB1 receptor, downstream signalling and subsequent changes in cell 
physiology (Thomas et al., 2002; Ohtsu et al., 2006b). Moreover, deletion of ErbB1 in vascular 
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smooth muscle cells reduces GPCR-mediated signalling and has marked effects on vascular and 
cardiac remodelling (Schreier et al., 2011; Schreier et al., 2013).  
One possible explanation for the discrepancy between this work and earlier studies relates to the 
method of inhibiting ErbB receptors. AG1478 is regarded as a selective inhibitor for ErbB1, 
however as an ATP-competitive antagonist it may also inhibit other receptor tyrosine kinases when 
used at higher concentrations (Levitzki et al., 1995; Anastassiadis et al., 2011). In this study, we 
used two different concentrations of AG1478 (0.5 and 5 μM), and found that the lower 
concentration selectively inhibited ErbB1, whereas the higher concentration inhibited both ErbB1 
and ErbB4, consistent with previous reports (Anastassiadis et al., 2011). Thus, it is possible that 
previous studies using AG1478 at 5 μM may have attributed actions to ErbB1 activation that are in 
fact being mediated by ErbB4 or other tyrosine kinases. Indeed, we have previously shown that 5 
μM AG1478 is required to abolish Ang II-induced ERK1/2 activation and cardiomyocyte 
hypertrophy (Thomas et al., 2002; Smith et al., 2011), which suggests that multiple ErbB receptor 
subtypes may involved in this process.  
We then sought to further validate these data using a third method of inhibiting ErbB receptors, 
siRNA. siRNAs to ErbB1, 2 and 4 all showed significant knockdown of their targeted receptor, and 
we found no evidence of compensatory up-regulation of the other receptor isoforms (Figure 3.5). 
Knockdown of individual ErbB receptors did not inhibit Ang II-induced ERK1/2 activation. Whilst 
it could be argued that perhaps the magnitude of ErbB receptor knockdown was insufficient to 
inhibit Ang II signalling, our results with NRG1β1 do not support this explanation. siRNA targeting 
of the ErbB4 receptor reduces both NRG1β1-induced ERK1/2 activation and cardiomyocyte 
hypertrophy, thus we would argue that siRNA-mediated down-regulation of ErbB4 was sufficient to 
cause a functional reduction in expression, but that Ang II does not appear to act via this receptor. 
Taken together, we have used three different methods to inhibit ErbB receptors (shRNA, siRNA 
and pharmacological inhibition) and found no evidence for the role of any individual ErbB receptor 
isoforms in Ang II-mediated hypertrophic signalling.  
By raising questions about the mechanism of AT1R-ErbB receptor transactivation in 
cardiomyocytes, this study highlights the potential for investigating signalling pathway networks 
using an unbiased, rather than candidate-driven, approach. Indeed, our group has recently used 
functional genomics to perform a siRNA screen of AT1R-ErbB1 transactivation in a mammary 
epithelial cell line, and have identified a number of novel molecules involved in this process 
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(George et al., 2013). It is also important to recognize the difficulties in characterizing systems that 
involve multiple molecular participants, and thus may have a high degree of redundancy. In the case 
of AT1R-ErbB transactivation, this is typified by the number of potential MMP/EGF ligand/ErbB 
receptor combinations. 
Transactivation of GPCRs and receptor tyrosine kinases is a broad phenomenon that is important in 
both normal physiology and numerous disease processes. We confirm an important role for 
NRG1β1-ErbB4 signalling in cardiomyocyte growth, yet our data calls into question the existence 
of a straightforward mechanism for the transactivation of ErbB receptors by the AT1R. 
Accordingly, I will focus on further examining the role of ErbB4 in cardiomyocytes in the 
following studies described in this thesis. 
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4. Investigation into the roles of ErbB4 isoforms in 
cardiomyocyte hypertrophy 
4.1 Background 
ErbB4 has four isoforms resulting from alternative splicing: JM-a CYT-1, JM-a CYT-2, JM-b 
CYT-1 and JM-b CYT-2 (as discussed in section 1.4). The four isoforms are structurally different in 
two domains: the extracellular juxtamembrane JM domain (JM-a and JM-b) and intracellular CYT 
domain (CYT-1 and CYT-2). Compared to the CYT-2 domain, the CYT-1 contains a 16 amino acid 
insertion that acts as a docking site for multiple factors including STAT5, Yap and PI3K (Elenius et 
al., 1999; Omerovic et al., 2004; Williams et al., 2004). The JM-a isoform contains 23 amino acids 
in the JM domain that allow for ectodomain shedding (Junttila et al., 2000). JM-b contains an 
alternative 13 amino acids that resistant to shedding (Junttila et al., 2000). Cleavage of the JM-a 
isoform occurs in 2 steps, and produces an 80-kDa soluble fragment. First, the JM-a isoform can be 
subjected to ectodomain cleavage by the metalloprotease ADAM17 to produce a 120-kDa 
ectodomain fragment released into the extracellular medium and an 80-kDa fragment anchored in 
the membrane (Vecchi et al., 1997; Rio et al., 2000; Zhou et al., 2000). The 80-kDa fragment can 
subsequently be subjected to further cleavage by γ-secretase within the lipid bilayer to release the 
intracellular domain (Chang-Yuan et al., 2001). The cleavage can be induced by various 
stimulations such as PMA, NRG1-β1 or GPCR agonists, which potentially activate the ADAMs 
(Chang-Yuan et al., 2001). The cleavage of JM-a isoform is cell type dependent. In breast cancer 
cells, ovarian cancer cells, lung cancer cells, and a glioma cell line (Vecchi et al., 1996; Zhou et al., 
2000; Määttä et al., 2006; Zeng et al., 2009), the JM-a isoform of ErbB4 is cleaved to produce an 
80 kDa intracellular domain (ICD). The ICD can enter the nucleus and interact with transcriptional 
factors to regulate transcriptional activity (Tidcombe et al., 2003; Zhu et al., 2006b; Gilmore-
Hebert et al., 2010). Depending on whether they can be cleaved to release the ICD, or possess the 
extra 16 amino acids in the intracellular domain, each ErbB4 isoform may therefore play a different 
role in regulating growth and differentiation (Muraoka-Cook et al., 2009). For instance, the 
cleavable JM-a isoform is capable of regulating the astrogenesis timing by suppressing astrocyte 
differentiation, whereas the non-cleavable isoform JM-b cannot (Sardi et al., 2006) (refer to the 
Chapter 1 section 1.4.3 for more detail); the CYT-2 ICD promotes mammary cell proliferation, 
whereas CYT-1 ICD promotes differentiation (more acinar structures in 3D culture) (Muraoka-
Cook et al., 2009). We have previously shown that all ErbB4 isoforms are detectable in rat neonatal 
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primary cardiomyocytes (Dr. Hsiu-wen Chan, PhD thesis). However, the regulation of these 
isoforms in cardiac development and pathological conditions has not been investigated. In addition, 
whether the JM-a-containing isoforms can be cleaved to release the ICD and enable trafficking of 
the ICD to the nucleus of cardiomyocytes is not known. Finally, the ability of each individual 
isoform to mediate cardiomyocyte hypertrophy has not been previously examined. The following 
studies aim to answer these questions.  
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4.2 Methods 
4.2.1 Animals 
To investigate the regulation of the ErbB4 isoforms in cardiac development and cardiac pathology 
models (ischaemia-reperfusion model and pathological cardiac hypertrophy model), we 
collaborated with other groups who have isolated RNA samples from these models. RNA isolated 
from embryonic CD-1 mouse hearts (E10.5, E13.5, E16.5, and E18.5) was a gift from Dr. David 
Pennisi (University of Queensland). The RNA from CD-1 mouse hearts at postnatal days 1, 6, 14 
and 28 was kindly provided by Dr. Enzo Porrello (University of Queensland). The hearts from an 
ischaemia-reperfusion model and a pathological cardiac hypertrophy model were from Prof. Eric N. 
Olson’s group (University of Texas) and RNA was extracted by Dr. Enzo Porrello. For the 
ischaemia model, 8-12-week old mice (under isoflurane anaesthesia) underwent 45 min of 
ischaemia induced by temporary ligation of the left anterior descending coronary artery (LAD) 
followed by reperfusion. Control animals underwent a sham operation without occlusion of the 
LAD. After 24 hours or 7 days recovery, cardiac tissues were collected from both groups (Aurora et 
al., 2012) and RNA extracted. For pathological cardiac hypertrophy model, the calcium-dependent 
phosphatase calcineurin driven by cardiac-specific gene promoter αMHC was overexpressed in 
mice. The mutant mice develop cardiac hypertrophy soon after birth and reached maximal 
hypertrophy at 8 weeks of age. Then they progressed to dilated cardiomyopathy and heart failure 
(Molkentin et al., 1998). RNA was extracted from hearts collected from transgenic and wild type 
animals at 8 weeks of age.  
4.2.2 Relative quantitation real-time PCR with TaqMan probes 
Real-time PCR quantification of ErbB4 isoforms was performed with specific primers and probes 
described previously in the literature (Junttila et al., 2003; Veikkolainen et al., 2012). Probes for 
JM-a, JM-b, CYT-1 and CYT-2 annealed to exons 16, 15, 26 or the junction between exons 25 and 
27, respectively (Figure 4.1 A). The primers were synthesized based on the exon sequences flanking 
the site recognized by the probe. Amplification of ribosomal 18S was used as an internal control. 
PCR was performed in a solution containing 300 nM of each primer (Sigma), 200 nM of probe, 
1×TaqMan advanced fast master mix (Applied Biosystems) and 5-10 ng cDNA template in a final 
volume of 10 µl. Thermal cycling was performed with StepOnePlus Real-Time PCR system 
(Applied Biosystems). Cycling was initiated 20 s at 95°C, followed by 40 cycles of 1 s at 95°C and 
20 s at 60°C. Expression levels of all isoforms were normalized to 18S expression using the 2(-ΔΔCT) 
method as described (Livak et al., 2001). 
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4.2.3 Absolute quantification real-time PCR 
Absolute quantification uses serially diluted standards of known concentrations to generate a 
standard curve. The standard curve produces a linear relationship between the initial amounts of 
DNA template (N0) and the threshold cycle (CT) and thus can be used to quantify the unknown 
samples. This method assumes all standards and samples have equal amplification efficiency. Thus, 
standards and samples have to be amplified in the same plate under same PCR conditions (same 
probe, primers, reagents, etc). The relationship between the log(N0) and log(CT) is described in the 
linear function: Log(N0)= -Log(E+1)·CT + Log(NT) as previously described (Rutledge et al., 2003). 
E is amplification efficiency; NT is the number of amplicon molecules at fluorescent threshold; NT 
and E are constants (Rutledge et al., 2003). In my study, serially diluted (1:5) standards for each 
ErbB4 isoform (see section 4.2.4 for standards generation) and the unknown samples were 
amplified in the same plates using the primers and probe described in section 4.2.2. Standard curves 
for each isoform of ErbB4 were generated by analyzing the initial amounts of standards and 
threshold cycle (Figure 4.2). The initial template amounts (N0) of unknowns can be calculated by 
putting its CT value into the corresponding function.  
4.2.4 Generation of standards for absolute quantification real-time PCR 
Standards should be made from a high quality template because any degradation will affect the 
results. PCR products can slightly degrade during storage and thus are not a suitable standards 
resource, whilst the cloned target sequence is more stable (Dhanasekaran et al., 2010). To get a 
clean and consistent source for the standards, the PCR products in section 4.2.2 were cloned into 
TA vectors. Briefly, the PCR products were subjected to DNA purification (DNA extraction kit, 
Qiagen) following agarose gel electrophoresis. Then the purified PCR products were ligated into 
linearized T-overhang vectors using TOPO
®
 TA Cloning
®
 Kit (Invitrogen). The ligation was 
transformed into competent E. coli cells (New England Biolabs) and then subjected to kanamycin 
selection on LB agar plates. Positive clones were confirmed with plasmid extraction followed by 
sequencing. The positive clone was preserved at -80°C supplemented with 40 % glycerine.  
The recombinant T vector cannot be used directly as a standard because it is circular DNA, whereas 
the samples to be tested are linear cDNAs. Circular DNA templates are amplified with a different 
efficiency from linear DNA templates even under the same PCR condition (Lin et al., 2011). Thus, 
before performing the real-time PCR, the concentrated standard is released from the recombinant T 
vector by double enzyme digestion with Hind III and EcoV (New England Biolabs). These two 
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digestion sites were in the T-vector, and flanked the sequence of the inserted standards. The digest 
was purified via agarose gel electrophoresis and DNA extraction (Qiagen).   
The concentration of the purified DNA fragment was measured in triplicate by Nano drop. The 
molar concentration was calculated as: molar concentration (mol/L) = mass concentration (g/L)/ 
molecular weight (g/mol). The molecular weight of each DNA fragment was determined by the 
online tool Oligo Calc (http://www.basic.northwestern.edu/biotools/oligocalc.html). 
4.2.5 Generation of pEGFP-N1-ErbB4 
The plasmid p-EGFP-N1-ErbB4, expressing full length rat ErbB4 individual isoform with a C-
terminal EGFP fusion was generated by subcloning the ErbB4 isoform from the pIRESpuro2 vector 
into pEGFP-N1. Rat ErbB4 isoforms (JM-a CYT-1, JM-a CYT-2, JM-b CYT-1 and JM-b CYT-2) 
in the pIRESpuro2 vector were gifts from Dr Giovanna Gambarotta (University of Torino, Italy). 
For subcloning, stop codons were removed and NheΙ and AgeΙ sites were introduced into the N- and 
C-terminals of the ErbB4 sequence using PCR. The PCR product was ligated with NheΙ and AgeΙ 
digested p-EGFP-N1 vector before transformation in competent E. coli cells (New England 
Biolabs). Kanamycin resistance was used for colony selection. Positive clones were determined via 
NheI/HpaI double digestion followed by agarose gel electrophoresis and sequencing. 
4.2.6 Live cell imaging using confocal microscopy 
For confocal microscopy, cardiomyocytes were plated in glass-bottomed confocal dishes (MatTek) 
and maintained in DMEM CCT SS2 medium (refer to Appendix A for medium recipe). The 
recombinant vectors expressing individual ErbB4-GFP isoforms were delivered into myocytes via 
DNA transfection, as described earlier (section 2.5). At 48h after transfection, cell dishes were 
subject to live imaging with an Olympus FV1000 confocal microscope system. All observations 
were performed at 37°C with 60×10 magnification. To avoid interference with the observation, the 
intracellular fluorescence of ErbB4-GFP in the cytoplasm was bleached before stimulation with 
NRG1 or PMA. For this, the region of interest (ROI) (cytoplasm) was manually selected by 
drawing a circle around the ROI with the Olympus FV1000 software. The ROI was then subjected 
to photo-bleaching with 50% of the maximum power of the 405 laser in the SIM light bleaching 
mode for 800ms at 10.0 µs/pixel. The bleaching process was repeated 2-3 times until no 
fluorescence remained observable in the cytoplasm and nucleus. After photobleaching, cells were 
treated with PMA (100nM), NRG1 (10nM) or vehicle. Images were acquired immediately before 
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and 1 min, 5 min and 15 min after stimulation. The 405 and 473 lasers were sequentially used for 
fluorescence excitation with 5% of maximum laser power. 
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4.3 Results  
4.3.1 Expression profiles of ErbB4 isoforms throughout development using 
relative quantification  
The expression of ErbB4 isoforms (JM-a CYT-1, JM-a CYT-2, JM-b CYT-1 and JM-b CYT-2) 
exhibits distinct tissue specific patterns (Elenius et al., 1997; Elenius et al., 1999). Moreover, some 
studies showed that the expression of ErbB4 isoform is developmentally regulated by physiological 
stage: the JM-a isoform is reduced in neuronal precursor cells at late stages of embryonic 
development (Fox et al., 2005; Sardi et al., 2006). In the adult mouse and human heart, JM-b CYT-
1 is predominant isoform (Elenius et al., 1997; Elenius et al., 1999), however there is limited 
information on how ErbB4 isoform expression is regulated during heart development. To address 
this, the developmental expression profile of each isoform was assessed. Mouse hearts at embryonic 
days (E) 13.5, 16.5, 18.5 and postnatal days (P) 1, 7, 14 and 28 were collected and RNA extracted. 
Quantitative PCR (TaqMan, relative expression) was used to detect each isoform with 18S as an 
internal control. Throughout development from E13.5 to P28 expression of all four isoforms 
decreased: JM-a isoform at P28 is approximately 300-fold lower than E13.5, JM-b is 17-fold lower, 
CYT-1 isoform is 73-fold lower, and CYT-2 is 40 fold lower (Figure 4.1 B). This pattern is similar 
for all four isoforms, suggesting that they are regulated in a similar manner during heart 
development. 
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Figure 4.1 The developmental expression profile of ErbB4 isoforms. A. Design of primers 
and probes to specifically detect individual isoforms using qPCR. Probes for JM-a, JM-b, 
CYT-1 and CYT-2 were designed to anneal to exons 17, 16, 27 or the junction between exons 
26 and 28, respectively. The primers were complementary to the exon sequences flanking the 
site recognized by the probe. The same pair of primer was used for detection of either JM-a 
and JM-b isoforms or CYT-1 and CYT-2 isoforms. B. Quantitative qPCR (TaqMan) was used 
to detect JM-a, JM-b, CYT-1 and CYT-2 isoforms at in mouse hearts embryonic days 13.5, 
16.5, 18.5 and postnatal days 1, 7, 14 and 28. Ribosomal 18S was used as an internal control. 
Data was expressed as ratio of expression at P28 and presented as mean ± SEM, n=3. 
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4.3.2 Expression profiles of ErbB4 isoforms throughout development using 
absolute quantification 
The results described above use different primer/probe sets to amplify the individual ErbB4 
isoforms, and therefore the efficiency of PCR amplification may differ for each isoform. Thus, we 
cannot directly compare the expression levels of individual isoforms to each other from the relative 
quantification PCR data. Instead, we used absolute real-time PCR to identify the predominant 
isoforms expressed at different stages of cardiac development. Generation of the standard curves 
(Figure 4.2) is described in section 4.2.3 - 4.2.4. All four isoforms were detectable in mice heart 
throughout development (Figure 4.3). From the embryo stage (E10.5) into young adulthood (P28), 
the expression profile of all four isoforms was consistent with that identified using relative 
quantification (Figure 4.1). The JM-b:JM-a ratio ranged from 3:1 at E10.5 to 40:1 at P28, 
suggesting that during embryogenesis expression of the two isoforms is similar, but the JM-b 
isoform dominates as the heart matures. This is consistent with the literature (Elenius et al., 1997; 
Elenius et al., 1999) that JM-b is the primary isoform in the adult mice heart. In contrast, the CYT-
2:CYT-1 ratio did not differ notably and only shifted from 1:1 at E10.5 to 1.7:1 at P28, suggesting 
that there are similar levels of CYT-1 and CYT-2 in the heart throughout development. The sum of 
the CYT-1 and CYT-2 copy numbers is approximately equal to the sum of the JM-a and JM-b copy 
numbers at each individual developmental stage, indicating this absolute quantification is accurate. 
Together, these suggest that the non-cleavable JM-b isoforms predominate in the adult heart, and 
may therefore be the isoforms most relevant for function. 
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Figure 4.2 Standard curves for individual ErbB4 isoforms. DNA template dilution series 
(1:5) was used to generate standard curves by qPCR using the primers and probes specific 
for the JM-a, JM-b, CYT-1 or CYT-2 isoforms. The template for standard curve was 
generated by digestion of recombinant vectors containing JM or CYT domain of ErbB4 
isoforms. N0 is the copy number of templates for each dilution. CT is the threshold cycle 
value.  
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Figure 4.3 Absolute expression of ErbB4 isoforms in the heart at different 
developmental stages. Absolute quantitative qPCR (TaqMan) was used to measure 
expression of JM-a, JM-b, CYT-1 and CYT-2 ErbB4 isoforms at in mouse heart at E10.5, 
E18.5, P1 and P28.  Ribosomal 18S was used as an internal control. Data was expressed as 
absolute copy number of each isoform per ng RNA, presented as mean ± SEM, n=3 for 
each time point. Data was analysed by one-way ANOVA with Bonferroni post-test, 
****P<0.0001, ***P<0.001, vs E10.5. 
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4.3.3 Regulation of ErbB4 isoform expression in models of cardiac pathology  
The regulation of ErbB4 isoform expression by cardiac stressors such as pathological cardiac 
hypertrophy or myocardial infarction was also assessed. First, we examined the regulation of the 
four isoforms in an ischaemia-reperfusion (IR) model (section 4.2.1). JM-a isoform expression was 
significantly increased at 24 h after reperfusion, whereas JM-b was not, suggesting that the 
cleavable JM-a isoform was up-regulated by the ischaemia-reperfusion injury (Figure 4.4). The 
mRNA level of the CYT-2 isoform was significantly reduced (by ~ 40 %) at 24 h after IR while 
CYT-1 was not changed (Figure 4.4). The JM-b:JM-a ratio is reduced by 50% at 24 h and 35% at 7 
days after reperfusion compared to the sham-operated controls (Figure 4.4), suggesting that these 
two isoforms may play different roles in regulating cardiac biological activity after IR. In contrast, 
the ratio of CYT-2/CYT-1 was not changed indicating no potential functional differences related to 
the CYT-2 and CYT-1 isoforms in the heart after IR (Figure 4.4).  
A transgenic model of cardiac hypertrophy caused by calcineurin overexpression was used to 
investigate the regulation of ErbB4 isoforms in pathological hypertrophy (section 4.2.1). 
Surprisingly, expression of all of four isoforms was significantly reduced in calcineurin-
overexpressing animals compared to the controls (Figure 4.5). The JM-b:JM-a and CYT-2:CYT-1 
ratios were not changed, suggesting that the reduction of all isoforms may be due to the inhibition 
of whole gene expression, but not specific regulation of an individual isoform. The down-regulation 
of ErbB4 expression in the pathologically hypertrophic heart suggests that ErbB4 may not mediate 
this pathological hypertrophy, and that calcineurin-induced signalling may negatively regulate 
ErbB4 signalling.  
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Figure 4.4 Regulation of ErbB4 isoform expression in an ischaemia-reperfusion 
model. Mouse hearts were collected following 24h (IR24h) or 7 days (IR7d) of 
reperfusion after 45 min of ischaemia, or from non-ischemic sham controls. Absolute 
quantitation qPCR (TaqMan) was used to measure the copy number of JM-a, JM-b, 
CYT-1 and CYT-2 isoforms per ng of total RNA. The right hand panels show the ratios 
(JM-b:JM-a and CYT-2:CYT-1) of the copy numbers. Data is presented as mean ± SEM 
and analysed with One-way ANOVA with Bonferroni’s multiple comparisons; n=3 for 
each treatment, *P<0.05, **P<0.01 vs. control. 
Chapter 4: Investigation into the roles of ErbB4 isoforms in cardiomyocyte hypertrophy 
 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Regulation of ErbB4 isoform expression in a transgenic model of cardiac 
hypertrophy. Hearts were collected from calcineurin-overexpressing and wild type mice 8 
weeks after birth and absolute quantitiation qPCR (TaqMan) used to measure the copy 
number of JM-a, JM-b, CYT-1 and CYT-2 isoforms per ng of total RNA. The right hand 
panels show the ratios (JM-b:JM-a and CYT-2:CYT-1) of the copy numbers. Data is 
presented as mean ± SEM and analysed with Student’s unpaired t-test; n=3, **P<0.01 vs. 
control. 
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4.3.4 The cleavage of ErbB4 isoforms in isolated cardiomyocytes 
As discussed in section 4.3.3, the JM-a isoform is significantly up-regulated and the JM-b:JM-a 
ratio reduced after ischaemia-reperfusion injury. It can be inferred that the JM-a isoform has a 
unique role in heart after IR. There are many biological processes occurring after IR, such as 
cardiomyocytes apoptosis, fibroblast proliferation, and activation of immune system. In addition, a 
few studies showed that a small proportion of cardiomyocytes can proliferate as part of regeneration 
after IR (Beltrami et al., 2001; Malliaras et al., 2013). Given the ErbB4 receptors are mainly 
expressed in cardiomyocytes and primarily function as growth regulators, I proposed that the up-
regulated JM-a isoform might play a role in cardiomyocyte regeneration, and this function might be 
contributed by the JM-a domain. The JM-a isoform has a protease cleavage site in the 
juxtamembrane domain, which allows the receptor to be cleaved, releasing an intracellular domain 
(ICD) that can enter into cytoplasm or nucleus (Vecchi et al., 1997; Rio et al., 2000; Zhou et al., 
2000). It has been suggested that the ICD plays a role in regulating cell apoptosis and proliferation 
in many cell types (Zhu et al., 2006b; Gilmore-Hebert et al., 2010). However, shedding of the ICD 
has not yet been demonstrated in primary cardiomyocytes. Thus, to investigate the function of the 
ICD in cardiomyocytes, we studied whether the JM-a isoform is cleaved after agonist stimulation. 
Phorbol 12-myristate 13-acetate (PMA) causes cleavage of the JM-a isoform and release of the ICD 
in many cell lines (Vecchi et al., 1996; Zhou et al., 2000; Määttä et al., 2006; Zeng et al., 2009). 
NRG1 also induces the cleavage of JM-a isoforms in fibroblast and ovarian carcinoma cell lines 
(Vecchi et al., 1996; Zhou et al., 2000). Thus, we stimulated isolated rat cardiomyocytes with PMA 
(10 nM - 5 µM) for 30 min and probed for the ICD and full-length intact ErbB4 using Western 
blotting. As shown in Figure 4.6 A, we detected no ICD in cardiomyocytes treated with increasing 
concentrations of PMA for 30 min. We then examined different time points for PMA (100 nM) 
stimulation. As shown in Figure 4.6 B treatment with PMA for 5 to 60 min did not produce any 
detectable ICD in cardiomyocytes. However, it should be noted that the endogenous JM-a isoform 
has very limited expression in primary cardiomyocytes, where expression of the ErbB4 JM-b 
isoforms is predominant (Figure 4.3). In addition, PMA only cleaves a portion of JM-a isoforms to 
generate the ICD in other cell types (Vecchi et al., 1996), which could make it difficult to detect. 
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Figure 4.6 No evidence for cleavage of endogenous ErbB4 in primary cardiomyocytes 
following PMA stimulation. A. Cardiomyocytes were treated with increasing 
concentrations (10 nM – 5 µM) PMA or a vehicle control for 30 min, harvested with lysis 
buffer and subjected to Western blotting. B. Cardiomyocytes were treated with 100 nM 
PMA for 0 – 60 min before harvesting and Western blotting. A primary antibody (sc-283, 
Santa Cruz) recognizing the C-terminal of ErbB4 was used to probe for both the ICD and 
intact ErbB4, and β-actin was used as a loading control. 
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To further examine the cleavage of ErbB4 isoforms in cardiomyocytes, we generated four vectors 
expressing the individual isoforms tagged with GFP at the C-terminus. The vectors were delivered 
into cardiomyocytes via transfection, and the cleavage and trafficking of the ICD following 
stimulation with PMA or NRG1 was observed by live-cell imaging using confocal microscopy. To 
confirm that the GFP-tagged ErbB4 isoforms can be successfully expressed, the recombinant 
expressing vector was delivered into HEK-293 cells and Western blot used to detect the 
exogenously expressed ErbB4-GFP. We also confirmed that the GFP-tag did not affect the response 
of ErbB4 to PMA and the ability of cleavable isoform to release the ICD by stimulating the HEK-
293 cells with PMA (100 nM) after transfection. Full-length ErbB4 and the ICD were detected by 
Western blot using an antibody to the C-terminus of ErbB4. As shown in Figure 4.7 A, a 210 kDa 
band was detected in all samples, representing the intact GFP-tagged JM-a CYT-1 isoform. An 110 
kDa band representing the ICD-GFP was detected after 3 min of stimulation with PMA. The 
intensity of this 110 kDa band increased with prolonged PMA treatment, suggesting that cleavage 
of JM-a CYT-1-GFP (a1-GFP) and release of the ICD-GFP is PMA dependent and that the 
minimum time required for cleavage is 3 min. Cells transfected with JM-a CYT-2-GFP (a2-GFP) 
showed low levels of ICD-GFP in the absence of stimulation (Figure 4.7 B), suggesting some auto-
cleavage of JM-a CYT-2 under basal conditions. The ICD-GFP band generated from JM-a CYT-2-
GFP has more intensity than the band from JM-a CYT-1-GFP under the same conditions, 
suggesting that the intracellular CYT-2 domain promotes cleavage of the JM-a isoform. This is 
consistent with previous work showing that cleavage of the JM-a isoform and generation of the ICD 
is kinase dependent, and the CYT-2 isoform possesses stronger kinase activity (Sundvall et al., 
2007). There were no ICD-GFP bands detected in HEK-293 cells transfected with the non-cleavable 
isoforms JM-b CYT-1-GFP (b1-GFP, Figure 4.7 C) and JM-b CYT-2-GFP (b2-GFP, Figure 4.7 D). 
 
 
 
 
Chapter 4: Investigation into the roles of ErbB4 isoforms in cardiomyocyte hypertrophy 
 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Cleavage of exogenous ErbB4-GFP in PMA-stimulated HEK-293 cells. 
HEK-293 cells were transfected with 600 ng of either JM-a CYT-1-GFP (a1-GFP, A), 
JM-a CYT-2-GFP (a2-GFP, B), JM-b CYT-1-GFP (b1-GFP, C) or JM-b CYT-2-GFP 
(b2-GFP, D).  Following transfection, cells were cultured in serum-free DMEM for 24 h 
before stimulation with 100 nM PMA for 1 to 30 min. Cells were then harvested for 
Western blot analysis. The primary antibody (sc-283, Santa Cruz) recognizing the C-
terminal of ErbB4 was used to detect both the ICD and the full-length ErbB4. 
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After confirming that the GFP tag did not affect the cleavage of ErbB4, we introduced these 
recombinant vectors to cardiomyocytes via transfection. Confocal microscopy was used to record 
the trafficking of ErbB4-GFP in primary cardiomyocytes following stimulation with PMA or NRG1 
(section 4.2.6). Before stimulation, the majority of fluorescence representing the ErbB4-GFP was 
located on the cell membrane, as expected (Figure 4.8). However, a small amount of intracellular 
fluorescence was observed, potentially due to activities such as ErbB4 protein synthesis, recycling 
and trafficking. The intracellular fluorescence might interfere with observing the location of the 
ICD-GFP stimulation. To avoid this, I photo-bleached the intracellular area without affecting 
membrane before stimulation (section 4.2.6). As shown in Figure 4.8, after bleaching the 
fluorescence was only located in the cell membrane. After PMA and NRG1 stimulation, a small 
amount of fluorescence in a1-GFP transfected cells accumulated in the cytosol (Figure 4.8 A). 
However, little fluorescence was observed in the nucleus after stimulation. Vehicle (PBS) treatment 
did not induce trafficking of the green fluorescence from the membrane into the cytosol. Similarly, 
a2-GFP transfected live cardiomyocytes displayed PMA- and NRG1- but not vehicle- induced 
accumulation of the green fluorescence in cytosol (Figure 4.8 B). However, unexpectedly, the non-
cleavable isoforms b1-GFP and b2-GFP also displayed intracellular fluorescence accumulation in 
cardiomyocytes (Figure 4.8 C and D). Thus, the fluorescence observed in the cytoplasm may 
represent the trafficking of intact receptor and not the released ICD. The mechanism by which the 
intact ErbB4 receptor trafficks into the cytosol is unclear. It is maybe due to receptor endocytosis, 
or movement of the receptor in cytoplasm following stimulation. When taken together with the 
Western blot data described above, this suggests that PMA or NRG1 do not cleave the JM-a 
isoform to release the ICD in cardiomyocytes.  
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Figure 4.8 Trafficking of ErbB4-GFP in cardiomyocytes following stimulation with PMA or 
NRG1. Cardiomyocytes were maintained in serum-free DMEM CCT SS2 and transfected with 
500ng pEGFP-N1-JM-a CYT-1 (A), pEGFP-N1-JM-a CYT-2 (B), pEGFP-N1-JM-b CYT-1 (C) 
or pEGFP-N1-JM-b CYT-2 (D). 48h after transfection cell nuclei were stained with 10 µg/ml 
Hoechst 333258 for 30 min before commencing live cell imaging. Cellular fluorescence was 
bleached as described in section 4.2.6. PMA (100 nM) or NRG1 (10 nM) were added immediately 
after bleaching and images taken at 1, 5 and 15 min after stimulation. All images were taken at 
60×10 magnification.  
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4.3.5 The role of individual ErbB4 isoforms in mediating NRG1-induced 
cardiomyocyte hypertrophy 
The results in section 4.3.4 suggest that the JM-a isoform cannot be cleaved in isolated 
cardiomyocytes in vitro, although it is endogenously expressed in neonatal cardiomyocytes (Dr. 
Hsiu-wen Chan, PhD thesis). This leads to the question of whether there is a functional difference 
between the JM-a and JM-b isoforms if the JM-a isoform cannot be cleaved in cardiomyocytes. In 
addition, whether there are any functional differences between the CYT-1 and CYT-2 isoforms in 
cardiomyocytes is unknown. The results in chapter 3 of this thesis show that NRG1-induced 
cardiomyocyte hypertrophy requires ErbB4. To investigate which isoform of ErbB4 contributes to 
this hypertrophic signalling, we designed a rescue system to generate cardiomyocytes in which only 
one ErbB4 isoform is expressed. In this system, the shRNA used to knockdown endogenous ErbB4 
was co-transfected with a vector expressing a knockdown resistant variant of one ErbB4 isoform. 
NRG1 was used to induce hypertrophic signalling, and activation of ANP, CyclinD and MLC-2V 
measured with promoter-reporter assays as previously described (section 2.6). Knockdown of 
ErbB4 reduced the NRG1-induced MLC-2V (Figure 4.9 A) ANP (Figure 4.9 B), and Cyclin D 
(Figure 4.9 C) promoter activity. Interestingly, all isoforms of ErbB4 could rescue the hypertrophic 
response, suggesting that they can all mediate hypertrophic signalling. This may indicate that 
ErbB4-mediated activation of hypertrophic gene expression is dependent on a function common to 
all four isoforms - i.e. the tyrosine kinase activity. The hypertrophic signalling mediated by the 
individual isoforms follows a similar pattern for all hypertrophic genes: the CYT-2 isoform seems 
to have a greater ability to promote the signalling than CYT-1 isoform, although this difference is 
not statistically significant. In contrast, the JM-a and JM-b isoforms both promote hypertrophic 
signalling to a similar extent. Promoter activity for each hypertrophic gene was elevated in cells 
expressing individual ErbB4 isoforms (compared to the knockdown group) even without 
stimulation, indicating a low level of auto-activation of ErbB4. This activation is probably caused 
by the over-expression of the delivered isoform(s) of ErbB4. 
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Figure 4.9: Hypertrophic gene promoter activity in NRG1-stimulated cardiomyocytes 
expressing only a single isoform of ErbB4. All cardiomyocytes were transfected with three 
separate constructs. The first construct (100 ng) encoded a knockdown resistant (kdr) isoform of 
ErbB4 (kdr-JM-a CYT1, a1; kdr-JM-a CYT2, a2; kdr-JM-b CYT1, b1; kdr-JM-b CYT2, b2) or 
an empty vector control. The second construct (100 ng) encoded either shErbB4 or shControl 
(shCon), whilst the third was a hypertrophic gene promoter driven luciferase reporter construct 
(300 ng) using the promoter sequence of either ANP (A), MLC-2V (B) or CyclinD (C). Cells 
were then stimulated with NRG1β1 for 48 h or left unstimulated. The promoter activity of each 
hypertrophic gene was measured using luciferase assays. Data are normalized to the 
unstimulated shControl group and presented as mean ± SEM. For statistical analysis, the 
original data was normalized by log transformation to achieve equal variance distribution for 
each group. Normalised data was then analysed by Two-way ANOVA with Dunnett’s multiple 
comparison tests. ****P<0.0001, ***P<0.001 and **P<0.01 vs. NRG1-stimulated knockdown 
(vector); ###P<0.001 and ####P<0.0001 vs. unstimulated knockdown (ANP, n=5; MLC-2V, 
n=4; CyclinD, n=5). 
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4.4 Discussion 
In this chapter, I investigated the expression and cleavage of ErbB4 isoforms, and their ability to 
promote hypertrophy in cardiomyocytes. The main discoveries of these studies are: (1) cardiac 
ErbB4 expression is highest in the embryonic state and declines postnatally. The expression of all 
four isoforms of ErbB4 gradually decreased from embryogenesis to the adult stage. The 
predominant isoform in the adult heart is the JM-b isoform. There is no obvious isoform alteration 
in IR injury or pathological models of cardiac hypertrophy. (2) JM-a cleavage cannot be observed in 
purified cultures of primary cardiomyocytes following stimulation with NRG1 or PMA. However, 
cleavage of the JM-a isoform could be demonstrated in HEK-293 cells. (3) All four ErbB4 isoforms 
could mediate NRG1-induced cardiomyocyte hypertrophy. 
In the literature, the JM-b isoform is proposed to be the only isoform in the adult mice heart 
(Elenius et al., 1997; Elenius et al., 1999). My study showed that, whilst the JM-b isoform is 
predominant, both the JM-a and JM-b isoforms are detectable in the adult mice heart. The reason 
these previous studies did not detect JM-a may be because they used traditional end-point PCR and 
agar gel electrophoresis, which is less sensitive than the TaqMan method used in my study. Despite 
this disagreement on the expression of JM-a in postnatal heart, my finding that the JM-b isoform is 
the major isoform in adult heart is in agreement with previous work. 
One interesting result in my study is that ErbB4 is expressed at a much higher level in the 
embryonic heart than in the adult. ErbB4 is essential for cardiac growth: deletion of ErbB4 inhibited 
normal cardiac growth in both the embryonic (Gassmann et al., 1995) and postnatal stages (Garcia-
Rivello et al., 2005). The high level of ErbB4 in embryonic heart is consistent with the strong 
requirement for cardiac growth during development. However, determining which isoforms of 
ErbB4 are predominant in embryonic heart has not been investigated previously. Our results 
showed that in the earlier embryonic stage (E10.5) the JM-b:JM-a ratio is 3:1, whilst in the adult 
this increases to 40:1. We were unable to detect the expression of four isoforms any earlier than E9 
due to the tiny size of the heart tube and inefficient RNA extraction from the heart tube at this stage. 
While alternative methods to detect RNA expression (i.e., in situ hybridisation) were not performed, 
based on the expression pattern throughout the cardiac development (Figure 4.1), it may be inferred 
that at earlier embryo stage E9, the JM-b and JM-a might be expressed at a similar level. Because 
ErbB4 is primarily expressed in cardiomyocytes (which comprise two thirds of the volume of the 
whole heart), and not detectable in fibroblasts (which comprise one third of the volume) (Zhao et 
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al., 1998), I would propose that my study reflects the developmental regulation of ErbB4 expression 
in cardiomyocytes instead of other cells, although further experiments can be employed to confirm 
this. The decrease in the JM-a:JM-b ratio is coincident with loss of the ability of cardiomyocytes to 
proliferate. In the embryonic heart, cardiomyocytes can both proliferate and enlarge to contribute to 
the cardiac growth. However, shortly after birth, the cardiomyocytes exit the cell cycle and heart 
growth becomes dependent on cardiomyocyte enlargement (cardiomyocyte hypertrophy) 
(Markwald et al., 2010).Whilst the ability of ErbB4 to promote cardiac development is well-
established in literature (section 1.6.7), it is not yet known whether the different isoforms of ErbB4 
can mediate different functional effects. In many cell lines, ErbB4 isoforms have different growth 
promoting abilities. These differences are primarily related to the JM and CYT domains. By 
overexpressing full-length JM-a and JM-b in mouse embryonic astrocytes in an ErbB4-null 
background, Sardi et al. found only the cleavable JM-a isoform is capable of suppressing astrocyte 
precursor differentiation and maintaining their neurogenic potential (Sardi et al., 2006). In human 
breast cancer cells, the JM-a CYT-2 isoform was found to promote the phosphorylation of itself and 
proliferation of the cancer cells, which was proposed to be related to cleavage of the receptor 
(Määttä et al., 2006; Zhu et al., 2006b). Mammary cell lines expressing exogenous CYT-2 ICD 
grow more rapidly than the same cell line expressing CYT-1 ICD (Muraoka-Cook et al., 2009). In a 
mouse fibroblast cell line, the ICD of JM-a CYT-2 was found to interact with AP-2 to positively 
regulate the platelet-derived growth factor receptor-alpha (PDGFA) promoter leading to cell 
proliferation (Sundvall et al., 2010). Taken together with these observations, our data suggests that 
cardiomyocytes require different isoforms to proliferate or hypertrophy. Embryonic 
cardiomyocytes, for example, might require the JM-a isoform, but not the JM-b isoform, to 
proliferate. 
Although it has been confirmed in the literature (Elenius et al., 1997; Elenius et al., 1999) as well as 
in our laboratory that primary isoforms of ErbB4 in the adult heart are JM-b isoforms, there was the 
possibility that this could be altered in pathological conditions. We therefore characterized the 
cardiac expression of ErbB4 isoforms using in vivo models of ischaemia-reperfusion injury and 
pathological hypertrophy. Only the JM-a and CYT-2 isoforms are regulated after ischaemia while 
the expression levels of the JM-b and CYT-1 isoforms were not significantly altered. Although the 
increase of JM-a isoforms at 24h after ischaemia reperfusion is up to 2 fold, the absolute amount of 
JM-a is still diminutive compared to the JM-b isoforms (approximately 1:20). This suggests there is 
no alteration in the primary isoform of ErbB4 expressed in cardiac tissue, and that expression of the 
JM-b isoforms dominates in the heart, even in pathological conditions. If JM-a does relate to the 
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proliferation of the cardiomyocytes as discussed above, the low expression levels of JM-a in IR 
model described here is consistent with the limited regenerative capacity of the injured heart 
(Laflamme et al., 2011). It is believed that shortly after birth the majority of cardiomyocytes in 
heart exit the cell cycle and lose the ability to proliferate. Thus, the injured adult heart cannot be 
repaired via generation of new cardiomyocytes.  
In the pathological hypertrophy model, expression of all four isoforms was significantly reduced. 
However, since this affects all isoforms equally this change may reflect reduced transcription of the 
entire gene and not isoform specific regulation. In this model, the pathological hypertrophy is 
induced by genetically overexpressed calcineurin, a calcium-dependent phosphatase. It causes 
cardiac hypertrophy via dephosphorylating the transcription factor NF-AT3 and enabling its 
translocation to the nucleus where NF-AT3 can interact with GATA4 to activate cardiac 
transcription and hypertrophic growth (Molkentin et al., 1998). The decrease of ErbB4 in 
pathological hypertrophy suggests that ErbB4 is not required by the calcineurin signalling to 
mediate cardiac hypertrophy. NRG1 induces cardiomyocyte hypertrophy via activation of ERK 
(Baliga et al., 1999), which can also activate the GATA4 to contribute to the hypertrophic growth 
(Yanazume et al., 2002; Akazawa et al., 2003). However, the activation of calcineurin signalling 
and NRG1-ErbB4 signalling in vivo leads to different results in the heart. The former eventually 
leads to heart failure following cardiac hypertrophy (Molkentin et al., 1998) whereas the latter 
enhances cardiac function via regulating contractile and sarcomere proteins in cardiomyocytes 
(Jiang et al., 2010) and reducing the cardiomyocyte death even in the presence of pathological 
stress, such as infarction, cardiomyopathy and myocarditis (Liu et al., 2006). 
In addition to investigating the regulation of ErbB4 isoform expression in various models, I also 
studied the cleavage of JM-a isoforms. While specific cleavage of JM-a ErbB4 isoforms was 
confirmed in transfected HEK294 cells, no cleavage was observed in neonatal rat cardiomyocytes 
stimulated with either PMA or NRG1. This result was first demonstrated by Western blot and 
confirmed by observing the trafficking of ErbB4 with confocal microscopy live cell imaging. If the 
JM-a isoform cannot be cleaved in cardiomyocytes, there may be no functional differences between 
the JM-a and JM-b isoforms. Our lab has previously detected expression of both isoforms in 
purified cultures of primary neonatal rat cardiomyocytes (Dr. Hsiu-wen Chan, PhD thesis) and 
expression of the JM-b isoform is much higher than the JM-a isoform (Mr. Hengbo Shi, 
unpublished data). If there is no functional difference, the reasons underlying the marked difference 
in the expression levels of JM-a and JM-b isoforms in postnatal cardiomyocytes remain unclear.  
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The reason for the lack of cleavage of JM-a in cardiomyocytes has not been identified. One 
possibility is that cardiomyocytes lose some components required for the cleavage during the 
isolation and purification of the cells, and therefore cannot cleave ErbB4 in vitro. For instance, the 
functional loss of protein, such as the expression of AT1R, during cardiomyocyte isolation has been 
proposed previously (Thomas et al., 2002). Another possibility is that cardiomyocytes require the 
surrounding cells, such as fibroblasts or endothelial cells, in order to undertake cleavage. As 
discussed in section 1.4.2, the mechanism for JM-a isoform cleavage (in other cell types) involves 
the activation of ADAM17 or MMP to cleave the JM-a isoform in the juxtamembrane region and 
remove the ectodomian from the receptor (Rio et al., 2000; Chang-Yuan et al., 2001). The 
remaining intracellular part of the receptor anchored in the cell membrane is then subjected to 
additional cleavage by γ-secretase to generate the 80 kD ICD (Rio et al., 2000; Chang-Yuan et al., 
2001). However, the mechanism is still not fully resolved and additional proteins may be involved 
in this process. Whether cardiomyocytes are subject to the full range of ErbB4 regulation observed 
in other cell types is unknown. Perhaps some unidentified components located on the membrane of 
neighbouring cells can cause cleavage of a substrate located on the membrane of adjacent 
cardiomyocytes - if so, this would explain why we did not observe JM-a cleavage in purified 
cardiomyocytes. Moreover, we only examined ErbB4 receptor trafficking after stimulation with 
factors that are known to induce cleavage of the JM-a isoform in other cell types. It is possible that 
there are additional factors that can induce cleavage of the JM-a isoform which have not yet been 
identified, and that these may initiate cleavage of the JM-a isoform in cardiomyocytes. 
Finally, my study found that all four isoforms of ErbB4 can mediate NRG1-induced cardiomyocyte 
hypertrophy. This suggests that the pro-hypertrophic ability of the four isoforms depends on a 
common feature among them (e.g. the tyrosine kinase activity), but does not relate to possession of 
the cleavable domain or intracellular binding domain. However, the magnitude of hypertrophy 
seems to be influenced by the CYT domain although this was not statistically significant due to 
inherent variability in the data set. One reason why the CYT2 isoform can promote hypertrophic 
signalling more than CYT1 may be due to the intracellular kinase domain, which is more easily 
phosphorylated in CYT2 isoforms (Sundvall et al., 2007). The mechanism for this is still not clear, 
however it is proposed that a “loop structure” exists in the intracellular domain possessing CYT1, 
and that this may inhibit tyrosine kinase activity (Sundvall et al., 2007). Our data suggests that the 
JM-a and JM-b isoforms have comparable abilities to promote hypertrophic signalling. This is 
consistent with earlier studies in this chapter suggesting the JM-a isoform cannot be cleaved in 
purified cardiomyocytes. The only known difference between the JM-a and JM-b isoforms is that 
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the JM-a isoform can be cleaved while the JM-b cannot. If cardiomyocytes lack the JM-a cleavage 
mechanism, I would not predict any functional difference between the JM-a and JM-b isoforms. 
This could explain the absence of functional differences between JM-a and JM-b isoforms in our 
hypertrophic signalling experiments. It should be noted that the hypertrophic gene signal in all the 
‘rescued’ groups is greater than that of the controls, suggesting that the expression level of the 
delivered ErbB4 isoforms is higher than endogenous expression levels. This high expression might 
mask the potential differences between the four isoforms in their ability to mediate hypertrophy. 
There is the possibility that when expressed at a lower level (closer to that of endogenous 
expression), the capacity of individual ErbB4 isoforms to differentially regulate hypertrophic gene 
expression may be exposed. Taken together, in my study, no cleavage of the JM-a isoforms has 
been found in cardiomyocytes, and the ability of ErbB4 to promote hypertrophic seems to be kinase 
activity dependent and independent of isoform cleavage.   
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5. Function of ErbB4 in the adult heart 
5.1 Background 
ErbB4 is critical for heart development, anti-apoptosis and hypertrophy. Global deletion of ErbB4 is 
lethal by embryonic day 11 in mice due to defective development of the heart (Gassmann et al., 
1995). The heart defect in the ErbB4 null mice could be rescued by expressing ErbB4 under a heart 
specific myosin promoter. These mice reached adulthood and are fertile (Tidcombe et al., 2003), 
indicating that ErbB4 plays a significant role in heart development. In addition to cardiac 
development, ErbB4 signalling also prevents cardiac injury in adults. The ErbB4 agonist 
neuregulin1 (NRG1) rescues adult ventricular myocytes from hypoxia-reoxygenation-induced 
apoptosis, whereas the endothelium-selective deletion of NRG1 decreases the ability of the 
myocytes to tolerate an ischemic insult (Hedhli et al., 2011). Exogenous NRG1 also decreased the 
number of apoptotic cells and improved heart function in a rat model of diabetic cardiomyopathy 
with systolic and diastolic dysfunction (Li et al., 2011), and in cultured myocytes NRG1 inhibits the 
apoptosis induced by serum starvation (Zhao et al., 1998). Taken together, these studies indicate 
that NRG-ErbB4 signalling is important in cardiac protection. Finally, ErbB4 also mediates cardiac 
hypertrophy. NRG1 promotes hypertrophy in both adult and neonatal rat primary cardiomyocytes, 
which is accompanied by enhanced expression of the hypertrophic genes ANP and skeletal α-actin 
(Zhao et al., 1998), indicating that ErbB4 might play an important role in adult cardiac function and 
structure maintenance. To date, few studies have examined the role of ErbB4 in the adult heart. A 
study using a targeted knockout model demonstrated that cardiac specific deletion of ErbB4 led to 
severe dilated cardiomyopathy in adult mice, characterized by thinner ventricular walls with 
reduced contractility and conduction delays (Garcia-Rivello et al., 2005). However, in this study 
deletion of the ErbB4 occurred before birth making it hard to exclude the possibility that the 
cardiomyopathy observed in the adult stage was due to a defect during cardiac development. To 
overcome the requirement of ErbB4 for cardiac development and investigate the function of ErbB4 
in the adult heart, we used a conditional knockout model, the αMHC-MerCreMer/loxP system 
(Sohal et al., 2001), to specifically delete ErbB4 from adult cardiomyocytes. 
The Cre-loxP system is a commonly used tool to provide targeted gene deletion. Cre recombinase is 
found in P1 bacteriophage and is a 38kD site-specific recombinase that catalyzes the recombination 
between two DNA recognition sites, termed loxP (Hamilton and Abremski, 1984). The loxP site is 
a 34 bp consensus sequence, consisting of a core spacer sequence of 8bp and two 13bp palindromic 
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flanking sequences. The asymmetric core sequence defines the orientation of the loxP site. The Cre 
recombinase can excise a DNA segment from the genome when the segment is flanked by loxP 
sites in the same orientation (Nagy, 2000). To delete genes in a tissue specific manner, Cre 
recombinase can be driven by a tissue specific gene promoter. To give temporal control of gene 
deletion, Cre recombinase can be fused to a mutated estrogen receptor ligand binding domain (ER-
LBD) (MerCreMer) (Nagy, 2000; Chien, 2001). This mutant ER selectively binds the synthetic ER 
antagonist tamoxifen (rather than endogenous estrogen), and upon tamoxifen treatment, the 
activated ER-LBD causes translocation of Cre recombinase to the nucleus, where it causes 
recombination of the gene flanked by loxP (Sohal et al., 2001). Thus, in this system, the targeted 
gene deletion is not only tissue specific but also temporally controlled by tamoxifen injection. The 
first application of this system to gene deletion from cardiomyocytes was achieved by Sohal et al. 
in 2001 (Sohal et al., 2001). They linked the cardiac-specific α-MHC (alpha-myosin heavy chain) 
promoter to the Cre/ER-LBD gene (αMHC-MerCreMer transgene). Transgenic mice with Cre-
dependent, loxP-inactivated lacZ were crossed with transgenic mice containing the αMHC-
MerCreMer gene to generate the αMHC-MerCreMer/lacZ mice. Using lacZ as a reporter, they 
demonstrated that tamoxifen-induced Cre activity caused 80% recombination of targeted gene in the 
embryonic, neonatal, or adult heart, but not other tissues. Taking advantage of this model, we will 
delete ErbB4 from adult mice heart to investigate its function in this stage. 
5.2 Methods  
5.2.1 Animals 
The homozygous ErbB4
fl/fl
 mouse line (with exon2 of ErbB4 gene flanked by loxP sites) was 
crossed with the homozygous αMHC-MerCreMer mouse line (Cre+/+) to generate double 
heterozygous αMHC-MerCreMer and ErbB4-floxed mice (Cre+/-/ErbB4fl/wt). These mice were then 
backcrossed with the ErbB4
fl/fl line to generate heterozygous αMHC-MerCreMer and homozygous 
ErbB4-floxed animals (Cre
+/-
/ErbB4
fl/fl
), and homozygous Cre
-/-
ErbB4
fl/fl 
mice in the offspring 
(Figure 5.1). To generate the Cre
+/-
/ErbB4
wt/wt 
animals, Cre
+/-
/ErbB4
fl/wt
 mice were backcrossed with 
Cre
+/+ 
mice (Figure 5.4). The original homozygous ErbB4
fl/fl
 and homozygous α-MHC-MerCreMer 
mice lines (Cre
+/+
) were obtained from Dr Kent Lloyd, University of California (Mutant Mouse 
Regional Resource Centres) and Jackson Laboratories, respectively. Both of the strains are on a 
B6/129 mixed background. 
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Animals were housed under standard conditions at 22°C with a 12-h light/12-h dark cycle and free 
access to water and commercial mouse chow. All experiments were conducted in accordance with 
the Australian Code of Practise for Care and Use of Animals for Scientific Purposes and approved 
by the institutional ethics committees of The University of Queensland. 
5.2.2 Genotyping 
Mice were toe-clipped at 7-10 days of age to provide tissue samples for genotyping. The toes were 
digested in DNA extraction buffer (100 mM Tris-HCl (pH8.5), 5 mM EDTA (pH8.0), 200 mM 
NaCl, 0.2% SDS and 0.48mg/ml proteinase K) at 55°C overnight. The genomic DNA was 
precipitated with ammonium acetate and ethanol before PCR amplification using primers specific 
for Cre, or ErbB4 wild type
 
and ErbB4 floxed DNA sequences (Figure 5.2 A). The former reaction 
will yield a 440bp band (Cre), and the latter will yield 350bp and 400bp products for ErbB4 wild 
type
 
and ErbB4 floxed alleles respectively. The primer sequences are listed in Appendix B. PCR 
reactions (20μl total volume) contained 20 ng genomic DNA, 0.5 µM of each primer, 0.2 mM each 
of dNTPs, 5% DMSO, 0.375 U of Phire Hot Start II DNA Polymerase (Finnzymes) and 1× Phire 
reaction buffer (final concentration). The PCR cycling conditions started with an initial denaturation 
at 98°C for 30s, followed by 35 cycles of denaturing at 98°C for 5 s, annealing at 58°C for 5 s (for 
ErbB4 floxed and wild type) or 55°C for 5 s (for Cre), extension at 72°C for 10s, and a final 
incubation at 72°C for 1 min. PCR products were separated using 1.5-2% agarose gel 
electrophoresis and images were captured with the Quantity One system. To detect the Cre copy 
number, qPCR (SYBR) was employed to quantify the genomic Cre level and genomic 18S level 
was used as an internal control. The qPCR condition followed the standard amplification protocol 
(refer to section 2.8). The sequence of primers used is listed in Appendix B.  
5.2.3 Tamoxifen injection 
To induce Cre-mediated recombination, all animals (9-10 week of age) were treated with tamoxifen 
(Sigma) by intraperitoneal injection for 10 consecutive days at a dosage of 20 mg/kg/day. 
Tamoxifen was dissolved in peanut oil at a concentration of 4 mg/ml at 37°C for 2 hours and made 
up fresh each day. The success of deletion of ErbB4 in the Cre
+/-
ErbB4
fl/fl 
mouse heart was 
determined by qPCR in an initial cohort of animals at 10 days after tamoxifen injection. Separate 
cohorts of animals were then phenotypically examined at 3-4 months or 7-8 months after tamoxifen 
injection. 
Chapter 5: Function of ErbB4 in adult heart 
 
103 
 
5.2.4 Echocardiography 
Echocardiography was conducted on all animals using a Philips HD15 ultrasound system equipped 
with a 15-MHz transducer. Mice were anesthetized with 2% isoflurane in O2 by inhalation and 
normal body temperature was maintained using an external heat source. Two-dimensional mid-
papillary level short axis views of the ventricle were captured. M-mode images were obtained by 
positioning a cursor in the 2-dimensional view from the anterior to the posterior wall of the left 
ventricle and adjacent to the two papillary muscles. M-mode images were used to obtain the 
following measurements during both systole and diastole: interventricular septal thickness (IVS), 
left ventricular posterior wall thickness (LVPW), left ventricular internal diameter (LVID). The 
fractional shortening (FS) was calculated using the equation (FS= (LVID (diastolic)-LVID 
(systolic))/LVID (diastolic)). The measurements were repeated 5 times over 5 cardiac cycles for 
each parameter and the average of these used for statistical analysis. Heart rate was monitored by 
electrocardiography during the procedure. The experimenter was blinded to the genotype of the 
animals for all echocardiographic assessments and decoded post-analysis.  
5.2.5 Measurement of heart/kidney/body weight and tibial length  
Animals were euthansed and the heart and kidneys was carefully removed and weighed. Tibial 
length was measured after the skeletal muscle was completely removed from the bone. The left and 
right tibias were measured three times each with a digital calliper, and the average of these 6 
measurements was used as the final tibial length for each mouse. 
5.2.6 Histology  
Mid-ventricular sections were fixed in 4% PFA for 48 hours and then embedded in paraffin. 
Sections (5 μm thick) cut from paraffin-embedded specimens was deparaffinised in xylene followed 
by hydration through an ethanol gradient to PBS or distilled water before being used for wheat germ 
agglutinin (WGA) staining, Masson's trichrome staining, TUNEL staining or immunofluoresence.  
5.2.7 WGA staining 
Sections were incubated with 50 μg/ml WGA conjugated with Alexa Fluor®594 (Invitrogen) for 60 
min, washed 3 times with PBS and mounted for fluorescence microscopy. 5 images were taken for 
each section under 400 × magnification. The images were taken randomly from two fields next to 
the endocardium, two fields next to the epicardium and one field in the papillary muscle area. In 
each field, the cross sectional area of 40 - 130 cells was measured. For the cell size quantification, 
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images were opened with Image J. To perform an unbiased measurement, a grid with 3×4 
(horizontal × vertical) test lines was generated with Image J and applied to every image. Only cells 
intersected with the grid lines were measured and the experimenter was blinded for all 
measurements. 
5.2.8 Masson’s trichrome staining 
Masson’s trichrome staining was performed according to the manufacturer’s protocol 
(Polysciences). Briefly, sections were merged in Bouin’s solution at 60°C for 1 hour, washed in 
running tap water to for 5 minutes, followed by incubation in Weigert’s iron hematoxylin working 
solution for 10 minutes. After washing in running tap water, sections were placed in Biebrich 
Scarlet-Acid Fuchsin Solution for 5 minutes and rinsed in distilled water. Sections were 
differentiated with phosphotungstic/phosphomolybdic acid for 10 minutes and transferred directly 
into Aniline blue for 5 minutes for counterstaining. Sections were rinsed in distilled water before 
differentiating in 1% Acetic acid for 1 minute and performing a final rinse in distilled water. This 
stains collagen fibres in blue, nuclei in black and the cytoplasm in red. Five images were captured 
for each section and the area of cardiac fibrosis (excluding the perivascular area) was measured 
using Image J.  
5.2.9 Immunofluorescence 
For phospho-histone3 (pH3) staining and Troponin-T co-staining, the slides were pretreated with 
antigen retrieval buffer (refer to Appendix A for composition) at 110°C for 20 min in a Decloaker 
apparatus before gradually cooling to room temperature by addition of PBS. Following this, the 
slides were permeabilized in 0.3% Triton for 5 min before being washed with PBS and blocked 
with 10% goat serum at room temperature for 20 min. Sections were then incubated with anti-
phosphohistone H3 (rabbit, Millipore) and anti-Troponin-T (mouse, Thermoscientific) primary 
antibodies (1:100 dilution with 2% goat serum in PBS) at 4°C overnight. After washing 3 times 
with PBS, the sections were incubated with Alexa Fluor 488-conjugated (goat anti-rabbit, 
Invitrogen) and Alexa Fluor 555-conjugated secondary antibodies (goat anti-mouse, Invitrogen) at 
RT for 1h. Hoechst (10µg/ml, Sigma) stain was used to visualize nuclei before slides were washed 
3 times in PBS and mounted with Fluoromount G mounting medium (Southern Biotech).  
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5.2.10 Statistical analysis 
Values are expressed as mean ± SEM, unless indicated otherwise. Comparisons between wild-type 
and ErbB4 conditional knockout animals were analysed by unpaired Student’s t-test using 
Graphpad Prism 6. P values ≤ 0.05 were considered significant. 
 
Chapter 5: Function of ErbB4 in adult heart 
 
106 
 
5.3 Result 
5.3.1 Generation of Cre+/-ErbB4fl/fl mice 
To investigate the function of ErbB4 in adult mice heart, I adopted the αMHC-MerCreMer/loxP 
system, which allowed me to delete the ErbB4 receptor from cardiomyocytes in adult mice. Two 
original breeding lines of mice (homozygous αMHC-MerCreMer mice (Cre+/+) and homozygous 
ErbB4
fl/fl
) were used to generate Cre
+/-
/ErbB4
fl/fl
, and Cre
-/-
/ErbB4
fl/fl 
mice (section 5.2.1 and Figure 
5.1). Following tamoxifen injection, the ErbB4 can be deleted from cardiomyocytes in Cre
+/-
/ErbB4
fl/fl 
animals since they contain both Cre and loxP flanked-ErbB4 genes, but not in the Cre
-/-
/ErbB4
fl/fl 
animals, which lack the Cre gene. Thus Cre
+/-
/ErbB4
fl/fl 
animals were used as the 
knockout group and ErbB4
fl/fl 
animals were used as the control group. In total, 9 breeding pairs of 
Cre
+/-
/ErbB4
fl/wt
 and ErbB4
fl/fl 
produced 75 offspring.  
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Figure 5.1 Breeding scheme for transgenic animal generation. The original homozygous 
ErbB4
fl/fl 
breeders were bred with homozygous Cre
+/+
 breeders to generate double heterozygous 
Cre
+/-
/ErbB4
fl/wt 
mice. These were then backcrossed with the ErbB4
fl/fl
 mice to generate Cre
+/-
/ErbB4
fl/fl
 mice (conditional knockout group) and the Cre
-/-
ErbB4
fl/fl
 mice (control group).  
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5.3.2 Genotyping  
All offspring were genotyped using separate PCR reactions for the Cre and Floxed ErbB4 
transgenes. To detect the inserted Cre gene, PCR was used to amplify a 440 bp Cre gene fragment 
from whole DNA genome (Figure 5.2 A). A single band in 440bp in electrophoresis indicates the 
Cre positive genotype and otherwise indicates the Cre negative genotype (Figure 5.2 B). To 
differentiate the ErbB4
fl/fl 
animals from the ErbB4
fl/wt
 animals, PCR was used to amplify the wild 
type ErbB4 gene fragment and the mutated fragment (flanked by loxP site) with three primer sets in 
one reaction. One is a common sense primer annealing the 5’ sequence in exon2 of ErbB4, and the 
others are two reverse primers annealing to the 3’ sequence in exon2 and the sequence in the loxP 
site, separately (Figure 5.2 A). A single band in 400 bp in electrophoresis indicates the ErbB4
fl/fl 
genotype, and two bands in a 350 bp and 400 bp, separately indicated the ErbB4
fl/wt 
genotype 
(Figure 5.2 B) (Jackson-Fisher et al., 2006). Among the 75 offspring produced, 20 mice were the 
Cre
+/-
/ErbB4
fl/fl 
genotype and 20 mice were the Cre
-/-
ErbB4
fl/fl
.  
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Figure 5.2 Genotyping of the Cre recombinase and floxed ErbB4 transgenes. A. The 
presence or absence of the Cre recombinase gene was determined by amplifying a 440 bp 
region of the Cre gene. In separate PCR reactions, we used a common sense primer binding 
within exon 2 of ErbB4, and two anti-sense primers which bound either the downstream 
region of exon2 or within the loxP site. This led to amplification of both the wild type (350 bp 
PCR product) and floxed ErbB4 (400 bp product) genes, respectively. Reaction products were 
separated by agarose gel electrophoresis (1.5% and 2% for Cre recombinase and ErbB4 
respectively) B. Representative image of agarose gel electrophoresis for genotyping. Lane 1 
represents the Cre
-/-
ErbB4
fl/wt 
genotype, lane 2 and 3 represent Cre
+/-
/ErbB4
fl/fl
, lane 4, 6, and 7 
represent Cre
-/-
ErbB4
fl/fl 
and lane 5 represents the Cre
+/-
ErbB4
fl/wt
 genotype. 
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5.3.3 Optimization of tamoxifen administration 
In this conditional knockout animal model, the deletion of ErbB4 is triggered by administration of 
tamoxifen. An insufficient dose of tamoxifen may cause failure of the deletion, but too high a dose 
of tamoxifen is toxic and may lead to the death of the mouse. Previous work in our lab used 3 
different doses of tamoxifen: 20, 30 and 40 mg/kg/day for four days of consecutive ip injection. At 
the highest dose (40 mg/kg/day), tamoxifen induced an efficient deletion of ErbB4, but with a high 
mortality rate. The intermediate dose of tamoxifen (30 mg/kg/day) induced less deletion of ErbB4, 
and greatly reduced the mortality rate. The lowest dose of tamoxifen (20 mg/kg/day) failed to 
induce the deletion of ErbB4 (Schlegel et al., unpublished data). To avoid the toxicity associated 
with high dose tamoxifen yet still achieve significant deletion of ErbB4, we tested the low dose of 
tamoxifen over an extended injection period (Hsieh et al., 2007). We injected Cre
+/-
/ErbB4
fl/fl 
and 
Cre
-/-
/ErbB4
fl/fl 
animals
 
with 20 mg/kg/day tamoxifen for 10 consecutive days. Animals were 
allowed 10 days recovery after the end of the tamoxifen treatment before being euthanased and 
tissues examined for ErbB4 expression by qPCR. This treatment regime had no obvious adverse 
effects on the health of the animals. The RT-qPCR revealed that the mRNA level of ErbB4 in heart 
was reduced by ~ 90% compared to the control, but the mRNA level of ErbB4 in skeletal muscle 
was not changed (Figure 5.3), thus confirming specific deletion of ErbB4 in the heart.  
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Figure 5.3 Heart-specific deletion of ErbB4 in knockout animals.  Mice in both groups were 
injected with tamoxifen (20 mg/kg/d ip) for 10 days. After 10 days of recovery, animals were 
euthansed and RNA was extracted from heart (A) and skeletal muscle (B) tissue. The 
expression level of ErbB4 was determined using RT-qPCR, and normalized to 18S (endogenous 
control). Data was expressed relative to the Cre
-/-
ErbB4
fl/fl
 group. Data was analysed by 
unpaired Student’s t-test and presented as mean  SEM. * P<0.05 compared with Cre-/-ErbB4fl/fl 
group; Cre
-/-
ErbB4
fl/fl
 group, n=6; Cre
+/-
ErbB4
fl/fl
 group, n=3.  
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5.3.4 Generation of the Cre+/-/ErbB4wt/wt animals 
In the study above, Cre
+/-
/ErbB4
fl/fl 
animals were used as the ErbB4 conditional knockout group 
(ErbB4-cKO)
 
and Cre
-/-
/ErbB4
fl/fl 
animals as the control group. Because all animals received 
tamoxifen treatment, the effect of the drug itself potentially affecting the result can be excluded in 
this model. Another advantage of this model is that ErbB4-cKO and control animals can be 
generated from the same breeding and thus the cost for breeding was reduced and the workload for 
genotyping was minimized. Using these animals, we answered the question whether the ErbB4 can 
be deleted from the heart with tamoxifen injection and screened the optimal dose and treatment 
period of tamoxifen. However, the obvious possible confounder in this model is that the ErbB4-
cKO group has increased Cre activity whereas the control group did not. Thus, enhanced Cre 
activity is another factor induced in the ErbB4-cKO group, besides the ErbB4 deletion. 
Accumulated studies have proposed that the Cre recombinase itself might be cardiotoxic 
(Koitabashi et al., 2009; Hall et al., 2011). Accordingly, whether any phenotype of the cardiac 
ErbB4 deleted mice (Cre
+/-
/ErbB4
fl/fl
) is due to the loss of ErbB4, or due to the induction of Cre 
activity might be hard to determine. To evaluate the effect of Cre recombinase activity, I compared 
cardiac parameters in Cre positive animals (Cre
+/-
/ErbB4
wt/wt
) and Cre negative animals (Cre
-/-
/ErbB4
fl/fl
) at 3-4 and 7-8 months after tamoxifen injection. The generation of the Cre
+/-
/ErbB4
wt/wt 
animals was described in 5.2.1. There are four potential genotypes in the offspring (Figure 5.4). To 
distinguish between offspring that were homozygous or heterozygous for Cre recombinase, we used 
qPCR to determine the Cre recombinase copy number. Two pairs of primers, pair Cre1 (pcre1) and 
pair Cre2 (pcre2) (refer to Appendix B for sequence), were designed to amplify two different region 
of Cre gene (Figure 5.5 A). Animals of a known genotype were used to show that we could 
successfully identify animals with any pair of primers that were heterozygous, homozygous or 
lacking the Cre gene (Figure 5.5 B). This method was then applied to detect the copy number of Cre 
in animals with unknown genotype (Figure 5.5 C). Among 107 offspring generated, 22 mice were 
Cre
+/-
ErbB4
wt/wt 
animals. 
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Figure 5.4 Breeding scheme for control animal generation. Homozygous ErbB4
fl/fl 
mice 
were bred with homozygous Cre
+/+
 mice to generate double heterozygous Cre
+/-
/ErbB4
fl/wt
 
mice. These were then backcrossed with the Cre
+/+
 mice to generate Cre
+/-
/ErbB4
wt/wt 
mice. 
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Figure 5.5 Cre copy number detected with qPCR. A. Two pairs of primers (termed as pcre1 
and pcre2, refer to the Appendix B for the primer sequence) were designed to amplify the 
different regions of the Cre gene. B. Homozygous, heterozygous and wild type Cre animals can 
be differentiated by qPCR with both pairs of primers (validation using animals of known 
genotype). C. Representative graph for detection of Cre copy number in animals with unknown 
genotypes. 
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5.3.5 Determining the effects of Cre recombinase on the heart 
To detect whether Cre activity itself induces a cardiac phenotype in adult mice without deletion of 
the floxed gene, we examined cardiac functional parameters on Cre
+/-
/ErbB4
wt/wt 
(Cre positive) and 
Cre
-/-
/ErbB4
fl/fl 
(Cre negative) animals at 3-4 or 7-8 months after the tamoxifen treatment. 
Echocardiography revealed that the left ventricular internal dimensions diastole (LVIDd) and 
systole (LVIDs) and fractional shortening (FS) (calculated as (LVIDd-LVIDs/LVIDd) was not 
significantly different between the two groups at 3-4 months post-tamoxifen, suggesting that the 
contractile ability of the heart was not affected by the induction of Cre (Figure 5.6 A and B). 
Similarly, the left ventricular wall thickness (reflected by the intraventricular septal wall thickness 
(IVS) and left ventricle posterior wall thickness (LVPW)) was not changed at 3-4 months post-
tamoxifen (Figure 5.6 C). There was a modest decrease in fractional shortening in Cre positive 
animals at 7-8 months after tamoxifen injection, but this was not statistically significant (Figure 5.7 
A). However, at 7-8 months post-tamoxifen both the IVS (systolic) and LVPW (both systolic and 
diastolic) were significantly decreased in Cre positive animals (Figure 5.7 B and C). This data 
suggests that that even short-term increases in Cre activity can have long-term effects on cardiac 
structure. This result was confirmed by the data from post-mortem studies, which showed that the 
heart weight:tibia length ratio of the Cre positive animals was significantly decreased at both 3-4 
and 7-8 months post-tamoxifen (Figures 5.8 and 5.9). This was specific to the heart, as kidney 
weight was not changed during this period. This indicates that the cardiac-specific induction of Cre 
activity might cause the loss of cardiac mass. Then we investigated the expression of hypertrophic 
(α-MHC,β-MHC and BNP) and fibrosis genes (COL1A1 and PAI-1) in Cre positive and negative 
animals. RT-qPCR revealed that the hypertrophic genes and fibrosis genes are expressed at similar 
levels in both groups (Figure 5.10 A and B). In addition, expression of the ErbB receptors (ErbB1 
and ErbB4) was also not affected by Cre activity (Figure 5.11). Together, these data indicate that 
induction of Cre activity can have a long term effect on the heart, although the mechanism of this is 
not clear. However, this does suggest that the Cre
-/-
/ErbB4
fl/fl 
genotype is not an appropriate control 
for our study. To circumvent the negative effect of Cre activity on cardiac tissues, I used the Cre-
only transgenic mice (Cre
+/-
/ErbB4
wt/wt
) as the control in our following study examining the effects 
of cardiac ErbB4 deletion (Molkentin et al., 2009). Both Cre
+/-
/ErbB4
fl/fl 
(ErbB4 conditional 
knockout group, ErbB4-cKO) and Cre
+/-
/ErbB4
wt/wt 
(control group) animals received tamoxifen 
treatment. Around 3-4 months or 7-8 months later, the cardiac phenotype of ErbB4 deletion was 
determined.
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Figure 5.6 Effect of Cre recombinase induction on cardiac function at 3-4 months post-
tamoxifen. A. Example of a typical echocardiogram in 2D (top) and M-mode (bottom) obtained in 
short axis view for the Cre negative (Cre
-/-
/ErbB4
fl/fl
, left) and Cre positive (Cre
+/-
/ErbB4
wt/wt
, right) 
animals. B. Left ventricular internal dimensions during diastole (left) and systole (middle) and 
fractional shortening (right) in Cre negative (Cre Neg.) and Cre positive (Cre Pos.) animals. C. 
Intraventricular septal wall thickness of diastolic (IVSd) and systolic (IVSs) dimension and left 
ventricle posterior wall thickness of diastolic (LVPWd) and systolic (IVPWs) dimension in Cre 
negative and Cre positive animals. Data was analysed by unpaired Student’s t-test and presented as 
mean  SEM.  
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Figure 5.7 Effect of Cre recombinase induction on cardiac function at 7-8 months post-
tamoxifen. A. Left ventricular dimensions during diastole (left) and systole (middle) and fractional 
shortening (right) in Cre negative (Cre
-/-
/ErbB4
fl/fl
,
 
Cre Neg.) and Cre positive (Cre
+/-
/ErbB4
wt/wt
,
 
Cre 
Pos.) animals. B. Intraventricular septal wall thickness of diastolic (IVSd) and systolic (IVSs) 
dimension and left ventricle posterior wall thickness of diastolic (LVPWd) and systolic (LVPWs) 
dimension in Cre negative and Cre positive animals. Data was analysed by unpaired Student’s t-test 
and presented as mean  SEM. * P<0.05 compared with Cre Neg.; ** P<0.01 compared with Cre 
Neg.; Cre Neg., n=9; Cre Pos., n=7. 
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Figure 5.8 Effect of Cre recombinase induction on heart weight at 3-4 months post-
tamoxifen. The heart weight normalized to tibial length (HW:TL) (A), kidney weight to tibial 
length (KW:TL) (B), the tibial length (TL) (C) and body weight (BW) (D) was measured in 
Cre positive and Cre negative animals at 3-4 months after induction of Cre activity. Data was 
analysed using unpaired Student’s t-test and presented as mean  SEM. * P<0.05 compared 
with Cre Neg.; Cre Neg., n=9; Cre Pos., n=8. 
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Figure 5.9 Effect of Cre recombinase induction on heart weight at 7-8 months post-
tamoxifen. The heart weight (normalized to tibial length) (A), kidney weight to tibial length 
(B), the tibial length (C) and body weight (D) was measured in Cre positive and Cre negative 
animals at 7 months after induction of Cre activity. Data was analysed using unpaired 
Student’s t-test and presented as mean  SEM. ** P<0.01 compared with Cre Neg.; Cre Neg., 
n=9; Cre Pos., n=8. 
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Figure 5.10 The regulation of hypertrophic genes and fibrosis genes at 8 months following Cre 
induction.  Expression of the hypertrophic genes BNP, α-MHC, β-MHC and fibrosis genes 
COL1A1 and PAI-1 were detected by RT-qPCR, normalized to 18S (endogenous control) and 
expressed relative to the Cre negative group. Data was analysed using unpaired Student’s t-test and 
presented as mean  SEM. Cre Neg., n=9; Cre Pos., n=8. 
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Figure 5.11 The expression of ErbBs was not affected by the induction of Cre activity. 
Expression of ErbB1 and ErbB4 was detected with RT-qPCR, normalized to18S (endogenous 
control) and expressed relative to the Cre negative group. Data was analysed using unpaired 
Student’s t-test and presented as mean  SEM. Cre Neg., n=9; Cre Pos., n=8. 
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5.3.6 Effect of cardiac-specific deletion of ErbB4 on cardiac function 
As shown in Figure 5.3, tamoxifen treatment of ErbB4-cKO (Cre
+/-
ErbB4
fl/fl
)
 
mice deleted 
approximate 90% of cardiac ErbB4 at 10 days after the tamoxifen treatment (measured by RT-
qPCR). At 3-4 months after the tamoxifen injection, we performed echocardiography on the mice to 
examine their cardiac function. Key echocardiography parameters were measured in both systolic 
and diastolic phase, including left ventricular internal dimension (LVID), intraventricular septum 
thickness (IVS) and left ventricle posterior wall thickness (LVPW). Statistical analysis revealed a 
marked increase in the diastolic LVID, suggesting the ErbB4-cKO animals might undergo heart 
enlargement. No significant difference in systolic LVID was observed between the ErbB4-cKO and 
control (Cre
-/-
ErbB4
fl/fl
) animals (Figure 5.12 A). In addition, there was no significant change in the 
fractional shortening in ErbB4-cKO animals, indicating that the contractile ability of the heart was 
not affected after 3-4 months of ErbB4 deletion. The systolic IVS in ErbB4-cKO animals was 
significantly increased and the diastolic IVS tended to increase, but was not statistically significant 
(Figure 5.12 B).  
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Figure 5.12 Echocardiographic assessment of cardiac function at 3-4 months after ErbB4 
deletion. A. The diastolic (left) and systolic (middle) left ventricular internal dimension and 
fractional shortening (right) were measured in ErbB4-cKO and control animals. B. The diastolic 
and systolic IVS and left ventricle posterior wall thickness in diastolic and systolic dimension were 
measured in ErbB4-cKO (n=5) and control animals (n=7). Data was analysed using unpaired 
Student’s t-test and presented as mean  SEM. * P<0.05 compared with control; control, n=7; 
ErbB4-cKO, n=5. 
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5.3.7 Effect of cardiac-specific deletion of ErbB4 on heart weight  
After the echocardiography measurement, both ErbB4-cKO animals and control animals were 
euthanased and the heart weight:tibia length ratio was determined. The ratio of heart weight to tibia 
length in ErbB4-cKO animals was significantly increased compared to the controls (Figure 5.13 A). 
In contrast, the kidney weight:tibia length was not changed (Figure 5.13 A). This suggested that the 
knockout of ErbB4 in cardiomyocytes leads to cardiac hypertrophy. RT-qPCR was used to examine 
whether this increase in heart weight was associated with altered expression of pathological 
hypertrophy marker genes. We found that the mRNA levels of α-MHC, β-MHC and BNP in ErbB4-
cKO animals were not changed relative to the controls (Figure 5.13 B). Together, this suggested 
that the ErbB4-cKO animals undergo physiological, not pathological, hypertrophy. 
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Figure 5.13 Effect of ErbB4 deletion on heart weight. A. Heart (left) and kidney (right) 
weight was measured and normalized to tibia length in control (n=8) and ErbB4-cKO 
(n=6) animals. B. The expression of BNP, α-MHC, β-MHC as detected by qPCR were 
normalized to the 18S (endogenous control) and expressed relative to the control group.  
Data was analysed using unpaired Student’s t-test and presented as mean  SEM. *** 
P<0.001 compared with control; control, n=8; ErbB4-cKO, n=6. 
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Following the study above, we investigated the mechanisms underlying the cardiac hypertrophy 
observed in ErbB4-cKO animals. We first investigated whether the cardiomyocytes undergo 
hypertrophy, which is defined as an increase in cell mass without proliferation. As we have not 
established a system in our lab to accurately determine the mass of individual cardiomyocytes, we 
used the measurement of cross sectional area to reflect cardiomyocyte hypertrophy. Statistical 
analysis showed that there was no significant change in the cross sectional area of cardiomyocytes 
in the ErbB4-cKO group compared to the control (Figure 5.14 A and B). To further confirm this 
result, the frequency distribution of cardiomyocyte area was analysed for both ErbB4-cKO and 
control groups. If cardiomyocytes undergo hypertrophic growth, the frequency of cardiomyocytes 
with a larger cell area will increase, thus shifting the frequency distribution curve to the right and 
increasing the area range in the X axis. However, our data showed no shift, and the frequency 
distribution curves for ErbB4-cKO and control groups were similar (Figure 5.14 C). Together, these 
studies suggested that the cardiac hypertrophy caused by cardiac ErbB4 deletion in vivo is not via 
hypertrophic growth of the cardiomyocytes, but occurs by some other mechanism.   
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Figure 5.14 Effect of ErbB4 deletion on cardiomyocyte cross sectional area.  A. 
Representative images of WGA stained sections of hearts from control (top) and ErbB4-cKO 
(bottom) animals (200×). B. The grouped data for cardiomyocyte cross sectional area. Data 
was analysed using unpaired Student’s t-test and presented as mean  SEM; control, n=8; 
knockout, n=6. C. The frequency distribution of cardiomyocyte cross sectional area for control 
and ErbB4-cKO animals. Bin width is set as 50 μm2.  
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5.3.8 Effect of cardiac-specific deletion of ErbB4 on cardiac fibrosis.  
Fibroblasts are the second major component of heart tissue besides cardiomyocytes (Brown et al., 
2005). Cardiac fibrosis (where lost cardiomyocytes are replaced by proliferating fibroblasts and the 
secreted collagen) can be observed in the late stages of pathological cardiac hypertrophy (Manabe et 
al., 2002). Cardiac fibrosis can be measured by histological staining for collagen or by qPCR for the 
expression of fibrosis molecular marker genes such as alpha-1 type I collagen (COL1A1), alpha-1 
type III collagen (COL3A1) and plasminogen activator inhibitor type 1 (PAI-1). In our study, RT-
qPCR revealed that the mRNA levels of COL1A1, COL3A1 and PAI-1 didn’t change in the ErbB4-
cKO animals compared to the controls (Figure 5.15 A). To further confirm these results, we 
examined collagen deposition in heart sections using Masson’s Trichrome. Masson’s Trichrome 
stains the collagen in blue, the cytoplasm in red and the nucleus in black. The normal heart should 
have little collagen accumulated around cardiomyocytes, but some should be present in the 
perivascular area. Here, we observed blue collagen staining around the vascular area in heart 
sections from both the ErbB4-cKO and control animals. However, the myocardial area of both 
groups showed minimal collagen staining (Figure 5.15 B), suggesting that knockout of ErbB4 did 
not lead to cardiac fibrosis 
. 
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Figure 5.15 Effect of ErbB4 deletion on cardiac fibrosis. A. The expression levels of the 
fibrosis marker genes, COL1A1, COL3A1, and PAI-1 were detected by RT-qPCR and 
normalized to 18S. Data was expressed relative to the control group. Data was analysed using 
unpaired Student’s t-test and presented as mean  SEM; control, n=8; ErbB4-cKO, n=6. B. 
Representative sections of Masson’s Trichrome staining on heart tissues from control (left) and 
ErbB4-cKO animals (right).  
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5.3.9 Expression of the ErbB receptor family following ErbB4 deletion 
Only a mild phenotype was observed in the ErbB4-cKO animals, which were characterized by 
physiological cardiac hypertrophy. No severe cardiac dysfunction or other structural abnormalities 
were found. This result was surprising because accumulated evidence in literature indicates that 
ErbB4 is critical for cardiac function and structural maintenance (Gassmann et al., 1995; Tidcombe 
et al., 2003; Garcia-Rivello et al., 2005). Thus in the following study, we investigated whether the 
deletion of ErbB4 was compensated for by other ErbB receptor systems. There are four subtypes of 
ErbB receptor (ErbB1, ErbB2, ErbB3, and ErbB4) detectable in the heart. We examined whether 
the deletion of ErbB4 may trigger a compensatory up-regulation of other ErbB receptors. At 3-4 
months after ErbB4 deletion, there was a small increase in ErbB3 mRNA levels and a small 
decrease in both ErbB1 and ErbB2, however these effects did not reach statistical significance 
(Figure 5.16). Together, this suggests that the other members of the ErbB family were not 
significantly up-regulated to compensate for the deletion of the ErbB4. 
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Figure 5.16 Expression of ErbB1, ErbB2 and ErbB3 following ErbB4 deletion. The 
expression level of ErbB1, ErbB2 and ErbB3 was detected by RT-qPCR and normalized 
to the 18S. Data was expressed relative to the control group. Data was analysed using 
unpaired Student’s t-test and presented as mean  SEM; control, n=8; ErbB4-cKO, n=6. 
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5.3.10 Expression of the EGF family following ErbB4 deletion. 
Although expression of other ErbB receptors does not change after ErbB4 deletion, the activity of 
ErbBs can also be influenced by up-regulation of endogenous agonists, and this may serve as 
compensation for the lost ErbB4. There are multiple agonists (EGF-like factors) for each ErbB 
receptor, and thus we investigated whether the expression of these agonists was altered by cardiac 
ErbB4 deletion. We first studied the ErbB4 selective agonists, the NRG family (NRG1, NRG2, 
NRG3 and NRG4). NRG1 has two isoforms, NRG1α and NRG1β that are generated by alternative 
splicing. Using RT-qPCR, the expression of both NRG1α and NRG1β is dramatically up-regulated 
in ErbB4-cKO animals compared to controls (Figure 5.17 A). In contrast, the expression of NRG2, 
NRG3 and NRG4 (Figure 5.17 B) didn’t change, suggesting that the up-regulation of NRG1 is a 
specific response to the lost ErbB4. We also examined the regulation of the endogenous agonists for 
other ErbB receptors. TGFα and amphiregulin (AREG) are selective agonists for ErbB1. HB-EGF, 
epiregulin (EREG) and betacellulin (BTC) are agonists for both ErbB1 and ErbB4. ErbB2 has no 
identified ligands. However, none of these factors were regulated at the mRNA level in ErbB4-cKO 
animals (Figure 5.18). Together, this suggests that NRG1 is the only member of the EGF family 
that is specifically up-regulated after deletion of ErbB4. NRG1 is a cardioprotective factor (see 
section 1.6.3) thus the up-regulation of NRG1 might serve as compensatory mechanism to for the 
deletion of ErbB4, and may explain why we did not see any cardiac dysfunction at 3-4 months after 
ErbB4 deletion.  
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Figure 5.17 Expression of NRG family following ErbB4 deletion. The expression 
levels of NRG1α, NRG1β, NRG2, NRG3 and NRG4 was detected by RT-qPCR and 
normalized to 18S. Data was expressed relative to the control group. Data was analysed 
using unpaired Student’s t-test and presented as mean  SEM. ** P<0.01 compared with 
control; control, n=8; ErbB4-cKO, n=6. 
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Figure 5.18 Expression of other EGF-like factors following deletion of ErbB4.  The 
expression level of TGF-alpha, amphiregulin (AREG), HB-EGF, epiregulin (EREG) and 
betacelulin (BTC) was detected by the RT-qPCR and normalized to 18S. Data was 
expressed relative to the control group. Data was analysed using unpaired Student’s t-test 
and presented as mean  SEM; control, n=8; ErbB4-cKO, n=6. 
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5.3.11 The proliferation of cardiomyocytes following ErbB4 deletion 
One question raised from the experiments described in 5.3.7 is how the ErbB4-cKO mice developed 
cardiac hypertrophy when there was no evidence of cardiomyocyte hypertrophy or fibrosis. The 
classic theory considers that in adult mammals the majority of cardiomyocytes are fully 
differentiated, and therefore have a very low rate of proliferation. However, a recent study 
suggested that NRG1 might promote the proliferation of adult cardiomyocytes (Bersell et al., 2009). 
To investigate whether the up-regulation of NRG1 in ErbB4-cKO animals causes cardiomyocyte 
proliferation, we used immunofluorescence to examine expression of the proliferation marker 
phosphorylated histone H3 (pH3) in heart sections (Figure 5.19). Statistical analysis shows that the 
total number of pH3 positive cells in ErbB4-cKO animals was significantly increased, although the 
absolute number of proliferating cells remains low.  
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Figure 5.19 The proliferation of cardiac cells at 3-4 months following ErbB4 deletion. 
Heart sections in control and ErbB4-cKO animals were stained for pH3 by  
immunofluorescence. Data was analysed using unpaired Student’s t-test and presented as mean 
 SEM. * P<0.05 compared with control; control, n=8; ErbB4-cKO, n=6. 
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5.3.12 Expression of ErbB4 at 3-4 months after tamoxifen treatment 
Following the investigation into the phenotype of ErbB4-cKO animals, we confirmed that the 
ErbB4 deletion is still valid 3-4 months after the tamoxifen injection. The RT-qPCR data revealed 
that the mRNA level of ErbB4 in the ErbB4-cKO group was reduced by ~67% compared to the 
control group (Figure 5.20). 
Chapter 5: Function of ErbB4 in adult heart 
 
138 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 Expression of ErbB4 at 3-4 months after tamoxifen injection. At 3-4 months after 
tamoxifen treatment, the expression level of the ErbB4 was measured by RT-qPCR and 
normalized to the 18S. Data was expressed relative to the control group. Data was analysed using 
unpaired Student’s t-test and presented as mean  SEM. * P<0.05 compared with control; control, 
n=8; ErbB4-cKO, n=6. 
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5.3.13 Cardiac function at 7-8 months after ErbB4 deletion 
All of the phenotypic experiments described above were conducted at 3-4 months after cardiac 
ErbB4 deletion was induced with tamoxifen. However, 3-4 months may be not long enough for the 
conditional ErbB4-cKO mice to develop a severe phenotype. To determine whether in the longer 
term the heart will develop dysfunction, we performed similar measurements on a separate cohort 
of ErbB4-cKO and control animals at 7-8 months after the deletion of ErbB4.  
At 7-8 months after tamoxifen injection, we measured left ventricular internal dimension (LVID), 
interventricular septum thickness (IVS) and left ventricle posterior wall thickness (LVPW) in both 
the systolic and diastolic phase using echocardiography. Remarkably, in contrast to 3-4 months, 
statistical analysis revealed there were no marked differences between ErbB4-cKO and control 
animals at 7-8 months. The LVPW in ErbB4-cKO animals tended to increase but was not 
statistically significant compared to the controls (Figure 5.21).  
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Figure 5.21 Echocardiographic assessment of cardiac function at 7-8 months following 
ErbB4 deletion. A. The diastolic (left) and systolic (middle) left ventricular internal 
dimension and fractional shortening (right) were measured in control and knockout animals. B. 
The diastolic and systolic IVS and LVPW dimension were measured in control and ErbB4-
cKO animals. Data was analysed using unpaired Student’s t-test and presented as mean  
SEM. * P<0.05 compared with control; control, n=7; knockout, n=7. 
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5.3.14 Cardiac hypertrophy at 7-8 months after ErbB4 deletion 
Animals were euthanased following echocardiography, and indices of cardiac hypertrophy 
measured. The heart weight:tibia length ratio (HW:TL) of the ErbB4-cKO group was significantly 
increased (~ 19 %) compared to the control group (Figure 5.22). This suggests that ErbB4-cKO 
animals undergo mild hypertrophy. However, the magnitude of this increase is lower than in 
previous experiments when HW:TL was measured at 3-4 months after tamoxifen injection (Figure 
5.13). We tested the expression of hypertrophic marker genes with RT-qPCR and found no 
significant changes in expression of the MHC isoforms or BNP (Figure 5.23 A). However, the ratio 
of α-MHC to β-MHC expression was reduced in the ErbB4-cKO, which may indicate a switch from 
α-MHC (which is predominant in adult heart) to β-MHC isoform (which is predominant in fetal 
heart) (Figure 5.23 A). This aligns with our data from the earlier set of experiments, which suggests 
that there may be increased generation of new cardiomyocytes. The fibrosis genes in both groups 
were expressed at similar levels (Figure 5.23 B), indicating there is no overt cardiac fibrosis in the 
ErbB4-cKO animals. Together, this suggests that the cardiac phenotype is milder at 7-8 months 
post-ErbB4 deletion compared to at 3-4 months after deletion, and that the phenotype observed at 3-
4 months seems to undergo recovery by 7-8 months.  
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Figure 5.22 Effect of ErbB4 deletion on heart weight at 7-8 months after deletion. Heart 
(left) and kidney (right) weight was measured and normalized to tibia length in control (n=8) and 
knockout (n=9) animals. Data was analysed using unpaired Student’s t-test and presented as 
mean  SEM. * P<0.05 compared with control; control, n=8; ErbB4-cKO, n=9. 
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Figure 5.23 Effect of ErbB4 deletion on expression of hypertrophic and fibrosis genes at 7-
8 months after deletion. The expression of hypertrophic genes BNP, α-MHC, β-MHC (A) and 
fibrosis genes COL1A1 and COL3A1 (B) detected by qPCR was normalized to 18S 
(endogenous control) and expressed relative to the control group.  Data was analysed using 
unpaired Student’s t-test and presented as mean  SEM. ** P<0.01 compared with control; 
control, n=7; ErbB4-cKO, n=9. 
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5.3.15 Expression of ErbB4 at 7-8 months after tamoxifen treatment 
After investigating the function of the heart after long-term deletion of ErbB4, we wanted to 
confirm that the ErbB4 is still absent in ErbB4-cKO animals at 7-8 months after ErbB4 gene 
deletion. We tested the expression of ErbB4 in heart tissues with RT-qPCR after 7-8 months of 
tamoxifen injection. Surprisingly, the ErbB4 expression in ErbB4-cKO animals was not 
significantly reduced compared to the controls (Figure 5.24). This indicated that either the gene was 
not initially deleted (unlikely), or that ErbB4 gene expression had somehow recovered by 7-8 
months following tamoxifen treatment. 
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Figure 5.24 Expression of ErbB4 at 7-8 months after tamoxifen injection. At 7-8 
months after tamoxifen treatment, the expression level of ErbB4 was measured by RT-
qPCR, normalized to 18S and expressed relative to the control group. Data was analysed 
using unpaired Student’s t-test and presented as mean  SEM; control, n=7; ErbB4-cKO, 
n=9. 
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5.4 Discussion 
The importance of NRG1 signalling in the cardiovascular system and its protective effect on the 
postnatal heart have been previously established (Zhao et al., 1998; Kuramochi et al., 2004; Liu et 
al., 2006). As NRG1’s primary receptor, ErbB4 is essential in heart (Gassmann et al., 1995; 
Tidcombe et al., 2003; Garcia-Rivello et al., 2005). Based on these studies, we hypothesised that 
ErbB4 would be essential for adult heart maintenance, and predicted that ErbB4 deletion from the 
adult heart would lead to severe cardiomyopathy or heart failure. In this chapter, I used the αMHC-
MerCreMer/loxP system to specifically delete ErbB4 from the adult heart, and investigated the 
cardiac phenotype for up to 7-8 months following deletion. The main findings in this study are: 1) 
An optimised tamoxifen treatment can specifically reduce ErbB4 mRNA levels by greater than 90% 
in the heart using the αMHC-MerCreMer/loxP system; 2) Transient Cre activity has long term 
effects on cardiac physiology; 3) Surprisingly, cardiac-specific deletion of ErbB4 did not lead to 
any obvious cardiac dysfunction or structural abnormalities except for a mild physiological 
hypertrophy; 4) Unique among EGF-like ligands, NRG1 was found to be selectively unregulated 
after ErbB4 deletion; and 5) There is increased proliferation of cardiac cells after ErbB4 deletion.  
Tamoxifen is a drug has been used to treat breast cancer due to its anti-estrogen effects, and it is 
also used in the laboratory to induce gene deletion in MerCreMer/loxP conditional knockout mouse 
models. The described treatment regimes (dose, method of administration, duration of treatment) 
for tamoxifen induced gene deletion are highly variable. However, a high dose of tamoxifen can be 
toxic. In a previous study in our lab, tamoxifen treatment at 40mg/kg/day ip for 4 consecutive days 
led to a high mortality rate in adult mice. However, lower doses are sometimes not sufficient to 
cause efficient deletion of the target gene. To conquer this, we adopted the low dose but long term 
treatment method (Hsieh et al., 2007). This idea is based on the fact that as long as the gene is 
deleted from genome, it cannot be recovered in the same cell. Although the efficiency of gene 
deletion is very low with a single tamoxifen injection at low dose, a prolonged accumulating 
treatment can achieve an excellent outcome. With this method, we achieved a more than 90 
percentage deletion of the ErbB4 gene in adult mouse heart with minimal toxicity. There is no 
obvious or marked difference in the physiology or behaviour between the tamoxifen treated and 
untreated animals.  
Although we were using the optimised dose tamoxifen which is not lethal, the potential side effect 
of this drug is hard to be excluded. To minimize the potential interference by tamoxifen itself, we 
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decided to treat both experimental and control groups with tamoxifen. The genotype of the 
conditional knockout animals is Cre
+/-
/ ErbB4
fl/fl
. Thus, the control animals have to lack either Cre 
(Cre
-/-
/ ErbB4
fl/fl
) or loxP sites (Cre
+/-
/ ErbB4
wt/wt
) to avoid deletion of ErbB4 when they received 
tamoxifen. If Cre
-/-
/ ErbB4
fl/fl
 animals are used as controls, tamoxifen injection will induce Cre 
activity in the ErbB4-cKO animals (Cre
+/-
/ ErbB4
fl/fl
) but not the controls (Cre
-/-
/ ErbB4
fl/fl
). Thus, 
Cre activity is another possible confounding factor induced in the ErbB4-cKO group besides the 
ErbB4 deletion. When Sohal et al. established the MHC-MerCreMer-loxP system in 2001, it was 
claimed that expression of the MerCreMer fusion protein in adult heart did not affect cardiac 
performance or cellular architecture. However, subsequent studies have indicated that the Cre 
recombinase is cardiotoxic. Hall et al. showed that the induction of Cre recombinase activity leads 
to decreased systolic function (SF) and alterations in proteins associated with cardiac oxidative 
phosphorylation. The decreased SF returned to baseline 10 days after tamoxifen injection (Hall et 
al., 2011). Another study showed that cardiac Cre activity induced a transient dilated 
cardiomyopathy marked by cardiac dysfunction and reduction in the expression of genes related to 
metabolism and calcium handling. Some of these defects had disappeared by 1 month after the Cre 
activity was induced (Koitabashi et al., 2009). Given these studies, supporting the idea that Cre 
activity might be cardiotoxic, it was important for me to evaluate the effect of Cre in our animals. 
To determine the Cre effect, we compared the cardiac function and structure of Cre positive animals 
to Cre negative animals. We found that the transient Cre activity decreased the heart weight (up to 8 
months), while the cardiac function is not altered at either 3-4 months or 7-8 months after tamoxifen 
treatment. To circumvent the negative effect of Cre activity on cardiac tissues, I decided to use the 
Cre-only transgenic mice (Cre
+/-
/ErbB4
wt/wt
) as the control for my studies. 
Against our expectations, we observed that the deletion of ErbB4 in adult mice did not lead to 
cardiac dysfunction. The important role of ErbB4 in cardiac development is well established 
(Gassmann et al., 1995; Tidcombe et al., 2003; Garcia-Rivello et al., 2005), and the essentiality of 
ErbB4 in postnatal heart was confirmed by Garcia-Rivello et al. using a MLC-2V-Cre/loxP system 
to demonstrate that specific deletion of ErbB4 in cardiomyocytes leads to severe dilated 
cardiomyopathy in adulthood. Interestingly, no obvious cardiac abnormality (ventricle wall 
thickness, cardiac cell number) was observed at birth, and the phenotype they observed in adulthood 
primarily resulted from lack of ErbB4 in the postnatal stage (juvenile or adult) (Garcia-Rivello et 
al., 2005). The results of my experiments in this chapter indicate that ErbB4 is not critical for 
maintenance and function of the adult heart, and remarkably its deletion did not result in 
cardiomyopathy. One interpretation could be that ErbB4 might be essential for the cardiac 
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development in the juvenile, but not in the older adult. Supporting this, Bersell et al. (Bersell et al., 
2009) showed that genetic deletion of ErbB4 at postnatal days 16-18 blocked the DNA synthesis of 
cardiomyocytes at baseline (measured by BrdU incorporation). Taken together, these studies and 
ours might suggest the ErbB4 is required for the cardiac development both in embryonic and early 
postnatal stages. However, once the cardiac development is completed, the subsequent loss of 
ErbB4 does not lead to severe cardiac dysfunction or structural abnormalities.  
One clinical study has indirectly indicated that ErbB4 might be important for adult heart 
maintenance: trastuzumab (an ErbB2 blocking antibody) has been used for breast cancer therapy 
and when combined together with other chemotherapy agents the rate of heart failure was 
significantly increased (27% incidence) (Seidman et al., 2002). Based on this observation, it has 
been proposed that ErbB2 is important in the adult heart. ErbB2 lacks any identified agonists, and 
preferentially dimerizes with other ErbB receptors to trigger downstream signalling (Timolati et al., 
2006). The inhibition of ErbB2 might affect the signalling of other ErbB receptors, especially its 
preferential partner ErbB4. Our study suggested ErbB4 deletion did not caused cardiac dysfunction. 
Thus, the cardiac dysfunction induced by trastuzumab treatment probably reflects effects on the 
signalling of other ErbB receptors. As mentioned earlier (section 1.2.1), the ErbB2 receptor can 
adopt an active formation without binding any agonists (Garrett et al., 2003). It is therefore possible 
that the active ErbB2 signalling itself is essential for the maintenance of heart function. 
ErbB4 has been suggested to play a role in the transition from hypertrophy to heart failure. In 
patients with heart failure, the cardiac expression of ErbB2 and ErbB4 are depressed (Rohrbach et 
al., 2005). A study in rats also showed that ErbB2 and ErbB4 are significantly reduced in the heart 
failure period, but not the preceding hypertrophic period in an aortic stenosis model (Rohrbach et 
al., 1999). However, in our study, the ErbB4-cKO mice developed significant hypertrophy but did 
not develop into heart failure in the longer term. This suggested that the loss of ErbB4 in the earlier 
studies might be the result of heart failure but not the reason.  
Another interesting result in my study is that ErbB4 deletion caused (somewhat paradoxically) 
cardiac hypertrophy. Cardiomyocyte hypertrophy and cardiac fibrosis were absent in the ErbB4-
cKO animals, and so we proposed that there might be more cardiomyocytes generated. Two 
potential sources could possibly regenerate new cardiomyocytes: one is stem cells or progenitor 
cells and another is existing cardiomyocytes. Detecting cardiac stem cells is currently not available 
in our lab, so I attempted to test whether cardiomyocytes were proliferating in our ErbB4-cKO 
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animals via co-staining of proliferation maker pH3 (located in nucleus) and the cardiomyocyte 
marker Troponin by immunofluorescence. However, the cell boundary could not be clearly resolved 
and there were many very small cells, such as endothelial cells, fibroblast or potential cardiac stem 
cells located among the cardiomyocytes. Thus, it was difficult to tell whether the positively stained 
nucleus for pH3 with positive Troponin staining around it was in a cardiomyocyte, or in a small cell 
among cardiomyocytes. This difficulty has also been described in the literature (Ang et al., 2010). 
Thus, the positively stained cell number was presented as total cardiac cell number instead of 
“cardiomyocyte number”. Although we cannot tell exactly the contribution of each cell type in this 
cardiac cell proliferation, we believe that new cardiomyocytes were generated by cardiomyocytes or 
stem cells, and contribute to the cardiac hypertrophy. It is important to note that pH3 only indicates 
cells undergoing the mitogenic phase, which is known to be transient in the whole cell cycle. The 
heart is one of the least regenerative organs in the body, so even if there is a regenerative response, 
it usually happens in a very small proportion of cells. Thus, the pH3 stained only a few cells in each 
section. It is still hard to predict how much of the heart can be regenerated with these proliferated 
cells. However, we believe with the accumulation effect over time, many new cardiomyocytes were 
generated in our ErbB4-cKO model and these might have contributed to the cardiac hypertrophy.  
Another important discovery of our study is that we observed the up-regulation of NRG1 in our 
animals after ErbB4 deletion. To our knowledge, this is a new observation in ErbB4 deletion 
studies, but is concordant with the observation made by Robrbach et al. in heart failure where the 
ErbB4 expression was decreased and NRG1 increased (Rohrbach et al., 1999; Rohrbach et al., 
2005). The link between the loss of ErbB4 and the compensatory up-regulation of its agonist NRG1 
is indicative, but the mechanism is unknown. However, given that NRG1 is predominantly released 
by microvascular endothelial cells (Kuramochi et al., 2004; Lemmens et al., 2006) and targets the 
cardiomyocytes, we predict that there is a crosstalk between the cardiomyocytes and endothelial 
cells to regulate the expression of NRG1 after the ErbB4 deletion. The up-regulated NRG1 may 
function to compensate for the ErbB4 loss. NRG1 is a cardioprotective factor that enhances cardiac 
contraction and reduces the cardiomyocyte apoptosis caused by stress (Liu et al., 2006; Bian et al., 
2009). I therefore propose that this NRG1 up-regulation explains why we haven’t observed a severe 
phenotype following ErbB4 deletion. If this assumption is true, the prevailing question will be how 
NRG1 can mediate a cardioprotective effect in the absence of its cognate receptor ErbB4. One 
possibility is that NRG1 is acting via a different receptor, possibly ErbB3. 
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Currently, it is unclear whether cardiac stem cells can respond to NRG1 stimulation to proliferate. 
However, NRG1 can promote cardiomyocyte proliferation in the adult heart (Zhao et al., 1998; 
Bersell et al., 2009). Another question from the present study is how NRG1 induced cardiac cell 
proliferation in the absence of its receptor ErbB4. One possibility is that ErbB4 was not completely 
deleted from 100% of cardiomyocytes, and that the proliferation happened in ErbB4-replete cells. 
They would then pass their intact genome to their progeny cells, which thus possess the unaffected 
ErbB4 gene and could in turn respond to NRG1. When the newly generated cardiac cells 
accumulate, the proliferation process is accelerated. However, NRG1 only induces a small 
proportion of cardiomyocytes to proliferate in wild type animals (Bersell et al., 2009). Accordingly, 
it can be inferred that in ErbB4 deleted animals, this cell population is even smaller and so it is very 
hard to imagine how a few cells proliferating at the initial stage (after deleting ErbB4 from the 
majority of cardiomyocytes) could promote such a robust increase in heart size in 3 months given 
the poor regenerative capacity of the adult heart. It is possible that the deletion of ErbB4 happens in 
cells expressing MHC but not in progenitor cells that do not express MHC. In this case, the 
proliferation rate of cardiac cells induced by NRG1 will be similar for wild type and ErbB4 deleted 
animals. Hence, when the NRG1 is up-regulated in ErbB4-cKO animals (but not wild type 
animals), the ErbB4-cKO animals will have more cardiomyocytes generated. A final possibility is 
that ErbB3 also plays a role in adult heart function and structural maintenance. ErbB3 is a receptor 
for NRG1 with a similar structure to ErbB4 but possessing additional PI3K binding domains, which 
contribute to cardiomyocyte survival. However, this possibility does not explain the recovery of the 
ErbB4 expression in the long-term after deletion. Whatever the merit of these speculations, we need 
to perform additional studies such as lineage tracing with immunofluorescence markers to tell if the 
proliferating cells are stem cells, cardiomyocytes with ErbB3 or ErbB4, or other cell types.  
A final surprising discovery from this work was that the expression of ErbB4 in the ErbB4-cKO 
group gradually recovered to the level of the control group at 7 months after ErbB4 deletion. One 
trivial possibility is we didn’t inject the tamoxifen properly. We cannot fully exclude this possibility 
because each set of animals was injected with tamoxifen independently, and the successful deletion 
of ErbB4 in one cohort does not mean the definite success of deletion in a later set of animals. 
However, the injections of tamoxifen were performed by the same person following the same 
procedures, and for ten consecutive days, so we consider that the possibility of technical failure is 
low. The only reasonable explanation is that ErbB4 was successfully deleted from the genome 
immediately after tamoxifen treatment, but that the expression of ErbB4 gradually recovered over 
7-8 months via a process that likely involves the generation of new cardiomyocytes to replace the 
Chapter 5: Function of ErbB4 in adult heart 
 
151 
 
cardiomyocytes with genomic deletion of ErbB4. The replacement of cardiomyocytes would 
presumably require apoptosis of the old cells in addition to new cell generation. We tried to detect 
cardiomyocyte apoptosis with TUNEL at 3 months after ErbB4 deletion, however, the results was 
not definitive due to the high levels of background staining in all groups. In summary, the cardiac 
specific deletion of ErbB4 in adult mice did not result in physiological hypertrophy without obvious 
cardiac dysfunction. The compensatory up-regulation of NRG1 in ErbB4-cKO mice heart might 
contribute to the cardiac function preservation and lead to cardiac hypertrophy via causing 
cardiomyocyte proliferation. 
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6. General Discussion 
This thesis has explored the role of the epidermal growth factor receptors (particularly ErbB4) in 
mediating cardiomyocyte hypertrophy, the potential signalling differences among the ErbB4 
isoforms, and the physiological function of ErbB4 in the adult mouse heart. While ErbB4 did not 
contribute to a classic model of cardiomyocyte hypertrophy (Ang II-induced hypertrophic 
signalling), this receptor was clearly involved in the hypertrophy caused by NRG1. ErbB4 has four 
isoforms due to alternative splicing, and the non-cleavable isoform JM-b was found to be 
predominant under both physiological and pathophysiological conditions. Interestingly, there was 
no significant difference in the ability of the four isoforms to mediate NRG1-induced hypertrophy. 
When ErbB4 was specifically deleted from the adult mouse heart using Cre-loxP technology, the 
mice developed physiological cardiac hypertrophy with up-regulation of NRG1 and no alterations 
in cardiac function and structure. Surprisingly, an increased proliferation of cardiac cells was 
observed following cardiac ErbB4 deletion, and I propose that the NRG1 up-regulation contributes 
to this cell proliferation, although the mechanisms remain unclear. 
Crosstalk between ErbB receptors and GPCRs in cardiomyocyte 
hypertrophy 
Cardiomyocytes are continuously exposed to diverse stimuli, such as soluble endocrine and 
paracrine factors from blood or neighboring cells. It is important that these signals are integrated to 
achieve an appropriate cellular response. Tyrosine kinase receptors (for factors including the EGF 
ligands, insulin-like growth factor-1, insulin, etc.) and GPCRs (for ligands such as angiotensin II, 
endothelin 1, adrenaline, etc.) play pivotal roles in interpreting such signals (Sugden et al., 1998; 
Clerk et al., 1999; Heineke et al., 2006). These receptor systems do not work in isolation and there 
is irrefutable evidence for crosstalk between GPCRs and the growth factor receptors. An 
accumulating literature supports the idea that the type 1 angiotensin receptor (AT1R) is able to 
transactivate the ErbB receptors (principally ErbB1) and thereby mediate cellular growth in a 
variety of tissues and organs (Eguchi et al., 1998; Shah et al., 2003b; Chen et al., 2006). In this 
setting, and based on previous work from my host laboratory that showed the ErbB4 selective 
agonist NRG1 was a more potent inducer of cardiomyocyte hypertrophy than ErbB1 ligands, my 
first aim was to investigate whether the classic AT1R-ErbB1 transactivation by extended to other 
ErbB receptors, explicitly ErbB4. To accomplish this aim, I used an approach that involved 
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knockdown of ErbB receptors using RNAi as well as pharmacological inhibition with the small 
molecule EGFR kinase antagonist, AG1478, which has been widely used in the field to discern 
EGFR function (Eguchi et al., 1998; Asakura et al., 2002; Thomas et al., 2002; Shah et al., 2003b; 
Chen et al., 2006). I was able to unambiguously demonstrate knockdown of each ErbB receptor, 
and tested the effect of this knockdown on the capacity of Ang II (and NRG1) to promote 
cardiomyocyte hypertrophic signalling. As expected, knockdown of ErbB4, but not ErbB1 or 
ErbB2, was able to prevent NRG1 mediated cardiomyocyte hypertrophy. However, despite careful 
experimentation, I found no evidence that Ang II-mediated cardiomyocyte hypertrophic signalling 
was dependent on ErbB4. Much to my initial disappointment, I was also unable to prevent AT1R-
mediated cardiomyocyte hypertrophy with RNAi targeting ErbB1 or ErbB2. Based on extensive, 
compelling, previous literature in the heart, but also in many other cellular systems (Shah et al., 
2003a; Mendez et al., 2005; Liebmann, 2011), our observation was unsettling but repeatable. 
Given the importance (and potential controversy) of my data questioning the role of ErbB receptors 
in AT1R hypertrophy, I undertook with my supervisors a systemic review of my approach and 
observations. We retested the specificity of my RNAi constructs - they were shown to be effective 
and specific - notably, the knockdown of individual ErbB receptors was confirmed by Western 
blotting and qPCR, showing there is up to 90% reduction of ErbB1or ErbB4 by RNAi. In addition 
to my initial data, using luciferase-based hypertrophic gene promoter reporter assays, I went on to 
confirm that there was also minimal effect of ErbB knockdown on the activation of AT1R-mediated 
MAPK signalling and hypertrophic growth (measured as protein:DNA ratios and sacromeric 
reorganisation). We performed power calculations for luciferase assay data and determined that my 
experimental repeats (n = 7-8) were more than sufficient to allow valid conclusions. My grouped 
data for all experiments clearly showed no differences between knockdown and control groups with 
Ang II treatment. In contrast, under parallel experimental conditions (i.e., same cells, same days, 
same experimenter, same analyses), I was able to consistently and unequivocally observe that 
ErbB4 RNAi (but not ErbB1/2 RNAi) reduced cardiomyocyte hypertrophic signalling in response 
to the ErbB4 selective agonist, NRG1. The only interpretation for these results is that NRG1 
requires the ErbB4 to mediate hypertrophy, whereas ErbB1, ErbB2 and ErbB4 are not individually 
required for AT1R mediated cardiomyocyte hypertrophy.   
So, how do I explain these results? It is difficult to answer this, as the experiments included 
appropriate controls, yet yielded different results from previous studies, where the majority of the 
literature indicates that GPCRs, like the AT1R, use EGFRs to mediate growth signalling (Porcile et 
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al., 2005; Ohtsu et al., 2006a; Ohtsu et al., 2006b; Luppi et al., 2007; Schlange et al., 2007). A 
number of possibilities might be considered: 1) the most trivial of explanations could be that despite 
overt knockdown of the ErbB mRNA/protein, the residual receptors were sufficient to mediate 
growth pathway signalling. This idea is consistent with the pharmacological concept of “spare 
receptors” (where in many cases only a portion of cell surface receptors are required for full 
efficacy) (Strickland et al., 1981). Obviously, my control experiment, detailing the loss of NRG1 
efficacy with ErbB4 RNAi knockdown, refutes such reasoning; 2) Primary cultures of neonatal 
cardiomyocytes vary tremendously in terms of cellular composition (i.e., % contamination by 
fibroblasts, endothelial cells etc) and sensitivity to hypertrophic stimuli, between laboratories and 
even within laboratories over time. This might reflect subtle changes in protocols and purity (or 
otherwise) of the cultures; 3) Many laboratories have evoked the contribution of EGFR 
transactivation based, almost exclusively, on experiments using pharmacological blockade with the 
small molecule inhibitor, AG1478. Certainly, the use of AG1478 alone (without confirmation with 
another technique like RNAi) can be problematic and is open to misinterpretation (detailed below); 
and 4) My RNAi experiments tested the hypothesis that individual ErbB receptors were involved in 
cardiomyocyte hypertrophy and it remains possible that some redundancy exists between the ErbB 
receptors (given that multiple receptors can bind multiple ligands) such that knockdown of a single 
receptor might be compensated by another. So, whatever the merits of these possibilities, it 
certainly raises some uncertainties and potentially some reevaluation of the some of the literature in 
this broad field.  
Indeed, as mentioned above, the reliance on data using AG1478 needs careful reexamination. There 
is no doubt that in controlled assays, under ideal conditions, AG1478 at nanomolar concentrations 
is a selective and specific inhibitor of the EGFR kinase (Anastassiadis et al., 2011). However, in 
cell-based assays, where often conditions can widely vary and concentrations of the inhibitor range 
up to tens of micromolar, that specificity/selectivity is not assured. In regard to the EGFRs, the 
current consensus is that AG1478 is reasonably selective for ErbB1 (the EGFR) at concentrations 
<0.5 µM, but can inhibit the other ErbBs (and probably other tyrosine kinases) at higher 
concentrations (>5 µM). My data on MAPK signalling in cardiomyocytes (where EGF activation of 
ErbB1 was blocked by 0.5 μM, but where NRG1 mediated MAPK via ErbB4 was only inhibited by 
5 μM AG1478) are entirely consistent with this consensus view. Previous studies, including some 
from my own laboratory, have used high μM levels of AG1478 and therefore cannot exclude the 
contribution of tyrosine kinases other than EGFR kinase. Indeed, other receptor tyrosine kinases, as 
well as soluble tyrosine kinases, have been associated with Ang II/AT1R signalling and growth (Yin 
Chapter 6: General discussion 
 
157 
 
et al., 2003), including, as an example, the platelet-derived growth factor receptors (Linseman et al., 
1995; Kelly et al., 2004). Finally, I am certainly not criticizing all previous studies using AG1478 - 
some have used this inhibitor in the appropriate range (100-250 nM) - in, for example, hepatic C9 
cells (Shah et al., 2002), renal epithelial cells (Chen et al., 2006), and vascular smooth muscles cells 
(Eguchi et al., 1998). Some have also combined this with RNAi, and my experience would concur 
that it is important for future studies to use a combination of RNAi and pharmacological approaches 
together with well considered controls.  
Another limitation of the EGFR transactivation field has been the strong focus on the entire triple 
membrane-passing signalling (TMPS) pathway occurring in a single cell - whereby the GPCR, 
ADAM, shed EGF ligand, and EGFR are all co-expressed and activated as a single unit. Of course, 
the possibility exists that shed ligands could work in a paracrine manner, perhaps even between 
different cell types as might occur in the heart. Indeed, the primary source of neuregulin in the heart 
is presumed to be the endothelial cells of the vasculature (Kuramochi et al., 2004; Lemmens et al., 
2006) but the primary target in terms of hypertrophy is ErbB4 on the cardiomyocytes. So, while 
there can be no argument that all the components (i.e., AT1R, ADAM12/15/17, ErbB receptors 
(ErbB1, ErbB2 and ErbB4) and multiple EGF-like factors) are present in cardiac tissue whether 
they necessarily need to occur in an individual cell type could be questioned, especially as I did not 
observe EGFR transactivation in the highly purified cardiomyocyte cultures. So when considering 
these mechanisms in an intact organism (or tissue), I would argue we need to consider that the ErbB 
receptor system does not have to be completed via transactivation in one cell type, like the 
cardiomyocyte, but it may happen via interaction of the many types of cells in response to 
neurohumoral factors/stimuli.  
The functional relevance of ErbB4 isoforms in cardiomyocytes 
In the initial stages of my candidature, we were strongly considering that the experiments detailed 
above would likely show, not only transactivation of ErbB1, but as I hypothesized, an additional 
ability to transactivate ErbB4. While ultimately this did not occur, in parallel I was initially 
interested in considering the possibility that this putative ErbB4 transactivation might result from 
one or more of the ErbB4 isoforms. As introduced earlier, ErbB4 has four isoforms due to 
alternative splicing, and these can be differentially processed in cells (Junttila et al., 2000). 
Moreover, there is evidence in the literature that GPCR activation (Higa‐Nakamine et al., 2012) 
and stimulation with NRG1 (Zhou et al., 2000) induce cleavage of the JM-a isoform, releasing a 
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functional intracellular domain (ICD) into the nucleus to regulate cell activity as first shown by 
Graham Carpenter’s group (Vecchi et al., 1996). So, even though I did not observe transactivation 
of ErbB4 by Ang II in purified cardiomyocytes, I was still interested in investigating whether the 
specific ErbB4 isoforms could be cleaved to release the ICD in cardiomyocytes and whether this 
might contribute to the NRG1-induced cardiomyocyte hypertrophic signalling. Because previous, 
unpublished work in our laboratory had detected all of the four ErbB4 isoforms in primary neonatal 
rat cardiomyocytes, my prediction was that the cleavable JM-a isoform would be present and that I 
would be able to demonstrate that it could be processed to release the intracellular domain (80 kD 
ICD), which might interact with transcriptional factors to regulate cellular activity. Secondly, based 
on a study in the brain, where a specific ErbB4 isoform was cleaved and shown to regulate the time 
of astrogenesis in the mouse (Sardi et al., 2006), I was intrigued by the idea that the four isoforms 
might make differing contributions to cardiomyocyte hypertrophy.   
As part of investigating the cleavage of ErbB4 and any isoform-specific differences, I first sought to 
establish whether these isoforms are indeed expressed in whole mouse heart. In addition, I 
wondered whether the isoforms were expressed differently in various stages of cardiac 
development, or during pathology. There is strong evidence that ErbB4 is required for normal 
mouse cardiac development (Gassmann et al., 1995; Tidcombe et al., 2003) but the relevance of a 
specific ErbB4 isoform in normal growth or disease has not been reported. I performed an 
expression profile in the heart of all four isoforms from embryonic day 10.5 to postnatal day 28. All 
isoforms declined throughout cardiac development - the expression of total ErbB4 at the earlier 
embryonic stage (E10.5) is 250 times higher than at postnatal day 28. Interestingly, the expression 
levels of JM-a and JM-b isoforms are similar in the earlier embryonic stages. However, by the 
postnatal stage in mice, JM-b is the overwhelmingly predominant isoform. Why this might be is 
currently unclear, but it could relate to the proliferative (i.e., embryonic) or hypertrophic (i.e., post-
natal) growth that occurs in the heart. It is tempting to speculate that perhaps JM-a is required for 
cardiac proliferation in the embryo and JM-b is required for hypertrophy in the adult. It would be 
interesting to isolate the embryonic cardiomyocytes and investigate whether the JM-a isoform 
mediates proliferation, especially given that JM-a is capable of regulating the timing of astrogenesis 
by suppressing astrocyte progenitor cell differentiation (Sardi et al., 2006). Moreover, the release of 
the ICD (from JM-a) allows interaction with YAP to facilitate the translocation of the ICD into the 
nucleus (Komuro, Nagai et al. 2003; Omerovic, Puggioni et al. 2004). Given that YAP activation is 
sufficient to stimulate both embronic and postnatal cardiomyocyte proliferation (von Gise et al., 
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2012), it would seem reasonable to hypothesise that release of the ICD from JM-a could associate 
with YAP to promote cardiomyocyte proliferation.  
Experiments aimed at examining whether the JM-a isoform can be cleaved in cardiomyocytes were 
critical in attempting to make this link between ErbB4 isoform expression and cardiac cell growth. 
It is important to note two things: 1) that I performed these experiments prior to the isoform 
characterisation mentioned above (which showed predominance of JM-b in postnatal mouse heart) 
and 2) that a previous student has some preliminary PCR data to suggest that JM-a was expressed in 
rat neonatal cardiomyocytes (Hsiu-wen Chan, PhD thesis). Based on previous studies showing that 
cleavage of JM-a to yield the ICD is sensitive to cell activation with the phorbol ester PMA, and 
also to NRG1 (Vecchi et al., 1996; Zhou et al., 2000), I initially attempted to demonstrate shedding 
of the 85KDa ICD using Western blotting as previously described (Vecchi et al., 1996; Zhou et al., 
2000). Disappointingly (but with hindsight not unexpectedly), no band corresponding to the ICD 
could be detected either basally or following stimulation of rat neonatal cardiomyocytes with PMA 
or NRG1. We went on to confirm that the primary isoform of ErbB4 in the rat heart is the JM-b 
isoform (Hengbo Shi, visiting scholar, unpublished data), as it is in mouse. So, the inability to 
detect generation of the ICD likely reflects the low expression level of the endogenous JM-a 
isoform in these cells.  
To examine the potential for JM-a cleavage in these cells (which, while difficult to examine on the 
endogenous lowly-expressed receptor, might be functionally important), I developed a series of C-
terminal GFP-tagged ErbB4 isoform constructs. These vectors were transfected into postnatal 
cardiomyocytes, allowing us to observe the potential cleavage and translocation of the ICD-GFP 
into the nucleus using confocal microscopy. If the cellular machinery for this process was present, I 
hypothesised that the ICD would be generated after stimulation and enter into nucleus. No obvious 
evidence for this was seen and no nuclear translocation of green fluorescence was observed 
following stimulation with PMA or NRG1 for up to 15 min. The lack of ICD generation is 
consistent with the low expression of JM-a, and indicates the shedding processes involved may also 
be postnatally down-regulated. Finally, I did not observe remarkable changes in ErbB4 isoform 
expression with cardiac disease (i.e., a model of myocardial infarction) and I therefore surmise that 
isoform-specific ErbB4 cleavage is unlikely to be a major driver of the effects of ErbB4 in heart.  
This then leads to the important question as to why the cardiomyocytes might express multiple 
isoforms of the ErbB4, and are there any functional differences among these isoforms in 
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cardiomyocytes? An initial focus of my thesis was the role of ErbB4 in NRG1-mediated 
cardiomyocyte hypertrophy, so I examined whether the four ErbB4 isoforms could all equally 
mediate this effect. For this purpose, I knocked down the endogenous ErbB4 receptor and then 
replaced it with individual knockdown-resistant version of the ErbB4 isoforms. Hypertrophy was 
induced with the ErbB4 agonist NRG1 and hypertrophic signalling measured with luciferase 
reporter assays. I observed that all four isoforms can rescue NRG1-induced hypertrophy, indicating 
that the most likely scenario is that the hypertrophic signalling is reliant on the common tyrosine 
kinase activity of the ErbB4 receptor isoforms, and does not seem to involve either shedding to 
release ICD or a particular docking event mediated by CYT1/2.   
The function of ErbB4 in the adult mice heart 
My thesis then moved away from the focus on transactivation to a broader investigation of the role 
of ErbB4 in adult heart in vivo. For this purpose, I adopted the tamoxifen inducible MHC-
MerCreMer/loxP system (Garcia-Rivello et al., 2005) to specifically delete the ErbB4 from 
cardiomyocytes in adult mice. As described in Chapter 5, tamoxifen treatment specifically 
decreased ErbB4 expression in the adult heart by ~ 90%. My prediction was that the mice would 
develop cardiac dysfunction or structural abnormalities in the weeks/months following ErbB4 
deletion. To my surprise, the knockout mice were active and healthy following ErbB4 deletion and 
no obvious pathology was observed, which suggested a potential lack of a cardiac phenotype in 
these mice. At 3 months after ErbB4 deletion, I measured cardiac contractility and heart weight, and 
analysed cardiac structure, including the cardiomyocyte size and cardiac fibrosis. Surprisingly, the 
cardiac function was not affected in the ErbB4 deleted mice. There were no structural changes 
(cardiomyocyte hypertrophy or cardiac fibrosis) observed in knockout animals, although these mice 
did develop cardiac hypertrophy (increased heart weight:tibia length ratio). This result is opposite to 
my original hypothesis that ErbB4 is essential in adult heart. This suggests a few possibilities. 
Firstly, there might be up-regulation of the EGFR family or their ligands to compensate for the 
reduced ErbB4 function. Secondly, maybe 3-4 months is not long enough to observe a phenotype. 
In addition to these questions, the mechanism by which the knockout mice developed cardiac 
hypertrophy without cardiomyocyte hypertrophy needs to be elucidated.  
To answer the first question, I investigated the expression of the other members of the ErbB family 
(ErbB1, ErbB2 and ErbB3) and their selective agonists (the EGF-like factors) after ErbB4 deletion, 
and found that only the ErbB4 selective agonist NRG1 was significantly up-regulated (4-5 fold 
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increase). Accumulated evidence suggests that NRG1 is a beneficial factor that can preserve cardiac 
function in various cardiac pathological models (Liu et al., 2006). NRG1 could protect the 
cardiomyocytes from apoptosis (Zhao et al., 1998) and regulate the contraction of the 
cardiomyocytes by regulating the sarcomere reorganization (Muraoka-Cook et al., 2006a; Bian et 
al., 2009) and Ca
2+
 intake (Mery et al., 1991; Brero et al., 2010). In our model, it is possible that 
ErbB4 deletion causes a cardiac phenotype, but this is concealed by the protective effect of NRG1. 
How NRG1 functions in the absence of ErbB4 remains a question. It has been accepted in the field 
in the past 15 years that ErbB4 is the only receptor for NRG1 in cardiomyocytes, as the other NRG1 
receptor, ErbB3, is not expressed. However, a recent publication found that the ErbB3 is also 
detected in cardiomyocytes, where it can be activated by NRG1 (Campreciós et al., 2011). Whether 
the ErbB3 is activated by up-regulated NRG1 in our ErbB4-cKO mice to compensate for the lost 
ErbB4 function is unknown and needs further investigation. 
There is evidence in the literature that NRG1 induces cardiomyocyte proliferation in adult mice 
(Bersell et al., 2009). Thus, I investigated whether there is proliferation of cardiac cells in our 
ErbB4-cKO mice. For this purpose, I used the mitosis marker pH3 to label the proliferating cells by 
immunofluorescence, and found the number of pH3 positive cardiac cells was significantly 
increased in ErbB4-cKO heart. Whilst we did not perform lineage-tracing studies in this thesis, I 
hypothesize that these new cells were generated from existing cardiomyocytes or a subpopulation of 
stem/progenitor cells, which contributes to the cardiac hypertrophy in ErbB4-cKO mice in the 
absence of cardiomyocyte hypertrophy.  
If the existing cardiomyocytes do proliferate in ErbB4-cKO mice to contribute to cardiac 
hypertrophy, the results will be very interesting. In chapter 3, I have shown that NRG1 induced 
cardiomyocyte hypertrophy in vitro. However, in chapter 5 the up-regulation of NRG did not result 
in cardiomyocyte hypertrophy in vivo but may have caused myocyte proliferation. Since 1998, the 
ability of NRG1 to promote the hypertrophic growth and proliferation of isolated cardiomyocytes 
has been documented (Zhao et al., 1998). However, few studies have reported NRG1 induced 
cardiomyocyte hypertrophy in vivo. One recent study showed that NRG1 infusion in adult mice 
induced the proliferation, but not hypertrophy of cardiomyocytes (Bersell et al., 2009). The reasons 
underlying the different observations in vitro and in vivo are unknown. However, differences in the 
local cardiomyocyte environment may provide one explanation. In vitro, the cardiomyocytes are 
purified and maintained at a subconfluent density. In contrast, in vivo cardiomyocytes are connected 
Chapter 6: General discussion 
 
162 
 
with each other via junctions, and surrounded by many other cells (e.g. fibroblasts, endothelial 
cells) that may potentially influence cardiomyocyte function. 
In addition to the proliferation of existing cardiomyocytes, another potential resource for new 
cardiomyocytes is cardiac progenitor cells or stem cells. This has been discussed in Chapter 5. If 
this does happen in our ErbB4-cKO mice, it remains to be seen whether these new cells have the 
same predominant isoforms of ErbB4 as the mature cardiomyocytes. In chapter 4, I found that 
expression of the JM-a isoform is much higher in embryonic hearts than adult hearts. It is possible 
that the JM-a expressing cells are the stem cells or cardiac progenitor cells. Currently, there have 
been no reports on the ErbB4 isoform expression in these cells. If the cardiac stem cells express the 
JM-a isoforms, it will be very important to know whether the JM-a isoforms can be cleaved in these 
cells to release the ICD. It is known that the coactivator of the ErbB4 ICD (Komuro et al., 2003), 
YAP, is essential for the proliferation of stem cells (Zhao et al., 2011). It will be interesting to know 
whether the cleavage of the JM-a isoform and release of the ICD are involved in the YAP 
controlled proliferation.  
To investigate whether ErbB4 deletion leads to cardiac dysfunction or structural changes in the 
longer term, I measured the cardiac phenotype at 7-8 months post deletion in a separate cohort of 
animals. Again, cardiac function was preserved in knockout animals. Interestingly, these animals 
have milder cardiac hypertrophy than that seen at 3 months after ErbB4 deletion. Similar to the 
results from the study at 3 months, we observed neither cardiomyocyte hypertrophy nor cardiac 
fibrosis. Astonishingly, at 8 months the expression of ErbB4 in knockout animals was no longer 
different from the control animals, whereas it was reduced by ~67% at 3-4 months post-tamoxifen 
and ~90% at 10 days after tamoxifen treatment. To my knowledge, there have been no reports of 
this type of deleted gene recovery. Cardiomyocytes (consisting of the two thirds volume of the 
whole heart) are the main source of ErbB4 in cardiac tissues whilst other cells either don’t express 
the ErbB4 (fibroblasts, taking one third volume of the heart), or express smaller amounts 
(endothelial cells). The only explanation I could propose is that new cardiomyocytes with an intact 
ErbB4 gene (that are thus able to express ErbB4) have been generated and replaced the 
cardiomyocytes lacking ErbB4. If this hypothesis is true, two processes would be required. First, 
new cardiomyocytes with an intact ErbB4 gene need to be generated. Second, the death of 
cardiomyocytes lacking ErbB4 would be needed for ErbB4 regeneration. I tried to detect 
cardiomyocyte apoptosis using TUNEL staining 3 months after ErbB4 deletion. However, we 
observed extensive positive staining in sections from both knockout and control animals. We 
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suspect that this staining may be an artifact of the fixation procedure (immersion in 4% PFA for 48 
hours). To conquer this, in a future set of experiments we will perfusion fix the hearts using a 
Langendorff setup to immediately fix the cardiomyocytes after heart collection.  
When taking my in vivo study along with those in the literature, it seems that the phenotype 
observed is closely related to the developmental stage where ErbB4 is deleted. Deletion of ErbB4 in 
the germline leads to embryonic death due to impaired cardiac development (Gassmann et al., 
1995). Targeted knockout of ErbB4 from cardiomyocytes using the MLC-2V promoter does not 
cause embryonic lethality, but does lead to dilated cardiomyopathy in the adult (Garcia-Rivello et 
al., 2005). The deletion of ErbB4 from the adult mouse heart in my study led to the development of 
physiological cardiac hypertrophy without cardiac dysfunction or structure abnormalities. This 
might indicate the primary function of ErbB4 under physiological conditions is to promote 
cardiomyocyte growth. As long as the cardiac development has been completed, the reduction in 
ErbB4 does not affect the heart function. This hypothesis is consistent with data in Chapter 4 
showing the relatively higher expression of ErbB4 in the embryonic stage (which probably reflects 
high demand for cardiomyocyte growth) compared to the adult (where there is a low requirement 
for cardiac growth in physiological conditions). However, it has been suggested that NRG1 is a 
beneficial cardiac factor that may protect the cardiomyocytes in various pathological conditions. 
Given that ErbB4 is the primary receptor for NRG1 in cardiomyocytes, these observations might 
suggest that ErbB4 may also be cardioprotective in pathological conditions. Thus, in a future study 
we plan to use our cardiac ErbB4 deletion model to investigate the function of ErbB4 in a model of 
pathological cardiac hypertrophy. 
Limitations and future directions 
In this thesis, the transactivation of ErbB receptors has been carefully studied with RNAi. Down-
regulation of individual ErbB receptors did not affect the Ang II signalling in cardiomyocytes, and 
we have excluded the possibility that other ErbB subtypes were up-regulation after knockdown. 
However, although the expression level was not changed, these ErbBs may have been activated via 
alternative mechanisms to compensate for the deleted subtypes. To exclude this possibility, in the 
future down regulation of all of the ErbB receptors should be employed. In addition, all of the 
transactivation studies in my thesis were performed in purified cardiomyocytes. However, the 
transactivation might require the involvement of multiple cardiac cell types such as fibroblasts, 
endothelial cells and cardiomyocytes. It is important to know how these cells interact in any 
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potential transactivation process (for instance, the “triple membrane signalling pathway” 
mechanism as discussed earlier), and the role of each cell type in this mechanism. Regarding the 
ErbB4 isoforms, the JM-a was abundantly expressed in the embryonic heart. Whilst cardiac ErbB4 
is predominantly localized to cardiomyocytes in the adult (Zhao et al., 1999), this has not been 
shown in the embryo. I propose that in the embryo ErbB4 is also mainly expressed in 
cardiomyocytes or cardiomyocyte precursor cells, however this will require experimental 
confirmation. Furthermore, the exact cell types (mature cardiomyocytes, progenitor cells, or others) 
that express the JM-a have yet to be identified. An intriguing possibility is that the JM-a expressing 
cells are mainly cardiac stem cells or progenitor cells. It will be interesting to investigate whether 
the JM-a isoform can be cleaved in these cells to regulate cardiomyocyte generation.  
In vivo, the physiological role of ErbB4 in the adult heart has been investigated using a conditional 
knockout model. The obtained data suggests that ErbB4 deletion leads to cardiac hypertrophy 
without affecting the cardiac function or structure, whereas the up-regulation of NRG1 in ErbB4-
cKO mice might promote cardiac cell proliferation. It is important to confirm these results with 
further studies. Whilst this study showed no change in cardiomyocyte size, the cross sectional area 
measured in my study only reflects the cardiomyocyte size in the short axis, yet cardiomyocyte 
enlargement during hypertrophy can occur in both the longitudinal and short axis. To measure 
longitudinal changes, we plan to isolate single cell cardiomyocytes and use microscopy to quantify 
cell size. To further confirm the proliferation results, alternative proliferation markers such as Ki67 
or measurement methods such as BrdU incorporation should be used to detect proliferation. It is 
critical to identify which cells are proliferating, which will require co-staining using cell-type 
specific and proliferation markers. In addition to these experiments, we are eager to explore the 
mechanism behind the observed phenomenon. The ErbB4 deficiency occurs in cardiomyocytes in 
our models, whist NRG1 is abundant in endothelial cells (Kuramochi et al., 2004; Lemmens et al., 
2006). It will be interesting to examine how the ErbB4 deficiency caused the up-regulation of 
NRG1, and to then determine whether the cardiac cell proliferation in knockout animals was driven 
by the up-regulated NRG1. More importantly, we plan to elucidate the mechanism by which ErbB4 
expression recovers in the months following recombination of the floxed gene. There is the 
possibility that the ErbB4 deficient cells are undergoing apoptosis and are being replaced by newly 
generated cardiomyocytes, however, this needs to be experimentally confirmed. One potential, but 
very important proposal, from my study is that another ErbB receptor (ErbB3) might be activated 
by the up-regulated NRG1 in cardiac tissues to compensate for the ErbB4 deficiency, and thus 
preserve cardiac function (as discussed in Chapter 5). The cardioprotective effect of NRG1 has been 
Chapter 6: General discussion 
 
165 
 
demonstrated in various pathological animal models whilst phase II clinical trials demonstrated that 
NRG1 could improve the cardiac function of patients with chronic heart failure (Gao et al., 2010) . 
Currently, ErbB4 is considered to be the only receptor for NRG1 in cardiomyocytes. If ErbB3 can 
be activated by NRG1 in the heart, the proposed molecular mechanism (where NRG1’s beneficial 
effect occurs via ErbB4) needs to be re-evaluated and this new potential pathway via ErbB3 
requires further exploration. Indeed, whether ErbB4 deficiency will affect the ability of NRG1 to 
protect the heart is yet to be determined. More fundamentally, the phenotype of the ErbB4-cKO 
mice under pathological conditions has not been elucidated. For this purpose, as a next step we are 
going to investigate how cardiac deletion of ErbB4 affects the response of the heart to a 
hypertrophic stimulus using an Ang II infusion model of hypertension and hypertrophy. This work 
will provide important information regarding the role of ErbB4 in cardiac function and structure 
under pathological conditions. 
Conclusion 
During my candidature, I have fully investigated the transactivation of ErbB family by Ang II in 
cardiomyocytes and provided evidence that the Ang II signalling in cardiomyocyte hypertrophy is 
independent of ErbB receptors. This is very important for elucidating the molecular pathway of the 
pathological cardiac hypertrophy related to the activation of local RAS system. My studies 
confirmed the requirement for ErbB4 in NRG1 induced hypertrophic signalling. The discovery that 
all four ErbB4 isoforms could mediate NRG1 signalling in postnatal cardiomyocytes suggested that 
NRG1 induced hypertrophic signalling is dependent on a fundamental common feature of the four 
isoforms. The decline in expression of the cleavable isoforms (JM-a) throughout development, and 
the lack of a cleavage mechanism in postnatal cardiomyocytes suggests that the postnatal heart does 
not require the ICD function. In contrast, the relative higher level of JM-a in embryonic stages 
suggests that the ICD might be released and required by the embryonic heart. This study indicates 
that further investigation on the biological function of JM-a isoform in the embryonic heart is 
required, particularly with respect to cardiomyocyte generation. The in vivo study established a new 
conditional knockout model in our lab, where the gene deletion is both tissue specific and 
temporally controlled. Using this model, we investigated the function of ErbB4 in adult mice heart. 
The cardiac specific deletion of ErbB4 in adult mice did not result in a severe cardiac phenotype 
(cardiac dysfunction and structural abnormality) but a series of compensatory responses (up-
regulation of NRG1 and physiological cardiac hypertrophy). This proposes that, in contrast to the 
embryonic heart, the intact adult heart adopts alternative mechanisms to satisfy cardiac 
physiological requirements when ErbB4 is absent. More importantly, the lack of an obvious 
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phenotype may indicate that the primary function of the ErbB4 in the adult heart is different from 
the embryonic heart. The former might be mediating the NRG1 signalling to preserve cardiac 
function and structure under pathological conditions, whereas the latter promotes growth. Thus, 
deletion of ErbB4 in embryonic heart leads to pre-birth death due to the cessation of cardiac growth. 
In contrast, the phenotype of ErbB4 deletion in adult heart may only be observed under pathological 
conditions. In a future study we plan to use our conditional knockout model to investigate the 
function of ErbB4 in a model of pathological cardiac hypertrophy. 
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Appendix A: Solutions and buffers 
DMEM + 10%FBS: DMEM powder (#12100-038, Invitrogen), NaHCO3 (3.75 g/L), penicillin 
(1×10
5 
U/L), streptomycin (100 mg/L), FBS (10%, v/v), pH7.2. 
DMEM CCTSS2: DMEM powder (#12100-038, Invitrogen), NaHCO3 (3.75g/L), 1×vitamins 
solution (#11120-052, Invitrogen), 1×essential amino acid solution (#11130-051, Invitrogen), 
1×non-essential amino acids solution (#11140-050, Invitrogen), sodium pyruvate (1 mM), insulin (5 
mg/L), BrdU(0.1 mM), antibiotic antimyocotic (#15240-062, Invitrogen), potassium chloride 
(50mM), pH7.2. 
MEM + 10% NBCS: MEM powder (#11900-016, Invitrogen), NaHCO3 (3.75 g/L), 1×vitamins 
solution (#11120-052, Invitrogen), 1×essential amino acid solution (#11130-051, Invitrogen), 
1×non-essential amino acids solution (#11140-050, Invitrogen), antibiotic antimyocotic (#15240-
062, Invitrogen), NBCS (10%, v/v), pH7.2. 
ADS buffer: NaCl (6.8 g/L), HEPES (4.76 g/L), NaH2PO4 (0.12 g/L), glucose (1 g/L), KCl (0.4 
g/L), MgSO4 (0.1 g/L), pH7.3-7.4. 
Myocyte enzyme solution: Collagenase II (1.15×10
5
 U/L, Worthington Biochemical Corporation), 
Pancreatin (0.8 g/L, Gibco) in ADS buffer. 
Cell line enzyme solution: 0.5% trypsin in PBS 
PBS: NaCl (80 g/L), KCl (2 g/L), Na2HPO4·12H2O (15.4 g/L), KH2PO4 (2 g/L), pH7.2. 
LB agar: tryptone (10 mg/ml), yeast extract (5 mg/ml), agar (15 mg/ml), NaCl (10 mg/ml), pH7.3. 
LB media: tryptone (10 mg/ml), yeast extract (5 mg/ml), NaCl (10 mg/ml), pH7.3. 
RIPA lysis buffer: Tris (50 mM, pH 7.4), NaCl (100 mM), EDTA (2 mM), sodium fluoride (50 
mM), TritonX-100 (1%, v/v), sodium deoxycholate (0.5%, w/v), sodium dodecyl sulfate (SDS) 
(0.1%, w/v), sodium pyrophosphate (10 mM), aprotinin (1 μg/ml), leupeptin (5 μg/ml), pepstatin 
(1μg/ml). 
5× SDS loading buffer: Tris-HCl (250 mM, pH 6.8), SDS (10%, w/v), bromophenol blue (0.5%, 
w/v), β-mercaptoethanol (20%, v/v), and glycerol (50%, v/v). 
Western blot running Buffer: Tris (25 mM), glycine (192 mM), SDS (0.1%, w/v). 
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Western blot wash Buffer: NaCl (80 g/L), KCl (2 g/L), Na2HPO4·12H2O (15.4 g/L), KH2PO4 (2 
g/L), Tween-20 (0.1%, v/v), pH7.3. 
Western blot transfer Buffer: Tris (48 mM), glycine (39 mM), methanol (0.2%, v/v).
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Appendix B: PCR primers 
Normal PCR primers:  
1. Genotyping 
ErbB4 
Primer1 CAAATGCTCTCTCTGTTCTTTGTGTCTG 
Primer2 TATTGTGTTCATCTATCATTGCAACCCAG  
Primer3 TTTTGCCAAGTTCTAATTCCATCAGAAGC 
Cre 
Forward AGGTGGACCTGATCATGGAG 
Reverse ATACCGGAGATCATGCAAGC 
2. Cloning  
pEGFP-N1-ErbB4 vector 
Forward CCACTGTGACTCCACTGCTTACTGGCTTATCG 
Reverse CCTAACCGGTAACACCACAGTATTCCGGTGTC 
Note: The Nhe I and Age l I restriction sites are underlined in the above forward and reverse 
primers, respectively.  
Real-time PCR primers (SYBR) 
α-MHC  
forward CTTCATCCATGGCCAATTCT 
reverse  GCGCATTGAGTTCAAGAAGA 
β-MHC 
forward GTGAAGGGCATGAGGAAGAGT 
reverse  AGGCCTTCACCTTCAGCTGC 
BNP 
forward CTT TAT CTG TCA CCG CTG GGA G 
reverse  TTT GGG TGT TCT TTT GTG AGG C 
Col1A1 
forward GCTCCTCTTAGGGGCCACT 
reverse  CCACGTCTCACCATTGGGG  
Appendix  
 
203 
 
Col3A1  
forward CACCCTTCTTCATCCCACTC 
reverse  TGGTTCTGGCTTCCAGACAT 
PAL 
forward TTCAGCCCTTGCTTGCCTC 
reverse  ACACTTTTACTCCGAAGTCGGT 
ErbB1 
Forward CAGATGGATGTCAACCCTGAAG 
Reverse TGGAGAGTGTGTCTTTAAATTCACC 
ErbB2 
Forward GCAAGCACTGTCTGCCATGC 
Reverse GGGCACAAGCCTCACACTGG 
ErbB3 
Forward CGAGATGGGCAACTCTCAGGC 
Reverse AGGTTACCCATGACCACCTCACAC 
HB-EGF 
Forward CGGGGAGTGCAGATACCTG 
Reverse TTCTCCACTGGTAGAGTCAGC 
TGFα  
Forward GCCCAGATTCCCACACTCAG 
Reverse CACGGCACCACTCACAGTG 
EREG 
Forward CTGCCTCTTGGGTCTTGACG 
Reverse GCGGTACAGTTATCCTCGGATTC 
BTC  
Forward AATTCTCCACTGTGTGGTAGCA 
Reverse GGTTTTCACTTTCTGTCTAGGGG 
NRG3  
Forward CCAGCCTATCAAGCACCACA 
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Reverse GGTGGTGCCCTTCTGAAAGT 
NRG1α  
Forward GTGCGGAGAAGGAGAAAACTTTC 
Reverse TTGCTCCAGTGAATCCAGGTTG 
NRG1β  
Forward GTGCGGAGAAGGAGAAAACTTTC 
Reverse AACGATCACCAGTAAACTCATTTGG 
m18s  
Forward TCGAGGCCCTGTAATTGGAA 
Reverse CCCTCCAATGGATCCTCGTT 
Cre1  
Forward  TTTCCCGCAGAACCTGAAGATG 
Reverse ATCCGCCGCATAACCAGTG 
Cre2 
Forward AACATGCTTCATCGTCGGTCC 
Reverse CCGCCGCATAACCAGTGAA 
TaqMan probe and primers set 
JM isoform: 
JM-a probe [6FAM]ATGGACGGGCCATTCCACTTTACCA[BHQ1] 
JM-b probe [6FAM]TTCAAGCATTGAAGACTGCATCGGCCT[BHQ1] 
JM-a/JM-b forward TTGCCATCCAAACTGCACC 
JM-a/JM-b reverse TCCAATGACTCCGGCTGC 
CYT isoform  
CYT-1 probe [6FAM]TGAAATTGGACACAGCCCTCCTCCTG[BHQ1] 
CYT-2 probe [6FAM]AAGAATTGACTCCAATAGGAATCAGTTTGTGTACCA[BHQ1] 
CYT-1/CYT-2 forward TCCTCCCATCTACACATCCAGAA 
CYT-1/CYT-2 reverse GGCATTCCTTGTTGTGTAGCAA 
18S 
18S probe [6FAM]CAGCAGGCGCGCAAATTACCCA[BHQ1] 
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18S forward CGGCTACCACATCCAAGGAA 
18S reverse GGGCCTCGAAAGAGTCCTGT 
 
The TaqMan probe and primer set used for amplifying following genes are predesigned and 
premixed by company: 
NRG2:  Mm01158087_m1 (Applied Biosystem) 
NRG4: Mm00446254_m1 (Applied Biosystem) 
AGEG: Mm00437583_m1 (Applied Biosystem) 
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Appendix C: pEGFP-N1-ErbB4 vector cloning strategy 
Individual isoforms of ErbB4 was PCR cloned from pIRESpuro-ErbB4 vector into pEGFP-
N1vector Two restricition sites (NheI and AgeI) were incorporated into primers to facilitate the 
cloning. 
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Appendix D: pCR®-TOPO-ErbB4-JM/CYT vector cloning 
strategy 
 
 
 
 
JM or CYT domains of ErbB4 were PCR cloned from mouse cDNA into pCR
®
-TOPO vector 
using the overhanging T-A sites.  
 
